Join Clinical Trials in North Carolina for Cancer

All Categories Most Often Searched » Cancer » North Carolina

An Observational Pilot Study Evaluating The Feasibility of Conducting Genomewide Association Studies Utilizing Subject-Provided Information in Subjects With Metastatic Breast Cancer Treated With Avastin (Bevacizumab)

Condition: Breast Cancer
Intervention:
Sponsors: Genentech; Genentech; 23andMe, Inc.
Recruiting - verified May 2012
Bovine Lactoferrin in Reducing Taste Disturbances in Patients With Colorectal Cancer Receiving Oxaliplatin-Based Chemotherapy

Conditions: Colorectal Cancer; Dysgeusia; Oral Complications of Chemotherapy
Interventions: Other: questionnaire administration; Procedure: quality-of-life assessment; Other: laboratory biomarker analysis; Biological: bovine lactoferrin
Sponsors: Comprehensive Cancer Center of Wake Forest University; Comprehensive Cancer Center of Wake Forest University; National Cancer Institute (NCI)
Not yet recruiting - verified May 2012
Phase I Study of LJM716 in Combination With Trastuzumab in Patients With HER2 Overexpressing Metastatic Breast Cancer

Condition: Advanced HER2-positive Breast Cancer
Interventions: Drug: LJM716; Drug: Trastuzumab
Sponsors: Novartis; Novartis Pharmaceuticals
Not yet recruiting - verified May 2012
Phase Ib/II Study of PLX 3397 and Eribulin in Patients With Metastatic Breast Cancer

Condition: Metastatic Breast Cancer
Interventions: Drug: PLX3397; Drug: Eribulin
Sponsors: University of California, San Francisco; Hope Rugo, MD; Susan G. Komen Breast Cancer Foundation; Plexxikon, Inc.; Eisai Inc.
Not yet recruiting - verified May 2012
Supportive Intervention Programs Study

Conditions: Fatigue; Nausea and Vomiting; Pain; Recurrent Colon Cancer; Recurrent Rectal Cancer; Stage I-IVB Colon Cancer; Stage I-IVB Rectal Cancer
Interventions: Procedure: Yoga therapy; Other: questionnaire administration; Procedure: quality-of-life assessment; Other: laboratory biomarker analysis; Other: assessment of therapy complications; Procedure: management of therapy complications; Other: educational intervention
Sponsors: Wake Forest University; Wake Forest University
Recruiting - verified May 2012
A Study of LY2784544 in Participants With Myeloproliferative Neoplasms

Condition: Neoplasms, Hematologic
Interventions: Drug: 200 mg LY2784544; Drug: 400 mg LY2784544; Drug: 600 mg LY2784544
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Not yet recruiting - verified May 2012
Mindful Movement and Breathing to Improve Outcomes of Gynecologic Surgery

Conditions: Gynecologic Malignancy; Abdominal Surgery by Laparotomy; Pain; Psychological Distress; Lung Function; Surgical Complications
Interventions: Other: Mindful Movement and Breathing program; Other: Questionnaire administration; Procedure: The Observer Mobility Scale; Procedure: Volumetric Incentive Spirometry
Sponsors: Wake Forest University; Wake Forest University
Not yet recruiting - verified May 2012
ch14.18 Pharmacokinetic Study in High-risk Neuroblastoma

Condition: Neuroblastoma
Interventions: Biological: ch14.18 -NCI; Biological: ch14.18-UTC; Biological: Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF); Biological: Aldesleukin (IL-2); Drug: Isotretinoin
Sponsors: United Therapeutics; United Therapeutics
Not yet recruiting - verified May 2012
Intensity-Modulated Radiation Therapy, Pemetrexed Disodium, and Erlotinib Hydrochloride in Treating Patients With Recurrent or Second Primary Head and Neck Cancer

Conditions: Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma; Recurrent Metastatic Squamous Neck Cancer With Occult Primary; Recurrent Squamous Cell Carcinoma of the Hypopharynx; Recurrent Squamous Cell Carcinoma of the Larynx; Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity; Recurrent Squamous Cell Carcinoma of the Oropharynx; Recurrent Verrucous Carcinoma of the Larynx; Recurrent Verrucous Carcinoma of the Oral Cavity
Interventions: Radiation: intensity-modulated radiation therapy; Procedure: quality-of-life assessment; Drug: erlotinib hydrochloride; Drug: pemetrexed disodium; Other: laboratory biomarker analysis; Other: liquid chromatography; Other: mass spectrometry; Other: immunohistochemistry staining method; Genetic: protein expression analysis
Sponsors: Comprehensive Cancer Center of Wake Forest University; Comprehensive Cancer Center of Wake Forest University; National Cancer Institute (NCI)
Recruiting - verified February 2010
Pioglitazone Hydrochloride in Preventing Radiation-Induced Cognitive Dysfunction in Patients With Brain Tumors

Conditions: Adult Anaplastic Astrocytoma; Adult Anaplastic Ependymoma; Adult Anaplastic Meningioma; Adult Anaplastic Oligodendroglioma; Adult Brain Stem Glioma; Adult Choroid Plexus Tumor; Adult Craniopharyngioma; Adult Diffuse Astrocytoma; Adult Ependymoblastoma; Adult Ependymoma; Adult Giant Cell Glioblastoma; Adult Glioblastoma; Adult Gliosarcoma; Adult Grade I Meningioma; Adult Grade II Meningioma; Adult Medulloblastoma; Adult Meningeal Hemangiopericytoma; Adult Mixed Glioma; Adult Myxopapillary Ependymoma; Adult Oligodendroglioma; Adult Papillary Meningioma; Adult Pilocytic Astrocytoma; Adult Pineal Gland Astrocytoma; Adult Pineoblastoma; Adult Pineocytoma; Adult Subependymal Giant Cell Astrocytoma; Adult Subependymoma; Adult Supratentorial Primitive Neuroectodermal Tumor (PNET); Meningeal Melanocytoma; Nonmalignant Neoplasm; Recurrent Adult Brain Tumor; Tumors Metastatic to Brain
Interventions: Drug: pioglitazone hydrochloride; Other: laboratory biomarker analysis; Radiation: external beam radiation therapy; Radiation: 3-dimensional conformal radiation therapy; Radiation: intensity-modulated radiation therapy; Procedure: management of therapy complications
Sponsors: Comprehensive Cancer Center of Wake Forest University; Comprehensive Cancer Center of Wake Forest University; National Cancer Institute (NCI)
Recruiting - verified April 2012
Neuroblastoma Biology Study

Condition: Neuroblastoma
Intervention:
Sponsors: New Approaches to Neuroblastoma Therapy Consortium; New Approaches to Neuroblastoma Therapy Consortium
Recruiting - verified April 2012
Surgery and Oxaliplatin or Mitomycin C in Treating Patients With Tumors of the Appendix

Conditions: Carcinoma of the Appendix; Primary Peritoneal Cavity Cancer
Interventions: Drug: mitomycin C; Drug: oxaliplatin; Procedure: therapeutic conventional surgery; Other: quality-of-life assessment; Drug: hyperthermic intraperitoneal chemotherapy
Sponsors: Comprehensive Cancer Center of Wake Forest University; Comprehensive Cancer Center of Wake Forest University; National Cancer Institute (NCI)
Recruiting - verified October 2009
Head to Head Study Epi proColon and FIT

Condition: Colorectal Cancer
Intervention:
Sponsors: Epigenomics, Inc; Epigenomics, Inc
Recruiting - verified April 2012
Erlotinib Hydrochloride and Surgery in Treating Patients With Head and Neck Cancer That Can Be Removed By Surgery

Conditions: Squamous Cell Carcinoma of the Skin; Stage I Squamous Cell Carcinoma of the Hypopharynx; Stage I Squamous Cell Carcinoma of the Larynx; Stage I Squamous Cell Carcinoma of the Lip and Oral Cavity; Stage I Squamous Cell Carcinoma of the Oropharynx; Stage I Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity; Stage I Verrucous Carcinoma of the Larynx; Stage I Verrucous Carcinoma of the Oral Cavity; Stage II Squamous Cell Carcinoma of the Hypopharynx; Stage II Squamous Cell Carcinoma of the Larynx; Stage II Squamous Cell Carcinoma of the Lip and Oral Cavity; Stage II Squamous Cell Carcinoma of the Oropharynx; Stage II Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity; Stage II Verrucous Carcinoma of the Oral Cavity
Interventions: Drug: erlotinib hydrochloride; Procedure: therapeutic conventional surgery
Sponsors: Comprehensive Cancer Center of Wake Forest University; Comprehensive Cancer Center of Wake Forest University; National Cancer Institute (NCI)
Recruiting - verified April 2012
Preventative Trial of DFMO in Patients With High Risk Neuroblastoma in Remission

Condition: Neuroblastoma in Remission
Intervention: Drug: DFMO
Sponsors: Van Andel Research Institute; Giselle Sholler; Cancer Prevention Pharmaceuticals, Inc.; University of Arizona; University of Hawaii Cancer Research Center; University of Vermont
Not yet recruiting - verified April 2012
Do Your Genes Put You at a Higher Risk of Developing Mesothelioma

Condition: Mesothelioma
Intervention:
Sponsors: Wake Forest University; Wake Forest University; University of Pennsylvania; Mayo Clinic; New York University School of Medicine; Johns Hopkins University; Mount Sinai School of Medicine; Memorial Sloan-Kettering Cancer Center; Mesothelioma Applied Research Foundation, Inc.
Recruiting - verified May 2012
Phase Ib, Dose Escalation Study of Oral LDE225 in Combination With BKM120 in Patients With Advanced Solid Tumors

Conditions: Dose Escalation; Safety; Preliminary Efficacy; Advanced Solid Tumors; Metastatic Breast Cancer; Advanced Pancreatic Adenocarcinoma; Metastatic Colorectal Cancer; Recurrent Glioblastoma Multiforme
Intervention: Drug: LDE225 and BKM120
Sponsors: Novartis; Novartis Pharmaceuticals
Not yet recruiting - verified May 2012
A Study in Recurrent Glioblastoma (GB)

Condition: Glioblastoma
Interventions: Drug: LY2157299 monohydrate; Drug: Lomustine; Drug: Placebo
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified May 2012
A Study Comparing Treatment With 177Lu-DOTA0-Tyr3-Octreotate to Octreotide LAR in Patients With Inoperable, Progressive, Somatostatin Receptor Positive Midgut Carcinoid Tumours

Conditions: Carcinoid Tumor of the Small Bowel; Neuroendocrine Tumour
Interventions: Drug: Octreotide; Drug: Octreotide; Drug: 177Lu-DOTA0-Tyr3-Octreotate
Sponsors: Advanced Accelerator Applications; Advanced Accelerator Applications; Pierrel Research Europe GmbH
Not yet recruiting - verified April 2012
Lenalidomide as Consolidation and Maintenance in Adults >/= 60 Years of Age With AML Following Standard Induction

Condition: Acute Myeloid Leukemia
Intervention: Drug: Lenalidomide
Sponsors: UNC Lineberger Comprehensive Cancer Center; UNC Lineberger Comprehensive Cancer Center; Celgene Corporation
Not yet recruiting - verified April 2012
Induction Chemotherapy w/ABVD Followed by Brentuximab Vedotin Consolidation in Newly Diagnosed, Non-Bulky Stage I/II Hodgkin Lymphoma

Condition: Hodgkin Lymphoma, Adult
Interventions: Drug: Brentuximab vedotin; Drug: ABVD Induction
Sponsors: UNC Lineberger Comprehensive Cancer Center; UNC Lineberger Comprehensive Cancer Center; Seattle Genetics, Inc.
Recruiting - verified May 2012
A Study of Pertuzumab in Combination With Herceptin (Trastuzumab) And Vinorelbine in First Line in Patients With Metastatic or Locally Advanced HER2-Positive Breast Cancer

Condition: Breast Cancer
Interventions: Drug: pertuzumab; Drug: trastuzumab [Herceptin]; Drug: pertuzumab; Drug: trastuzumab [Herceptin]; Drug: vinorelbine
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified May 2012
Lapatinib With Trastuzumab in Treating Patients With HER2-Negative/HER2 Mutant Metastatic Breast Cancer

Condition: Breast Neoplasms
Interventions: Drug: lapatinib ditosylate; Biological: trastuzumab
Sponsors: Washington University School of Medicine; Washington University School of Medicine
Not yet recruiting - verified March 2012
Evaluation of the Safety and Efficacy of TXA127 (Angiotensin 1-7) to Enhance Engraftment in Pediatric Patients Undergoing Single or Double Umbilical Cord Blood Transplantation

Conditions: Cord Blood Transplant; Hematologic Malignancy; Inherited Metabolic Disease
Intervention: Drug: TXA127
Sponsors: US Biotest, Inc.; US Biotest, Inc.; Tarix Pharmaceuticals
Recruiting - verified March 2012
Docetaxel and Cyclophosphamide Compared to Anthracycline-Based Chemotherapy in Treating Women With HER2-Negative Breast Cancer

Condition: Breast Cancer
Interventions: Drug: AC regimen; Drug: TAC regimen; Drug: cyclophosphamide; Drug: docetaxel; Drug: doxorubicin hydrochloride; Drug: paclitaxel
Sponsors: National Cancer Institute (NCI); National Surgical Adjuvant Breast and Bowel Project (NSABP); National Cancer Institute (NCI)
Recruiting - verified May 2012
Healing Touch or Guided Imagery In Treating Pain, Fatigue, Nausea, and Anxiety in Patients Undergoing Chemotherapy

Conditions: Anxiety Disorder; Fatigue; Malignant Neoplasm; Nausea and Vomiting; Pain
Interventions: Other: questionnaire administration; Procedure: therapeutic touch; Behavioral: management of therapy complications; Behavioral: management of therapy complications; Procedure: standard follow-up care
Sponsors: Comprehensive Cancer Center of Wake Forest University; Comprehensive Cancer Center of Wake Forest University; National Cancer Institute (NCI)
Recruiting - verified March 2012
Veliparib in Treating Patients With Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Conditions: brca1 Mutation Carrier; brca2 Mutation Carrier; Fallopian Tube Cancer; Ovarian Cancer; Primary Peritoneal Cavity Cancer
Interventions: Drug: veliparib; Genetic: DNA analysis; Genetic: polymorphism analysis; Other: laboratory biomarker analysis
Sponsors: National Cancer Institute (NCI); Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Linsitinib or Topotecan Hydrochloride in Treating Patients With Relapsed Small Cell Lung Cancer

Condition: Lung Cancer
Interventions: Drug: linsitinib; Drug: topotecan hydrochloride
Sponsors: National Cancer Institute (NCI); H. Lee Moffitt Cancer Center and Research Institute; National Cancer Institute (NCI)
Recruiting - verified April 2012
Gemtuzumab Ozogamicin in Treating Patients With Acute Myeloid Leukemia

Conditions: Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities; Adult Acute Myeloid Leukemia With Del(5q); Adult Acute Myeloid Leukemia With Inv(16)(p13;q22); Adult Acute Myeloid Leukemia With t(15;17)(q22;q12); Adult Acute Myeloid Leukemia With t(16;16)(p13;q22); Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); Adult Acute Promyelocytic Leukemia (M3); Recurrent Adult Acute Myeloid Leukemia
Interventions: Drug: gemtuzumab ozogamicin; Other: laboratory biomarker analysis
Sponsors: Comprehensive Cancer Center of Wake Forest University; Comprehensive Cancer Center of Wake Forest University; National Cancer Institute (NCI)
Not yet recruiting - verified March 2012
Trial Evaluating Dovitinib Combined With Fulvestrant, in Postmenopausal Patients With HER2- and HR+ Breast Cancer

Condition: Metastatic Breast Cancer
Interventions: Drug: Dovitinib; Drug: Fulvestrant
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified April 2012
LUX-Lung 8: A Phase III Trial of Afatinib (BIBW 2992) Versus Erlotinib for the Treatment of Squamous Cell Lung Cancer After at Least One Prior Platinum Based Chemotherapy

Condition: Carcinoma, Non-Small-Cell Lung
Interventions: Drug: erlotinib; Drug: afatinib
Sponsors: Boehringer Ingelheim Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals
Recruiting - verified May 2012
A Phase I Study To Evaluate The Antitumor Activity And Safety Of AVX901

Condition: HER2+ Cancer
Intervention: Biological: AVX901
Sponsors: Duke University; Duke University; Department of Defense
Not yet recruiting - verified February 2012
De-intensification of Radiation and Chemotherapy for Low-Risk Human Papillomavirus-related Oropharyngeal Squamous Cell Carcinoma

Conditions: Carcinoma, Squamous Cell; Head and Neck Neoplasms; Oropharyngeal Neoplasms
Interventions: Radiation: Intensity Modulated Radiotherapy (IMRT); Drug: Cisplatin; Procedure: Limited surgical evaluation
Sponsors: UNC Lineberger Comprehensive Cancer Center; UNC Lineberger Comprehensive Cancer Center; University of Florida
Recruiting - verified February 2012
Local Anesthetic Cream in Younger Patients Undergoing Lumbar Punctures

Condition: Malignant Neoplasm
Interventions: Drug: placebo administration; Drug: EMLA; Drug: propofol; Drug: fentanyl citrate
Sponsors: Comprehensive Cancer Center of Wake Forest University; Comprehensive Cancer Center of Wake Forest University; National Cancer Institute (NCI)
Recruiting - verified March 2012
The CATCH Prostate Cancer Trial: Cabazitaxel And Tasquinimod in Men With Prostate Cancer

Condition: Prostate Cancer
Interventions: Drug: tasquinimod; Drug: tasquinimod 0.25 mg; 0.5 mg; Drug: tasquinimod 0.25 mg; 0.5 mg; 1.0 mg
Sponsors: Duke University; Duke University
Recruiting - verified January 2012
Azacitidine With or Without Lenalidomide or Vorinostat in Patients With Higher-Risk Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia

Conditions: Leukemia; Myelodysplastic Syndromes
Interventions: Drug: azacitidine; Drug: lenalidomide; Drug: vorinostat
Sponsors: National Cancer Institute (NCI); Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Veliparib, Radiation Therapy, and Temozolomide in Treating Younger Patients With Newly Diagnosed Diffuse Pontine Gliomas

Condition: Brain and Central Nervous System Tumors
Interventions: Drug: temozolomide; Drug: veliparib; Genetic: gene expression analysis; Genetic: protein analysis; Other: laboratory biomarker analysis; Other: pharmacological study; Radiation: 3-dimensional conformal radiation therapy; Radiation: intensity-modulated radiation therapy
Sponsors: National Cancer Institute (NCI); Pediatric Brain Tumor Consortium; National Cancer Institute (NCI)
Recruiting - verified April 2012
Study of Cabozantinib (XL184) Versus Mitoxantrone Plus Prednisone in Men With Previously Treated Symptomatic Castration-resistant Prostate Cancer

Conditions: Prostate Cancer; Castration Resistant Prostate Cancer; Pain; Prostatic Neoplasms
Interventions: Drug: cabozantinib; Drug: mitoxantrone; Drug: prednisone
Sponsors: Exelixis; Exelixis
Recruiting - verified April 2012
Symptom-Adapted Physical Activity Intervention in Minimizing Physical Function Decline in Older Patients With Acute Myeloid Leukemia Undergoing Chemotherapy

Conditions: Adult Acute Myeloid Leukemia in Remission; Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities; Adult Acute Myeloid Leukemia With Del(5q); Adult Acute Myeloid Leukemia With Inv(16)(p13;q22); Adult Acute Myeloid Leukemia With t(15;17)(q22;q12); Adult Acute Myeloid Leukemia With t(16;16)(p13;q22); Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); Recurrent Adult Acute Myeloid Leukemia; Untreated Adult Acute Myeloid Leukemia
Interventions: Procedure: quality-of-life assessment; Other: counseling intervention; Behavioral: exercise intervention; Other: educational intervention; Procedure: standard follow-up care
Sponsors: Comprehensive Cancer Center of Wake Forest University; Comprehensive Cancer Center of Wake Forest University; National Cancer Institute (NCI)
Not yet recruiting - verified April 2012
Safety, Efficacy, and Dosing of Stereotactic Radiosurgery for Hepato-cellular Carc/Colo-rectal Liver Metastases

Conditions: Liver Neoplasms; Colonic Neoplasms; Metastatic Cancer to Liver
Intervention: Radiation: Stereotactic Radiosurgery using the CyberKnife System.
Sponsors: UNC Lineberger Comprehensive Cancer Center; UNC Lineberger Comprehensive Cancer Center
Recruiting - verified February 2012
Phase 3 Trial in Subjects With Metastatic Melanoma Comparing 3 mg/kg Ipilimumab Versus 10 mg/kg Ipilimumab

Condition: Melanoma
Interventions: Biological: Ipilimumab; Biological: Ipilimumab
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb
Recruiting - verified March 2012
Validation of Colon Biomarkers for the Early Detection of Colorectal Adenocarcinoma

Conditions: Colon Cancer; Rectal Cancer
Intervention:
Sponsors: University of Michigan; University of Michigan; Early Detection Research Network
Recruiting - verified January 2012
A Study of Fractionated 90Y-hPAM4 Plus Gemcitabine in Pancreatic Cancer Patients Receiving at Least 2 Prior Therapies.

Conditions: Metastatic Pancreatic Adenocarcinoma; Pancreatic Cancer; Metastatic Pancreatic Cancer
Intervention: Drug: 90Y-hPAM4
Sponsors: Immunomedics, Inc.; Immunomedics, Inc.
Recruiting - verified May 2012
BKM120 + mFOLFOX6 in Advanced Solid Tumors With Expansion Cohorts in KRAS Wild Type Metastatic Colorectal and Pancreatic Cancer

Conditions: Advanced Solid Tumors; Metastatic Colorectal Cancer; Metastatic Pancreatic Cancer
Interventions: Drug: BKM120; Drug: mFOLFOX6
Sponsors: UNC Lineberger Comprehensive Cancer Center; UNC Lineberger Comprehensive Cancer Center
Not yet recruiting - verified January 2012
Sorafenib Tosylate in Treating Younger Patients With Relapsed or Refractory Rhabdomyosarcoma, Wilms Tumor, Liver Cancer, or Thyroid Cancer

Conditions: Head and Neck Cancer; Kidney Cancer; Liver Cancer; Sarcoma
Interventions: Drug: sorafenib tosylate; Genetic: gene expression analysis; Genetic: mutation analysis; Genetic: polymerase chain reaction; Other: enzyme-linked immunosorbent assay; Other: laboratory biomarker analysis; Other: pharmacological study
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Randomized Efficacy Study of TPI 287 to Treat Primary Refractory or Early Relapsed Neuroblastoma

Condition: Neuroblastoma
Interventions: Drug: TPI 287; Drug: Temozolomide; Drug: Irinotecan
Sponsors: Van Andel Research Institute; Giselle Sholler; Archer Biosciences, Inc.
Recruiting - verified April 2012
Study Assessing Compliance With Mercaptopurine Treatment in Younger Patients With Acute Lymphoblastic Leukemia in First Remission

Condition: Leukemia
Interventions: Behavioral: compliance monitoring; Behavioral: telephone-based intervention; Drug: mercaptopurine; Other: computer-assisted intervention; Other: counseling intervention; Other: questionnaire administration; Other: study of socioeconomic and demographic variables; Procedure: standard follow-up care
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Combination Chemotherapy in Treating Patients With Advanced or Metastatic Esophageal Cancer, Gastric Cancer, or Gastroesophageal Junction Cancer

Conditions: Adenocarcinoma of the Gastroesophageal Junction; Esophageal Cancer; Gastric Cancer
Interventions: Drug: FOLFOX regimen; Drug: docetaxel; Drug: fluorouracil; Drug: irinotecan hydrochloride; Drug: leucovorin calcium; Drug: oxaliplatin
Sponsors: National Cancer Institute (NCI); Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
A Study of Onartuzumab (MetMAb) in Combination With Bevacizumab (Avastin) Plus Platinum And Paclitaxel or With Pemetrexed Plus Platinum in Patients With Non-Squamous Non-Small Cell Lung Cancer

Condition: Non-Small Cell Lung Cancer
Interventions: Drug: RO5490258; Drug: bevacizumab [Avastin]; Drug: pemetrexed; Drug: Placebo; Drug: cisplatin/carboplatin; Drug: paclitaxel
Sponsors: Genentech; Genentech
Not yet recruiting - verified January 2012
A Study of Rindopepimut/GM-CSF in Patients With Relapsed EGFRvIII-Positive Glioblastoma

Conditions: Glioblastoma; Small Cell Glioblastoma; Giant Cell Glioblastoma; Gliosarcoma; Glioblastoma With Oligodendroglial Component; Recurrent Glioblastoma; Relapsed Glioblastoma
Interventions: Drug: Bevacizumab; Drug: Rindopepimut (CDX-110) with GM-CSF; Drug: KLH
Sponsors: Celldex Therapeutics; Celldex Therapeutics
Recruiting - verified May 2012
Caris Biorepository Research Protocol

Condition: Cancer
Intervention:
Sponsors: Caris Science, Inc.; Caris Science, Inc.
Recruiting - verified February 2012
Study Evaluating the Safety and Efficacy Of Carboplatin/Paclitaxel And Carboplatin/Paclitaxel/Bevacizumab With and Without GDC-0941 in Patients With Previously Untreated Advanced Or Recurrent Non-small Cell Lung Cancer

Condition: Non-Small Cell Lung Cancer
Interventions: Drug: GDC-0941; Drug: carboplatin; Drug: paclitaxel; Drug: bevacizumab; Drug: Placebo
Sponsors: Genentech; Genentech
Recruiting - verified February 2012
The BEACON Study (Breast Cancer Outcomes With NKTR-102)

Conditions: Locally Recurrent Breast Cancer; Metastatic Breast Cancer
Interventions: Drug: NKTR-102; Drug: Treatment of Physician's Choice (TPC)
Sponsors: Nektar Therapeutics; Nektar Therapeutics
Recruiting - verified April 2012
Zevalin and Velcade in Relapsed/Refractory Mantle Cell Lymphoma

Condition: Mantle-Cell Lymphoma
Intervention: Drug: Rituximab, Bortezomib,Y90 ibritumomab tiuxetan
Sponsors: Duke University; Duke University; Spectrum Pharmaceuticals, Inc
Recruiting - verified March 2012
Efficacy & Safety Study of MORAb-004 to Treat Metastatic Colorectal Cancer

Conditions: Metastatic Colorectal Cancer; Colorectal Cancer
Interventions: Drug: MORAb-004; Drug: Placebo
Sponsors: Morphotek; Morphotek
Recruiting - verified May 2012
Specialized Radiation Therapy and Chemotherapy in Treating Patients With Stage III Non-Small Cell Lung Cancer That Cannot Be Removed by Surgery

Condition: Lung Cancer
Interventions: Drug: carboplatin; Drug: paclitaxel; Radiation: 3-dimensional conformal radiation therapy; Radiation: hypofractionated radiation therapy; Radiation: intensity-modulated radiation therapy
Sponsors: National Cancer Institute (NCI); Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified May 2012
Everolimus and Pasireotide (SOM230) in Patients With Advanced or Metastatic Hepatocellular Carcinoma

Condition: Advanced Adult Hepatocellular Carcinoma
Interventions: Drug: Everolimus; Drug: Pasireotide
Sponsors: UNC Lineberger Comprehensive Cancer Center; UNC Lineberger Comprehensive Cancer Center; Novartis Pharmaceuticals
Recruiting - verified March 2012
Dose Escalation Study of Pazopanib Plus TH-302

Condition: Solid Tumors
Intervention: Drug: Pazopanib and TH-302
Sponsors: Duke University; Duke University; National Comprehensive Cancer Network; GlaxoSmithKline; Threshold Pharmaceuticals
Recruiting - verified January 2012
Safety and Efficacy of Kanglaite Gelcaps in Prostate Cancer

Condition: Prostate Cancer
Interventions: Drug: kanglaite gelcap; Drug: Kanglaite gelcap
Sponsors: KangLaiTe USA; KangLaiTe USA
Recruiting - verified November 2011
Telemonitoring Study - for Chronic Myeloid Leukemia (CML)

Condition: Chronic Myeloid Leukemia
Interventions: Behavioral: no access to eMedonline; Behavioral: eMedonline access
Sponsors: Rex Cancer Center, Raleigh, NC; Rex Cancer Center, Raleigh, NC; Northwestern University
Recruiting - verified December 2011
A Study of Siltuximab (Anti- IL 6 Monoclonal Antibody) in Patients With High-risk Smoldering Multiple Myeloma

Condition: Smoldering Multiple Myeloma
Interventions: Drug: Siltuximab; Drug: Placebo
Sponsors: Janssen Research & Development, LLC; Janssen Research & Development, LLC
Recruiting - verified February 2012
Poliovirus Vaccine for Recurrent Glioblastoma Multiforme (GBM)

Conditions: Recurrent Supratentorial Glioblastoma Multiforme; GBM; Glioblastoma Multiforme
Intervention: Biological: Live attenuated, oral (Sabin) serotype 1 poliovirus vaccine (PVSRIPO)
Sponsors: Duke University; Duke University; National Cancer Institute (NCI)
Recruiting - verified March 2012
Mibefradil Dihydrochloride and Temozolomide in Treating Patients With Recurrent Glioma

Condition: Brain and Central Nervous System Tumors
Interventions: Drug: mibefradil dihydrochloride; Drug: temozolomide; Other: 3'-deoxy-3'-[18F]fluorothymidine; Other: pharmacological study
Sponsors: Sidney Kimmel Comprehensive Cancer Center; Sidney Kimmel Comprehensive Cancer Center; National Cancer Institute (NCI); Tau Therapeutics LLC
Recruiting - verified April 2012
Intramuscular Injections of Degarelix Administered in 1-Month Dosing Regimens in Patients With Prostate Cancer

Condition: Prostate Cancer
Intervention: Drug: Degarelix
Sponsors: Ferring Pharmaceuticals; Ferring Pharmaceuticals
Recruiting - verified April 2012
A Study Combining mFOLFOX6 With Tivozanib or Bevacizumab in Patients With Metastatic Colorectal Cancer as First Line Therapy

Condition: Colorectal Cancer
Interventions: Drug: Tivozanib; Drug: Bevacizumab; Drug: mFOLFOX6
Sponsors: Astellas Pharma Inc; Astellas Pharma Inc; AVEO Pharmaceuticals, Inc.
Recruiting - verified March 2012
Safety and Efficacy Study of TPI-287 in Neuroblastoma and Medulloblastoma

Conditions: Neuroblastoma; Medulloblastoma
Intervention: Drug: TPI 287
Sponsors: Van Andel Research Institute; Giselle Sholler; Van Andel Research Institute; Archer Biosciences, Inc.
Recruiting - verified April 2012
A Pilot Study of Decitabine and Vorinostat With Chemotherapy for Relapsed ALL

Conditions: Acute Lymphoblastic Leukemia; Precursor B-Cell Lymphoblastic Leukemia; Precursor T-Cell Lymphoblastic Leukemia
Interventions: Drug: Decitabine; Drug: Vorinostat; Drug: Vincristine; Drug: Dexamethasone; Drug: Mitoxantrone; Drug: Pegaspargase; Drug: Methotrexate
Sponsors: Therapeutic Advances in Childhood Leukemia Consortium; Therapeutic Advances in Childhood Leukemia Consortium
Recruiting - verified March 2012
Alisertib (MLN8237) or Investigator's Choice in Patients With Relapsed/Refractory Peripheral T-Cell Lymphoma

Conditions: Relapsed Peripheral T-Cell Lymphoma; Refractory Peripheral T-Cell Lymphoma
Interventions: Drug: Alisertib; Drug: Pralatrexate; Drug: Romidepsin; Drug: Gemcitabine
Sponsors: Millennium Pharmaceuticals, Inc.; Millennium Pharmaceuticals, Inc.
Recruiting - verified May 2012
NBRST: Prospective Neo-adjuvant REGISTRY Trial

Condition: Breast Cancer
Interventions: Device: MammaPrint; Device: BluePrint; Device: TargetPrint; Device: TheraPrint
Sponsors: Agendia; Agendia
Recruiting - verified April 2012
GRN1005 Alone or in Combination With Trastuzumab in Breast Cancer Patients With Brain Metastases

Conditions: Breast Cancer; Brain Metastases
Interventions: Drug: GRN1005; Drug: Trastuzumab
Sponsors: Geron Corporation; Geron Corporation
Recruiting - verified May 2012
Prophylactic Antibiotic Regimens in Tumor Surgery (PARITY): Pilot Study

Conditions: Infection; Bone Neoplasms
Intervention: Procedure: Prophylactic Cefazolin Antibiotic Regimen
Sponsors: McMaster University; Michelle Ghert
Not yet recruiting - verified April 2012
Phase III Study of Rindopepimut/GM-CSF in Patients With Newly Diagnosed Glioblastoma

Conditions: Glioblastoma; Small Cell Glioblastoma; Giant Cell Glioblastoma; Gliosarcoma; Glioblastoma With Oligodendroglial Component
Interventions: Drug: Rindopepimut (CDX-110) with GM-CSF; Drug: Temozolomide; Drug: KLH
Sponsors: Celldex Therapeutics; Celldex Therapeutics
Recruiting - verified May 2012
Safety and Efficacy Trial of Ipilimumab Versus Pemetrexed in Non-Squamous Non-Small Cell Lung Cancer

Condition: Lung Cancer - Non Small Cell
Interventions: Biological: Ipilimumab; Biological: Pemetrexed
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb
Not yet recruiting - verified February 2012
A Study to Evaluate the Efficacy and Safety of GS-6624 Combined With Gemcitabine for Metastatic Pancreatic Adenocarcinoma

Condition: Pancreatic Cancer
Interventions: Drug: GS-6624; Drug: GS-6624; Drug: Placebo; Drug: Gemcitabine; Drug: Gemcitabine; Drug: Gemcitabine; Drug: Gemcitabine; Drug: GS-6624
Sponsors: Gilead Sciences; Gilead Sciences
Recruiting - verified March 2012
Efficacy and Safety of GS-6624 With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma

Condition: Colorectal Cancer
Interventions: Drug: GS-6624; Drug: FOLFIRI; Drug: GS-6624; Drug: FOLFIRI; Drug: GS-6624; Drug: FOLFIRI; Drug: Placebo; Drug: FOLFIRI
Sponsors: Gilead Sciences; Gilead Sciences
Recruiting - verified March 2012
Paclitaxel With or Without Pazopanib Hydrochloride in Treating Patients With Persistent or Recurrent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cavity Cancer

Conditions: Fallopian Tube Cancer; Ovarian Cancer; Primary Peritoneal Cavity Cancer
Interventions: Drug: paclitaxel; Drug: pazopanib hydrochloride; Other: placebo
Sponsors: National Cancer Institute (NCI); Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Efficacy and Safety Study of Apaziquone vs. Placebo in Patients With Non-Muscle Invasive Bladder Cancer (NMIBC)

Condition: Bladder Cancer
Interventions: Drug: Apaziquone; Drug: Placebo
Sponsors: Spectrum Pharmaceuticals, Inc; Spectrum Pharmaceuticals, Inc; Allergan
Recruiting - verified May 2012
IIT CTI Bendamustine, Rituximab, Pixantrone in Relapsed/Refractory B Cell Non-Hodgkin's Lymphoma

Condition: Non-Hodgkin's Lymphoma
Intervention: Drug: Bendamustine + Rituximab + Pixantrone
Sponsors: Duke University; Duke University; Cell Therapeutics
Recruiting - verified March 2012
Clinical and Biological Predictors of Chemotherapy Toxicity in Older Adults

Condition: Breast Cancer
Intervention:
Sponsors: City of Hope Medical Center; City of Hope Medical Center; National Institutes of Health (NIH); National Institute on Aging (NIA)
Recruiting - verified November 2011
Study of Bortezomib and Dexamethasone With or Without Elotuzumab to Treat Relapsed or Refractory Multiple Myeloma

Condition: Multiple Myeloma
Interventions: Biological: Elotuzumab; Drug: Bortezomib; Drug: Dexamethasone; Drug: Dexamethasone; Drug: Dexamethasone; Drug: Dexamethasone
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb; Abbott Biotherapeutics Corp.
Recruiting - verified February 2012
Sunitinib Malate in Treating Younger Patients With Recurrent, Refractory, or Progressive Malignant Glioma or Ependymoma

Condition: Brain and Central Nervous System Tumors
Interventions: Drug: sunitinib malate; Genetic: gene expression analysis; Genetic: protein expression analysis; Other: laboratory biomarker analysis; Other: pharmacological study
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Vascular and Cognitive Assessments in Patients With Breast Cancer Undergoing Chemotherapy After Surgery

Conditions: Cognitive/Functional Effects; Recurrent Breast Cancer; Stage IA Breast Cancer; Stage IB Breast Cancer; Stage II Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer
Interventions: Procedure: ultrasound imaging; Other: questionnaire administration; Procedure: assessment of therapy complications; Procedure: quality-of-life assessment; Procedure: magnetic resonance imaging
Sponsors: Comprehensive Cancer Center of Wake Forest University; Comprehensive Cancer Center of Wake Forest University; National Cancer Institute (NCI)
Recruiting - verified February 2012
Prolonged or Standard Infusion of Cefepime Hydrochloride in Treating Patients With Febrile Neutropenia

Conditions: Adult Acute Lymphoblastic Leukemia; Adult Acute Myeloid Leukemia; Adult Burkitt Lymphoma; Adult Diffuse Large Cell Lymphoma; Adult Diffuse Mixed Cell Lymphoma; Adult Diffuse Small Cleaved Cell Lymphoma; Adult Hodgkin Lymphoma; Adult Immunoblastic Large Cell Lymphoma; Adult Lymphoblastic Lymphoma; Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative; Breast Cancer; Chronic Eosinophilic Leukemia; Chronic Lymphocytic Leukemia; Chronic Myelogenous Leukemia; Chronic Myelomonocytic Leukemia; Chronic Neutrophilic Leukemia; Cutaneous T-cell Non-Hodgkin Lymphoma; Disseminated Neuroblastoma; Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue; Grade 1 Follicular Lymphoma; Grade 2 Follicular Lymphoma; Grade 3 Follicular Lymphoma; Malignant Testicular Germ Cell Tumor; Mantle Cell Lymphoma; Marginal Zone Lymphoma; Multiple Myeloma; Mycosis Fungoides/Sezary Syndrome; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Neoplasms; Neutropenia; Nodal Marginal Zone B-cell Lymphoma; Ovarian Epithelial Cancer; Ovarian Germ Cell Tumor; Plasma Cell Neoplasm; Poor Prognosis Metastatic Gestational Trophoblastic Tumor; Primary Myelofibrosis; Prolymphocytic Leukemia; Small Lymphocytic Lymphoma; Splenic Marginal Zone Lymphoma
Intervention: Drug: cefepime hydrochloride
Sponsors: Comprehensive Cancer Center of Wake Forest University; Comprehensive Cancer Center of Wake Forest University; National Cancer Institute (NCI)
Recruiting - verified November 2011
Cognitive Assessments in Patients With Cancer Undergoing Chemotherapy

Conditions: Malignant Neoplasm; Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Procedure: cognitive assessment; Procedure: quality-of-life assessment
Sponsors: Comprehensive Cancer Center of Wake Forest University; Comprehensive Cancer Center of Wake Forest University; National Cancer Institute (NCI)
Recruiting - verified January 2012
Trivalent Influenza Vaccine in Preventing Flu in Patients With Central Nervous System Tumors

Condition: Central Nervous System Neoplasm
Interventions: Biological: trivalent influenza vaccine; Other: laboratory biomarker analysis
Sponsors: Comprehensive Cancer Center of Wake Forest University; Comprehensive Cancer Center of Wake Forest University; National Cancer Institute (NCI)
Recruiting - verified November 2011
Adverse Event Toxicity Intervention Study To Evaluate The Effect Of Prophylactic Treatment And An Interrupted Dosing Schedule On The Incidence Of Adverse Events In Patients Treated With Dacomitinib (PF-00299804)

Condition: Non Small Cell Lung Cancer (NSCLC)
Interventions: Drug: PF-00299804 Plus Blinded Doxycycline Placebo; Drug: PF-00299804 Plus Blinded Doxycycline; Drug: PF-00299804
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2012
Efficacy and Safety of Masitinib in Multiple Myeloma

Condition: Multiple Myeloma
Interventions: Drug: masitinib 6 mg/kg/day; Drug: placebo
Sponsors: AB Science; AB Science
Recruiting - verified November 2011
Comparing Robotics and Laparoscopy With Laparotomy/Open Surgery for Endometrial Cancer

Condition: Cancer of the Endometrium
Intervention:
Sponsors: University Health Network, Toronto; University Health Network, Toronto
Not yet recruiting - verified November 2011
Clinical Study With Blinatumomab in Patients With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (ALL)

Condition: Acute Lymphoblastic Leukemia
Intervention: Drug: Blinatumomab
Sponsors: Micromet GmbH; Micromet GmbH
Recruiting - verified February 2012
BMS-936558 (MDX-1106) In Combination With Sunitinib or Pazopanib in Subjects With Metastatic Renal Cell Carcinoma (RCC)

Conditions: Renal Cell Carcinoma; Clear-cell Metastatic Renal Cell Carcinoma
Interventions: Biological: BMS-936558; Drug: Sunitinib; Drug: Pazopanib
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb; Ono Pharmaceutical Company, Ltd.
Recruiting - verified March 2012
Pediatric Philadelphia Positive Acute Lymphoblastic Leukemia

Condition: Leukemia, Pediatric
Intervention: Drug: Dasatinib
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb; Children's Oncology Group; EsPhALL - European Intergroup Study on Post Induction Treatment of Philadelphia Positive Acute Lymphoblastic Leukaemia with Imatinib
Recruiting - verified April 2012
Study of ABT-700 in Subjects With Advanced Solid Tumors

Condition: Subjects With Advanced Solid Tumors (Including, But Not Limited to Gastric, Head and Neck, NSCLC, Colon, Mesothelioma and Triple Negative Breast Cancer).
Interventions: Drug: ABT-700; Drug: ABT-700 plus erlotinib; Drug: ABT-700 plus Oxaliplatin and Capecitabine
Sponsors: Abbott; Abbott
Recruiting - verified March 2012
A Study of GDC-0980 in the Treatment of Recurrent or Persistent Endometrial Carcinoma

Condition: Endometrial Carcinoma
Intervention: Drug: GDC-0980
Sponsors: Genentech; Genentech
Recruiting - verified October 2011
A Safety Study of Carfilzomib and Pomalidomide With Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma

Condition: Multiple Myeloma
Interventions: Drug: Carfilzomib; Drug: Pomalidomide; Drug: Dexamethasone
Sponsors: Academic Myeloma Consortium; Academic Myeloma Consortium; CORE Science Solutions; Onyx Pharmaceuticals; Celgene Corporation
Recruiting - verified February 2012
Defining the Triple Negative Breast Cancer Kinome Response to GSK1120212

Condition: Breast Cancer
Intervention: Drug: GSK1120212
Sponsors: UNC Lineberger Comprehensive Cancer Center; UNC Lineberger Comprehensive Cancer Center; GlaxoSmithKline
Recruiting - verified February 2012
Development of a Tumor Molecular Analyses Program and Its Use to Support Treatment Decisions

Condition: Neoplasm
Intervention:
Sponsors: UNC Lineberger Comprehensive Cancer Center; UNC Lineberger Comprehensive Cancer Center
Recruiting - verified April 2012
Evaluating the Effectiveness of the Quadrivalent Human Papillomavirus (HPV) Vaccine at Preventing Anal HPV Infection in HIV-Infected Men

Condition: HIV Infections
Interventions: Biological: Quadrivalent HPV Vaccine; Biological: Placebo Vaccine
Sponsors: National Institute of Allergy and Infectious Diseases (NIAID); National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified May 2012
Patient Preferences for Breast Reconstruction After Mastectomy

Condition: Breast Cancer
Intervention:
Sponsors: UNC Lineberger Comprehensive Cancer Center; UNC Lineberger Comprehensive Cancer Center; National Cancer Institute (NCI); North Carolina TraCS Institute
Not yet recruiting - verified December 2011
Trial in Extensive-Disease Small Cell Lung Cancer (ED-SCLC) Subjects Comparing Ipilimumab Plus Etoposide and Platinum Therapy to Etoposide and Platinum Therapy Alone

Condition: Small Cell Lung Carcinoma
Interventions: Biological: Ipilimumab; Biological: Placebo matching Ipilimumab; Drug: Etoposide; Drug: Cisplatin; Drug: Carboplatin
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb
Recruiting - verified October 2011
A Study Comparing Siltuximab Plus Best Supportive Care to Placebo Plus Best Supportive Care in Anemic Patients With International Prognostic Scoring System Low- or Intermediate-1-Risk Myelodysplastic Syndrome

Condition: Myelodysplastic Syndrome
Interventions: Drug: Siltuximab + BSC; Drug: Placebo + BSC
Sponsors: Janssen Research & Development, LLC; Janssen Research & Development, LLC
Recruiting - verified April 2012
A Safety Study of MM-121 With Cetuximab and Irinotecan in Patients With Advanced Cancers

Conditions: Colorectal Cancer; Squamous Cell Head and Neck Cancer; Non-small Cell Lung Cancer; Triple Negative Breast Cancer; Other Tumors With EGFR Dependence
Interventions: Drug: MM-121 (SAR256212); Drug: Irinotecan; Drug: Cetuximab
Sponsors: Merrimack Pharmaceuticals; Merrimack Pharmaceuticals; Sanofi-Aventis
Recruiting - verified January 2012
Pilot Study to Assess Telemonitoring of Gleevec (Imatinib Mesylate) or Tasigna (Niltinib) Therapy

Condition: Chronic Phase CML
Interventions: Behavioral: no access to eMedonline; Behavioral: eMedonline access
Sponsors: Rex Cancer Center, Raleigh, NC; Rex Cancer Center, Raleigh, NC; Northwestern University
Recruiting - verified December 2011
Emend and Ondansetron Compared to Ondansetron Alone to Prevent CINV in Glioma Patients Receiving Temozolomide

Conditions: Nausea; Vomiting; Glioma
Interventions: Drug: Aprepitant and Ondansetron; Drug: Ondansetron
Sponsors: Duke University; Duke University; Merck
Not yet recruiting - verified March 2012
A Study of MM-121 With Paclitaxel in Platinum Resistant/ Refractory Advanced Ovarian Cancers

Conditions: Epithelial Ovarian Cancer; Fallopian Tube Cancer; Peritoneal Cancer
Interventions: Drug: MM-121 (SAR256212) + Paclitaxel; Drug: Paclitaxel
Sponsors: Merrimack Pharmaceuticals; Merrimack Pharmaceuticals; Sanofi-Aventis
Recruiting - verified May 2012
Relating Clinical Outcomes in Multiple Myeloma to Personal Assessment of Genetic Profile

Condition: Multiple Myeloma
Intervention:
Sponsors: Multiple Myeloma Research Foundation; Multiple Myeloma Research Foundation; Translational Genomics Research Institute, Phoenix, Arizona.; Spectrum Health Hospitals; Van Andel Research Institute; Quintiles
Recruiting - verified May 2012
Phase 1 Study of CEP-37250/KHK2804 in Subjects With Advanced Solid Tumors

Conditions: Solid Tumour; Adenocarcinoma of the Colon; Adenocarcinoma of the Pancreas
Intervention: Drug: CEP-37250/KHK2804
Sponsors: Kyowa Hakko Kirin Pharma, Inc.; Kyowa Hakko Kirin Pharma, Inc.; Cephalon
Recruiting - verified February 2012
TRINOVA-3: A Study of AMG 386 or AMG 386 Placebo in Combination With Paclitaxel and Carboplatin to Treat Ovarian Cancer

Conditions: Fallopian Tube Cancer; Ovarian Cancer; Peritoneal Cancer
Interventions: Drug: AMG 386; Drug: Paclitaxel; Drug: AMG 386 Placebo; Drug: Carboplatin
Sponsors: Amgen; Amgen
Recruiting - verified May 2012
A Phase 2, Multicenter, Open-label Study of MEDI-551 in Adults With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)

Condition: Chronic Lymphocytic Leukemia (CLL)
Interventions: Drug: MEDI-551; Drug: Rituximab; Drug: Bendamustine
Sponsors: MedImmune LLC; MedImmune LLC
Recruiting - verified April 2012
Multi-arm Study of BMS-936558 in Combination With 3 Platinum-based Doublet Chemotherapy Regimens in Subjects With Treatment-Naive Stage IIIB/IV Non-small Cell Lung Cancer

Condition: Non-small Cell Lung Cancer
Interventions: Drug: BMS-936558 (Anti-PD1); Drug: BMS-936558 (Anti-PD1); Drug: BMS-936558 (Anti-PD1); Drug: Gemcitabine; Drug: Cisplatin; Drug: Pemetrexed; Drug: Paclitaxel; Drug: Carboplatin
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb; Ono Pharma
Recruiting - verified February 2012
Phase 1 Study of PI3 (Phosphatidylinositol-3)-Kinase Inhibitor BAY80-6946 With Gemcitabine or Cisplatin Plus Gemcitabine in Patients With Advanced Cancer

Condition: Neoplasms
Interventions: Drug: Gemcitabine; Drug: BAY80-6946; Drug: Cisplatin; Drug: NaCl; Drug: BAY80-6964 fixed dose
Sponsors: Bayer; Bayer
Recruiting - verified May 2012
Pilot Study of Model Based Iterative Reconstruction Using 64-Slice Multidetector-Row CT Datasets Obtained From the Central Nervous System, Thorax, and Abdomen

Conditions: Pathology of Posterior Fossa; Lung Cancer; Flank Pain; Urolithiasis; Focal Liver Lesion
Intervention:
Sponsors: GE Healthcare; GE Healthcare; American College of Radiology - Image Metrix
Recruiting - verified January 2012
A Study of Ramucirumab (IMC-1121B) in Combination With Eribulin Versus Eribulin Alone in Patients With Breast Cancer

Condition: Breast Cancer
Interventions: Biological: Ramucirumab (IMC-1121B); Drug: Eribulin
Sponsors: ImClone LLC; ImClone LLC
Recruiting - verified May 2012
Safety and Efficacy Pre-Menopausal Women With Heavy Uterine Bleeding and Uterine Fibroids

Conditions: Uterine Fibroids; Heavy Uterine Bleeding
Interventions: Drug: placebo; Drug: elagolix, elagolix sodium; Drug: Placebo; Drug: elagolix, elagolix sodium; Other: Elagolix Dose 1 plus estradiol/norethindrone acetate; Drug: Placebo Cohort 4; Drug: Elagolix, elagolix sodium; Drug: Elagolix, elagolix sodium
Sponsors: Abbott; Abbott; Neurocrine Biosciences
Recruiting - verified April 2012
MK2206 in Treating Patients With Advanced Refractory Biliary Cancer That Cannot Be Removed by Surgery

Conditions: Extrahepatic Bile Duct Cancer; Gallbladder Cancer; Liver Cancer
Interventions: Drug: Akt inhibitor MK2206; Genetic: mutation analysis; Genetic: proteomic profiling; Other: laboratory biomarker analysis; Other: pharmacogenomic studies; Other: pharmacological study
Sponsors: National Cancer Institute (NCI); Arthur G. James Cancer Hospital & Richard J. Solove Research Institute; National Cancer Institute (NCI)
Recruiting - verified August 2011
Patient Controlled Tissue Expansion for Breast Reconstruction

Condition: Breast Cancer
Interventions: Device: AeroForm Patient Controlled Tissue Expander; Procedure: Implantation of Saline Tissue Expander
Sponsors: AirXpanders, Inc.; AirXpanders, Inc.
Recruiting - verified April 2012
Study of Ruxolitinib in Pancreatic Cancer Patients

Condition: Metastatic Pancreatic Adenocarcinoma
Interventions: Drug: Number 1 - Capecitabine and ruxolitinib; Drug: Number 2 - Capecitabine and placebo
Sponsors: Incyte Corporation; Incyte Corporation
Recruiting - verified May 2012
PF-04856884 (CVX-060) In Combination With Axitinib In Patients With Previously Treated Metastatic Renal Cell Carcinoma

Condition: Metastatic Renal Cell Carcinoma
Interventions: Biological: PF-04856884; Drug: AG-013736
Sponsors: Pfizer; Pfizer
Recruiting - verified April 2012
A Study of Trastuzumab Emtansine in Comparison With Treatment of Physician's Choice in Patients With HER2-Positive Breast Cancer Who Have Received at Least Two Prior Regimens of HER2-Directed Therapy (TH3RESA)

Condition: Breast Cancer
Interventions: Drug: trastuzumab emtansine; Drug: anti-cancer therapy
Sponsors: Genentech; Genentech
Recruiting - verified March 2012
Validation of Cancer Questionnaire for Skin Toxicities in Patients With Colorectal Cancer or Lung Cancer Receiving Cetuximab, Panitumumab, or Erlotinib Hydrochloride

Conditions: Colorectal Cancer; Dermatologic Complications; Lung Cancer; Therapy-related Toxicity
Interventions: Biological: cetuximab; Biological: panitumumab; Drug: erlotinib hydrochloride; Other: questionnaire administration; Procedure: assessment of therapy complications; Procedure: psychosocial assessment and care; Procedure: quality-of-life assessment
Sponsors: National Cancer Institute (NCI); Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified April 2012
Efficacy and Safety of Leuprolide Acetate 22.5 mg Depot in Treatment of Prostate Cancer

Condition: Prostate Cancer
Intervention: Drug: Leuprolide acetate 22.5 mg depot, GP-Pharm SA
Sponsors: GP-Pharm; GP-Pharm
Recruiting - verified March 2012
Bioequivalence of 2 Formulations of TKI258 in Patients With Advanced Solid Tumors

Conditions: Advanced Solid Tumors; Excluding Breast Cancer
Intervention: Drug: TKI258
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified May 2012
Cisplatin and Radiation Therapy With or Without Carboplatin and Paclitaxel in Patients With Locally Advanced Cervical Cancer

Conditions: Cervical Cancer; Chemotherapeutic Agent Toxicity; Cognitive/Functional Effects; Psychosocial Effects of Cancer and Its Treatment; Radiation Toxicity; Sexuality and Reproductive Issues
Interventions: Drug: carboplatin; Drug: cisplatin; Drug: paclitaxel
Sponsors: National Cancer Institute (NCI); Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Cancer Vaccines CRS-207 and GVAX Pancreas for Metastatic Pancreatic Adenocarcinoma

Condition: Pancreatic Cancer
Interventions: Drug: GVAX Pancreas, Cyclophosphamide and CRS-207; Drug: GVAX Pancreas and Cyclophosphamide
Sponsors: Aduro BioTech, Inc.; Aduro BioTech, Inc.; Johns Hopkins University
Recruiting - verified May 2012
Decitabine With or Without Bortezomib in Treating Older Patients With Acute Myeloid Leukemia

Condition: Leukemia
Interventions: Drug: bortezomib; Drug: decitabine
Sponsors: National Cancer Institute (NCI); Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified May 2012
Carboplatin and Paclitaxel With or Without Vorinostat in Treating Patients With Advanced Non-Small Cell Lung Cancer

Conditions: Stage IIIA Non-small Cell Lung Cancer; Stage IIIB Non-small Cell Lung Cancer; Stage IV Non-small Cell Lung Cancer
Interventions: Drug: paclitaxel; Drug: carboplatin; Drug: vorinostat; Other: placebo; Other: laboratory biomarker analysis; Other: immunohistochemistry staining method; Genetic: protein analysis; Genetic: gene expression analysis; Genetic: proteomic profiling
Sponsors: California Cancer Consortium; California Cancer Consortium; National Cancer Institute (NCI)
Recruiting - verified February 2012
Induction Chemotherapy for Locally Advanced Squamous Cell Carcinoma of the Head and Neck

Condition: Head and Neck Cancer
Interventions: Drug: Cetuximab; Drug: Nab-paclitaxel; Drug: Carboplatin
Sponsors: UNC Lineberger Comprehensive Cancer Center; UNC Lineberger Comprehensive Cancer Center; Celgene Corporation
Recruiting - verified February 2012
A Study of RO5072759 (GA101) in Combination With CHOP Chemotherapy in Patients With Previously Untreated Advanced Diffuse Large B-Cell Lymphoma (GATHER)

Condition: Lymphoma, B-Cell
Interventions: Drug: RO50722759; Drug: cyclophosphamide; Drug: doxorubicin; Drug: vincristine; Drug: prednisone
Sponsors: Genentech; Genentech
Recruiting - verified May 2012
Genetic Susceptibility to Radiation-Induced Skin Reactions in Racial/Ethnic Groups of Patients With Breast Cancer

Conditions: Breast Cancer; Cognitive/Functional Effects; Depression; Fatigue; Pain; Psychosocial Effects of Cancer and Its Treatment; Radiation Toxicity; Skin Reactions Secondary to Radiation Therapy
Interventions: Genetic: DNA analysis; Genetic: gene expression analysis; Other: enzyme-linked immunosorbent assay; Other: flow cytometry; Other: laboratory biomarker analysis; Other: questionnaire administration; Procedure: adjuvant therapy; Procedure: assessment of therapy complications; Procedure: quality-of-life assessment; Radiation: 3-dimensional conformal radiation therapy; Radiation: breast irradiation; Radiation: external beam radiation therapy; Radiation: hypofractionated radiation therapy; Radiation: intensity-modulated radiation therapy; Radiation: whole breast irradiation
Sponsors: National Cancer Institute (NCI); Comprehensive Cancer Center of Wake Forest University; National Cancer Institute (NCI)
Recruiting - verified May 2012
A Phase I Study of AC220 for Children With Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myelogenous Leukemia

Conditions: Lymphoblastic Leukemia, Acute, Childhood; Myelogenous Leukemia, Acute, Childhood
Interventions: Drug: AC220; Drug: Cytarabine; Drug: Etoposide; Drug: Methotrexate
Sponsors: Therapeutic Advances in Childhood Leukemia Consortium; Therapeutic Advances in Childhood Leukemia Consortium; Ambit Biosciences Corporation
Recruiting - verified September 2011
A Study Evaluating the Efficacy and Safety of MEGF0444A Dosed to Progression in Combination With Bevacizumab and Folfox in Patients With Previously Untreated Metastatic Colorectal Cancer (CONGO)

Condition: Metastatic Colorectal Cancer
Interventions: Drug: bevacizumab; Drug: MEGF0444A; Drug: mFOLFOX6; Drug: placebo
Sponsors: Genentech; Genentech
Recruiting - verified March 2012
Combination Chemotherapy in Treating Young Patients With Newly Diagnosed High-Risk Acute Lymphoblastic Leukemia

Conditions: Cognitive/Functional Effects; Leukemia; Neurotoxicity; Pain; Therapy-related Toxicity
Interventions: Drug: clofarabine; Drug: cyclophosphamide; Drug: cytarabine; Drug: doxorubicin hydrochloride; Drug: etoposide; Drug: hydrocortisone sodium succinate; Drug: leucovorin calcium; Drug: mercaptopurine; Drug: methotrexate; Drug: pegaspargase; Drug: prednisone; Drug: thioguanine; Drug: vincristine sulfate; Radiation: selective external radiation therapy
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Multi-Target Colorectal Cancer Screening Test for the Detection of Colorectal Advanced Adenomatous Polyps and Cancer

Conditions: Colorectal Neoplasms; Digestive System Diseases; Colonic Diseases; Colorectal Cancer
Intervention:
Sponsors: Exact Sciences Corporation; Exact Sciences Corporation
Recruiting - verified August 2011
Cosmetic Evaluation of Lumpectomy Versus Oncolytic Mammoplasty With Bilateral Breast Reduction for Early Stage Breast Cancer

Condition: Breast Carcinoma
Intervention:
Sponsors: New Hanover Regional Medical Center; New Hanover Regional Medical Center; National Cancer Institute (NCI); Coastal Carolina Radiation Oncology (CCRO)
Recruiting - verified August 2011
Temsirolimus, Dexamethasone, Mitoxantrone Hydrochloride, Vincristine Sulfate, and Pegaspargase in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Non-Hodgkin Lymphoma

Conditions: Leukemia; Lymphoma
Interventions: Drug: dexamethasone; Drug: methotrexate; Drug: mitoxantrone hydrochloride; Drug: pegaspargase; Drug: temsirolimus; Drug: vincristine sulfate; Other: laboratory biomarker analysis; Other: pharmacological study
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Dasatinib Added to Gemcitabine for Subjects With Locally-advanced Pancreatic Cancer

Condition: Pancreatic Cancer
Intervention: Drug: dasatinib
Sponsors: Otsuka Pharmaceutical Development & Commercialization, Inc.; Otsuka Pharmaceutical Development & Commercialization, Inc.
Recruiting - verified February 2012
Omega-3-Fatty Acid Supplements in Treating Muscle and Bone Pain and Stiffness in Patients With Stage I, Stage II, or Stage III Breast Cancer Receiving Hormone Therapy

Conditions: Arthralgia; Breast Cancer; Pain
Interventions: Dietary Supplement: omega-3 fatty acid; Other: placebo
Sponsors: National Cancer Institute (NCI); Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
BKM120 in Metastatic Castration-resistant Prostate Cancer

Conditions: Prostate Cancer; Metastatic
Intervention: Drug: BKM120
Sponsors: Duke University; Duke University; Novartis Pharmaceuticals
Recruiting - verified October 2011
Randomized Phase II Study of Single Agent OSI-906 Versus Topotecan for Relapsed Small Cell Lung Cancer (SCLC)

Condition: Lung Cancer
Interventions: Drug: Topotecan; Drug: OSI-906
Sponsors: H. Lee Moffitt Cancer Center and Research Institute; H. Lee Moffitt Cancer Center and Research Institute; National Cancer Institute (NCI)
Recruiting - verified February 2012
A Study of Abiraterone Acetate Plus Prednisone With or Without Exemestane in Postmenopausal Women With Estrogen Receptor-Positive (ER+) Metastatic Breast Cancer Progressing After Letrozole or Anastrozole Therapy

Conditions: Metastatic ER+ Her2- Breast Cancer; Postmenopausal
Interventions: Drug: Exemestane; Drug: Abiraterone acetate + Prednisone/ Prednisolone + Exemestane; Drug: Abiraterone acetate + Prednisone or Prednisolone
Sponsors: Janssen Research & Development, LLC; Janssen Research & Development, LLC
Recruiting - verified May 2012
MRD Testing Before and After Hematopoietic Cell Transplantation Transplantation for Pediatric Acute Myeloid Leukemia

Condition: Acute Myeloid Leukemia
Intervention:
Sponsors: Center for International Blood and Marrow Transplant Research; Center for International Blood and Marrow Transplant Research; Resource for Clinical Investigations in Blood and Marrow Transplantation (RCI-BMT); Pediatric Blood and Marrow Transplant Consortium
Recruiting - verified May 2012
Pilot Study to Measure Lung Biopsy Diagnostic Yield Using Always On Electromagnetic Tip Tracked Devices

Condition: Pulmonary Coin Lesion
Intervention: Procedure: Lung biopsy using Always On EM Tip Tracked Device
Sponsors: Veran Medical Technologies; Veran Medical Technologies; Institute for Quality Resource Management
Recruiting - verified July 2011
Prasterone (Dehydroepiandrosterone) in Treating Postmenopausal Cancer Survivors With Vaginal Symptoms

Condition: Cancer
Interventions: Drug: prasterone; Other: placebo
Sponsors: National Cancer Institute (NCI); North Central Cancer Treatment Group; National Cancer Institute (NCI)
Recruiting - verified February 2012
A Study of Vemurafenib in Metastatic Melanoma Patients With Brain Metastases

Condition: Malignant Melanoma
Intervention: Drug: vemurafenib
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified May 2012
Study of the Safety and Pharmacokinetics of MPDL3280A Administered Intravenously As a Single Agent to Patients With Locally Advanced or Metastatic Solid Tumors

Condition: Solid Cancers
Intervention: Drug: MPDL3280A
Sponsors: Genentech; Genentech
Recruiting - verified March 2012
BIBF 1120 for Recurrent High-Grade Gliomas

Conditions: Glioblastoma; Gliosarcoma; Anaplastic Astrocytoma; Anaplastic Oligodendroglioma; Anaplastic Oligoastrocytoma
Intervention: Drug: BIBF 1120
Sponsors: Dana-Farber Cancer Institute; Patrick Y. Wen, MD; Boehringer Ingelheim Pharmaceuticals; Wake Forest University Baptist Medical Center; Dartmouth-Hitchcock Medical Center; University of Virginia; Massachusetts General Hospital
Not yet recruiting - verified December 2011
Study of Bevacizumab/mFOLFOX6 Versus Bevacizumab/Folfiri With Biomarker Stratification in Patients With Previously Untreated Metastatic Colorectal Cancer

Condition: Colorectal Cancer
Interventions: Drug: bevacizumab; Drug: FOLFIRI regimen; Drug: mFOLFOX6
Sponsors: Genentech; Genentech
Recruiting - verified December 2011
Efficacy of Everolimus Alone or in Combination With Pasireotide LAR in Advanced PNET

Condition: Islet Cell Tumor
Interventions: Drug: Everolimus; Drug: Pasireotide + Everolimus
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified April 2012
A Novel Optical Spectral Imaging System for Imaging Breast Tumor Margins

Condition: Breast Cancer
Intervention:
Sponsors: Duke University; Duke University; National Institutes of Health (NIH)
Recruiting - verified February 2012
Pazopanib, Docetaxel, Prednisone Prostate

Condition: Prostate Cancer
Interventions: Drug: Pazopanib; Drug: Docetaxel; Drug: Pazopanib; Drug: Prednisone
Sponsors: Duke University; Duke University; GlaxoSmithKline
Recruiting - verified July 2011
Quality of Life and Care Needs of Patients With Persistent or Recurrent Ovarian Cancer, Fallopian Tube Cancer, or Peritoneal Cancer

Conditions: Anxiety Disorder; Fallopian Tube Cancer; Fatigue; Nausea and Vomiting; Neurotoxicity; Ovarian Cancer; Primary Peritoneal Cavity Cancer
Interventions: Other: medical chart review; Other: questionnaire administration; Other: study of socioeconomic and demographic variables; Procedure: assessment of therapy complications; Procedure: cognitive assessment; Procedure: fatigue assessment and management; Procedure: psychosocial assessment and care; Procedure: quality-of-life assessment
Sponsors: National Cancer Institute (NCI); Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Stereotactic Radiosurgery or Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases That Have Been Removed By Surgery

Conditions: Cognitive/Functional Effects; Metastatic Cancer; Neurotoxicity; Radiation Toxicity; Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Radiation: stereotactic radiosurgery; Radiation: whole-brain radiation therapy
Sponsors: National Cancer Institute (NCI); North Central Cancer Treatment Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Androgen-Deprivation Therapy and Radiation Therapy in Treating Patients With Prostate Cancer

Condition: Prostate Cancer
Interventions: Radiation: radiation therapy; Radiation: selective external radiation therapy
Sponsors: National Cancer Institute (NCI); Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Chemoradiotherapy With Elective Low Dose Nodal Radiation for Locally Advanced Head and Neck Cancer

Condition: Head and Neck Cancer
Interventions: Drug: Cisplatin; Radiation: Elective Nodal Irradiation (ENI)
Sponsors: New Hanover Regional Medical Center; New Hanover Regional Medical Center; National Cancer Institute (NCI); Coastal Carolina Radiation Oncology (CCRO)
Recruiting - verified June 2011
Bortezomib and Sorafenib Tosylate in Patients With Newly Diagnosed Acute Myeloid Leukemia With or Without Mutations

Condition: Leukemia
Interventions: Drug: asparaginase; Drug: bortezomib; Drug: cytarabine; Drug: daunorubicin hydrochloride; Drug: etoposide; Drug: mitoxantrone hydrochloride; Drug: sorafenib tosylate
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Chemotherapy Toxicity On Quality of Life in Older Patients With Stage I, Stage II, Stage III, or Stage IV Ovarian Epithelial, Primary Peritoneal Cavity, or Fallopian Tube Cancer

Conditions: Fallopian Tube Cancer; Ovarian Cancer; Primary Peritoneal Cavity Cancer
Interventions: Biological: filgrastim; Drug: carboplatin; Drug: paclitaxel; Other: pharmacological study; Other: questionnaire administration; Procedure: assessment of therapy complications; Procedure: quality-of-life assessment
Sponsors: National Cancer Institute (NCI); Gynecologic Oncology Group
Recruiting - verified May 2012
Lenalidomide + Plerixafor in Previously Treated Chronic Lymphocytic Leukemia (CLL)

Condition: Leukemia, Lymphocytic, Chronic, B-Cell
Intervention: Drug: Lenalidomide + Plerixafor (+ Rituximab)
Sponsors: Duke University; Duke University; Celgene Corporation; Genzyme
Recruiting - verified January 2012
A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)

Conditions: Crohn's Disease; IBD; Colitis; Inflammatory Bowel Disease
Interventions: Drug: Group 2 ustekinumab 130 mg; Drug: Group 3: ustekinumab approximately 6 mg/kg; Drug: Group 1: Placebo
Sponsors: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Recruiting - verified April 2012
Levofloxacin in Preventing Infection in Young Patients Receiving Chemotherapy For Acute Leukemia or Undergoing Stem Cell Transplantation

Conditions: Bacterial Infection; Leukemia; Musculoskeletal Complications; Neutropenia
Interventions: Drug: levofloxacin; Procedure: standard follow-up care
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
A Double-blind Study Evaluating IPI-504 and Docetaxel in Patients With Non-Small Cell Lung Cancer

Condition: Non Small Cell Lung Cancer
Interventions: Drug: IPI 504 plus Docetaxel; Drug: Placebo plus Docetaxel
Sponsors: Infinity Pharmaceuticals, Inc.; Infinity Pharmaceuticals, Inc.
Recruiting - verified February 2012
National Marrow Donor Program Long-Term Donor Follow-Up

Condition: Hematologic Neoplasms
Intervention:
Sponsors: Center for International Blood and Marrow Transplant Research; Center for International Blood and Marrow Transplant Research; National Marrow Donor Program
Recruiting - verified June 2011
Gemcitabine and ON 01910.Na in Previously Untreated Metastatic Pancreatic Cancer

Condition: Metastatic Pancreatic Adenocarcinoma
Interventions: Drug: ON 01910.Na; Drug: Gemcitabine; Drug: Gemcitabine
Sponsors: Onconova Therapeutics, Inc.; Onconova Therapeutics, Inc.; Academic Oncology Gastrointestinal Cancer Consortium (AGICC)
Recruiting - verified March 2012
A Study of Pertuzumab in Addition to Chemotherapy and Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With HER2-Positive Primary Breast Cancer

Condition: Breast Cancer
Interventions: Drug: pertuzumab; Drug: placebo; Drug: trastuzumab [Herceptin]; Drug: Chemotherapy
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche; Breast International Group; Genentech
Recruiting - verified February 2012
An Open-label Study of GSK1120212 Compared With Docetaxel in Stage IV KRAS-mutant Non-small Cell Lung Cancer

Condition: Lung Cancer, Non-Small Cell
Interventions: Drug: GSK1120212; Drug: docetaxel
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified May 2012
Neoadjuvant Pazopanib in Renal Cell Carcinoma

Condition: Renal Cell Carcinoma
Intervention: Drug: Pazopanib
Sponsors: UNC Lineberger Comprehensive Cancer Center; UNC Lineberger Comprehensive Cancer Center; GlaxoSmithKline
Recruiting - verified April 2012
E7050 in Combination With Cisplatin and Capecitabine Versus Cisplatin and Capecitabine Alone in Patients With Advanced or Metastatic Solid Tumors and Previously Untreated Gastric Cancer

Conditions: Advanced or Metastatic Solid Tumors; Previously Untreated Gastric Cancer
Interventions: Drug: E7050; Drug: cisplatin; Drug: capecitabine
Sponsors: Eisai Inc.; Eisai Inc.; PharmaBio Development Inc.
Recruiting - verified April 2012
Zarnestra in Newly Diagnosed Acute Myelogenous Leukemia (AML)With 2 Gene Expression Signature Ratio

Condition: Acute Myelogenous Leukemia
Intervention: Drug: R115777
Sponsors: H. Lee Moffitt Cancer Center and Research Institute; H. Lee Moffitt Cancer Center and Research Institute; National Cancer Institute (NCI)
Recruiting - verified April 2012
Phase III Study of the Effect of GTx-024 on Muscle Wasting in Patients With Non-Small Cell Lung Cancer (NSCLC)

Conditions: Muscle Wasting; Non Small Cell Lung Cancer
Interventions: Drug: GTx-024; Drug: placebo
Sponsors: GTx; GTx; Harrison Clinical Research
Recruiting - verified May 2012
Effect of GTx-024 on Muscle Wasting in Patients With Non-Small Cell Lung Cancer (NSCLC) on First Line Platinum

Conditions: Muscle Wasting; Non-Small Cell Lung Cancer
Interventions: Drug: GTx-024; Drug: placebo
Sponsors: GTx; GTx; Harrison Clinical Research
Recruiting - verified May 2012
Phase I Biomarker Study (BMS-936558)

Condition: Renal Cell Carcinoma
Interventions: Drug: BMS-936558 (Anti-PD-1); Drug: BMS-936558 (Anti-PD-1); Drug: BMS-936558 (Anti-PD-1)
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb; Ono Pharma
Recruiting - verified February 2012
PET-Directed Therapy in Treating Patients With Limited-Stage Diffuse Large B-Cell Lymphoma

Condition: Lymphoma
Interventions: Biological: rituximab; Drug: cyclophosphamide; Drug: doxorubicin hydrochloride; Drug: prednisone; Drug: vincristine sulfate; Other: R-CHOP regimen; Other: laboratory biomarker analysis; Radiation: fludeoxyglucose F 18; Radiation: selective external radiation therapy; Radiation: yttrium Y 90 ibritumomab tiuxetan
Sponsors: National Cancer Institute (NCI); Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)

Conditions: Hematological Malignancies; Certain Lysosomal Storage and Peroxisomal Enzyme Deficiency Disorders; Hurler Syndrome (MPS I); Krabbe Disease (Globoid Leukodystrophy); X-linked Adrenoleukodystrophy; Primary Immunodeficiency Diseases; Bone Marrow Failure; Beta-thalassemia
Intervention: Drug: A multicenter access and distribution protocol for unlicensed cryopreserved cord blood units (CBUs)
Sponsors: Center for International Blood and Marrow Transplant Research; Center for International Blood and Marrow Transplant Research; National Marrow Donor Program
Recruiting - verified April 2012
Higher-Dose Radiation Therapy or Standard Radiation Therapy in Treating Patients With Early-Stage Breast Cancer That Was Removed by Surgery

Condition: Breast Cancer
Interventions: Radiation: 3-dimensional conformal radiation therapy; Radiation: accelerated radiation therapy; Radiation: hypofractionated radiation therapy; Radiation: intensity-modulated radiation therapy; Radiation: whole breast irradiation
Sponsors: National Cancer Institute (NCI); Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Study to Assess the Safety, Tolerability, and Pharmacokinetics of AMP-224 in Patients With Advanced Cancer

Condition: Cancer
Interventions: Drug: AMP-224; Drug: AMP-224
Sponsors: Amplimmune; Amplimmune; GlaxoSmithKline
Recruiting - verified May 2012
Molecular Guided Therapy for Refractory or Recurrent Neuroblastoma

Condition: Neuroblastoma
Intervention: Device: Guided Therapy
Sponsors: Van Andel Research Institute; Giselle Sholler
Recruiting - verified April 2012
Study of Ganetespib (STA-9090) + Docetaxel in Advanced Non Small Cell Lung Cancer

Conditions: Non-small Cell Lung Cancer Stage IIIB; Non-small Cell Lung Cancer Stage IV; Non-small Cell Lung Cancer Metastatic
Interventions: Drug: Docetaxel; Drug: Combination of ganetespib and docetaxel
Sponsors: Synta Pharmaceuticals Corp.; Synta Pharmaceuticals Corp.
Recruiting - verified November 2011
BMS-936558 (MDX-1106) In Subjects With Advanced/Metastatic Clear-Cell Renal Cell Carcinoma (RCC)

Condition: Renal Cell Carcinoma
Interventions: Biological: BMS-936558; Biological: BMS-936558; Biological: BMS-936558
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb; Ono Pharma
Recruiting - verified February 2012
Acupressure in Controlling Nausea in Young Patients With Central Nervous System or Solid Tumors Receiving Cisplatin-Containing Chemotherapy

Conditions: Brain and Central Nervous System Tumors; Nausea and Vomiting; Unspecified Childhood Solid Tumor, Protocol Specific
Interventions: Procedure: acupressure therapy; Procedure: sham intervention
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified October 2011
DN24-02 as Adjuvant Therapy in Subjects With High Risk HER2+ Urothelial Carcinoma

Condition: Urothelial Carcinoma
Interventions: Biological: DN24-02; Other: Standard of Care
Sponsors: Dendreon; Dendreon
Recruiting - verified May 2012
Carboplatin, Pemetrexed Disodium, and Bevacizumab in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer Who Are Light or Never Smokers

Condition: Lung Cancer
Interventions: Biological: bevacizumab; Drug: carboplatin; Drug: erlotinib hydrochloride; Drug: pemetrexed disodium
Sponsors: UNC Lineberger Comprehensive Cancer Center; UNC Lineberger Comprehensive Cancer Center; National Cancer Institute (NCI)
Recruiting - verified February 2012
Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma

Conditions: Cancer; Hematologic Malignancies; Multiple Myeloma; Oncology; Bone Metastases; Multiple Myeloma Bone Lesions
Interventions: Drug: Denosumab; Drug: Zoledronic acid
Sponsors: Amgen; Amgen; Daiichi Sankyo Inc.
Recruiting - verified May 2012
A Pilot Study of Tumor-Derived Exosomes as Diagnostic and Prognostic Markers in Breast Cancer Patients Receiving Neoadjuvant Chemotherapy

Condition: Breast Neoplasms
Intervention:
Sponsors: Leo W. Jenkins Cancer Center; Leo W. Jenkins Cancer Center
Recruiting - verified January 2012
Alvocidib, Cytarabine, and Mitoxantrone Hydrochloride or Cytarabine and Daunorubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia

Condition: Leukemia
Interventions: Drug: alvocidib; Drug: cytarabine; Drug: daunorubicin hydrochloride; Drug: idarubicin; Drug: mitoxantrone hydrochloride
Sponsors: National Cancer Institute (NCI); Sidney Kimmel Comprehensive Cancer Center; National Cancer Institute (NCI)
Recruiting - verified May 2012
MaxAn Post Market Surveillance Validation

Conditions: DDD; Deformity; Tumor; Fracture
Intervention:
Sponsors: Biomet, Inc.; Biomet, Inc.
Recruiting - verified February 2012
A Study of Trabectedin or Dacarbazine for the Treatment of Patients With Advanced Liposarcoma or Leiomyosarcoma

Condition: Advanced Liposarcoma or Leiomyosarcoma
Interventions: Drug: Trabectedin; Drug: Dacarbazine
Sponsors: Janssen Research & Development, LLC; Janssen Research & Development, LLC; Pharma Mar, S.A.U.
Recruiting - verified May 2012
Surgery With or Without Internal Radiation Therapy Compared With Stereotactic Body Radiation Therapy in Treating Patients With High-Risk Stage I Non-Small Cell Lung Cancer

Condition: Lung Cancer
Interventions: Procedure: therapeutic conventional surgery; Radiation: iodine I 125; Radiation: stereotactic body radiation therapy
Sponsors: National Cancer Institute (NCI); American College of Surgeons; National Cancer Institute (NCI)
Recruiting - verified May 2012
ARCHER 1009 : A Study Of PF-00299804 (Dacomitinib) Vs. Erlotinib In The Treatment Of Advanced Non-Small Cell Lung Cancer

Condition: Non-Small Cell Lung Cancer (NSCLC)
Interventions: Drug: Dacomitinib (PF-00299804); Drug: Active Comparator (erlotinib)
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2012
Long Term Safety of Sativex® Oromucosal Spray (Sativex®; Nabiximols) as Adjunctive Therapy in Patients With Uncontrolled Persistent Chronic Cancer Related Pain

Conditions: Pain; Advanced Cancer
Intervention: Drug: Sativex®
Sponsors: GW Pharmaceuticals Ltd.; GW Pharmaceuticals Ltd.; Otsuka Pharmaceutical Development & Commercialization, Inc.
Recruiting - verified April 2011
An Efficacy and Safety Study of Oral Netupitant and Palonosetron for the Prevention of Nausea and Vomiting

Condition: Chemotherapy-Induced Nausea and Vomiting
Interventions: Drug: Netupitant and Palonosetron; Drug: Palonosetron
Sponsors: Helsinn Healthcare SA; Helsinn Healthcare SA; Parexel
Recruiting - verified December 2011
Reduced Intensity Conditioning Versus Myeloablative Conditioning for Acute Myeloid Leukemia or Myelodysplastic Syndrome (BMT CTN 0901)

Condition: Leukemia, Myelocytic, Acute
Interventions: Drug: Fludarabine and Busulfan (Flu/Bu); Drug: Fludarabine and Melphalan (Flu/Mel); Drug: Busulfan and Fludarabine (Bu/Flu); Drug: Busulfan and Cyclophosphamide (Bu/Cy); Drug: Cyclophosphamide and Total Body Irradiation (Cy/TBI)
Sponsors: National Heart, Lung, and Blood Institute (NHLBI); National Heart, Lung, and Blood Institute (NHLBI); National Cancer Institute (NCI); Blood and Marrow Transplant Clinical Trials Network
Recruiting - verified March 2012
Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma

Condition: Multiple Myeloma
Interventions: Drug: Lenalidomide; Drug: Dexamethasone; Drug: Dexamethasone; Drug: Dexamethasone; Drug: Dexamethasone; Biological: Elotuzumab (BMS-901608; HuLuc63); Biological: Elotuzumab (BMS-901608; HuLuc63)
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb; Abbott Biotherapeutics Corp.
Recruiting - verified October 2011
PET Scan Imaging in Assessing Response in Patients With Esophageal Cancer Receiving Combination Chemotherapy

Conditions: Adenocarcinoma of the Gastroesophageal Junction; Esophageal Cancer
Interventions: Drug: FOLFOX regimen; Drug: carboplatin; Drug: fluorouracil; Drug: leucovorin calcium; Drug: oxaliplatin; Drug: paclitaxel
Sponsors: National Cancer Institute (NCI); Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified April 2012
Exercise and Metformin in Colorectal Cancer Survivors

Condition: Colorectal Cancer
Interventions: Behavioral: Exercise training; Drug: Exercise training plus metformin; Drug: Metformin; Other: Educational information
Sponsors: Dana-Farber Cancer Institute; Dana-Farber Cancer Institute
Recruiting - verified February 2012
Study in Patients With Untreated Multiple Myeloma and Renal Insufficiency

Conditions: Multiple Myeloma; Renal Insufficiency
Interventions: Drug: BHQ880; Drug: BHQ990
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified May 2012
Biological Therapy, Sargramostim, and Isotretinoin in Treating Patients With Relapsed or Refractory Neuroblastoma

Condition: Neuroblastoma
Interventions: Biological: hu14.18-IL2 fusion protein; Biological: sargramostim; Drug: isotretinoin; Other: laboratory biomarker analysis
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
A Study of ALT-801 in Combination With Cisplatin and Gemcitabine in Muscle Invasive or Metastatic Urothelial Cancer

Conditions: Transitional Cell Carcinoma of Bladder; Urethra Cancer; Ureter Cancer; Malignant Tumor of Renal Pelvis
Interventions: Drug: Cisplatin; Drug: Gemcitabine; Biological: ALT-801
Sponsors: Altor Bioscience Corporation; Altor Bioscience Corporation; National Cancer Institute (NCI)
Recruiting - verified February 2012
A Study of RO5083945 in Combination With FOLFIRI Versus FOLFIRI Plus Cetuximab or FOLFIRI Alone as Second Line Treatment in Patients With Metastatic Colorectal Cancer

Condition: Colorectal Cancer
Interventions: Drug: RO5083945; Drug: FOLFIRI; Drug: cetuximab
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified May 2012
A Phase 3 Efficacy Study of a Recombinant Vaccinia Virus Vaccine to Treat Metastatic Prostate Cancer

Condition: Prostate Cancer Metastatic
Interventions: Biological: PROSTVAC-V/F-TRICOM + GM-CSF; Biological: PROSTVAC-V/F-TRICOM + GM-CSF placebo; Biological: Placebo
Sponsors: BN ImmunoTherapeutics; BN ImmunoTherapeutics
Recruiting - verified January 2012
A Study Of Panobinostat In Children With Refractory Hematologic Malignancies

Conditions: Lymphoblastic Leukemia, Acute, Childhood; Myelogenous Leukemia, Acute, Childhood; Hodgkin's Disease; Non-Hodgkin's Lymphoma
Interventions: Drug: Panobinostat; Drug: Cytarabine; Drug: Panobinostat
Sponsors: Therapeutic Advances in Childhood Leukemia Consortium; Therapeutic Advances in Childhood Leukemia Consortium; Novartis
Recruiting - verified November 2011
A Study in Cancer Patients to Evaluate the Effect of Lapatinib on the QTc Interval

Condition: Cancer
Interventions: Drug: lapatinib; Drug: placebo matching lapatinib
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified February 2012
A Study of ALT-836 in Combination With Gemcitabine for Locally Advanced or Metastatic Solid Tumors

Conditions: Locally Advanced Malignant Neoplasm; Malignant Solid Tumour
Intervention: Biological: ALT-836 in combination with gemcitabine
Sponsors: Altor Bioscience Corporation; Altor Bioscience Corporation
Recruiting - verified September 2011
Bavituximab Plus Carbo and Pemetrexed in Chemo-Naive Stage IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC) Subjects

Condition: Non Small Cell Lung Cancer (NSCLC)
Intervention: Drug: Bavituximab
Sponsors: UNC Lineberger Comprehensive Cancer Center; UNC Lineberger Comprehensive Cancer Center; Peregrine Pharmaceuticals
Recruiting - verified April 2012
IMAAGEN: Impact of Abiraterone Acetate in Prostate-Specific Antigen

Conditions: Prostate Cancer; Prostatic Neoplasm
Intervention: Drug: abiraterone acetate in combination with prednisone
Sponsors: Janssen Biotech, Inc.; Janssen Biotech, Inc.
Recruiting - verified May 2012
Abiraterone Acetate in Treating Patients With Prostate Cancer Who Have Undergone Initial Hormone Therapy

Condition: Prostate Cancer
Interventions: Drug: abiraterone acetate; Drug: degarelix; Drug: goserelin acetate; Drug: leuprolide acetate; Procedure: orchiectomy
Sponsors: National Cancer Institute (NCI); Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified February 2012
Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer

Condition: Prostate Cancer
Interventions: Drug: Cabazitaxel (XRP6258); Drug: Docetaxel (XRP6976); Drug: Prednisone
Sponsors: Sanofi-Aventis; Sanofi-Aventis
Recruiting - verified April 2012
Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer

Condition: Prostate Cancer
Interventions: Drug: Cabazitaxel (XRP6258); Drug: Prednisone
Sponsors: Sanofi-Aventis; Sanofi-Aventis
Recruiting - verified May 2012
A Registry of Sipuleucel-T Therapy in Men With Advanced Prostate Cancer

Conditions: Advanced Prostate Cancer; Prostatic Neoplasms
Intervention: Biological: sipuleucel-T
Sponsors: Dendreon; Dendreon
Recruiting - verified March 2012
A Study Of Everolimus, Trastuzumab And Vinorelbine In HER2-Positive Breast Cancer Brain Metastases

Condition: HER-2 Positive Breast Cancer
Interventions: Drug: Everolimus; Drug: Vinorelbine; Drug: Trastuzumab
Sponsors: UNC Lineberger Comprehensive Cancer Center; UNC Lineberger Comprehensive Cancer Center; Novartis Pharmaceuticals
Recruiting - verified April 2012
Bevacizumab With or Without Fosbretabulin Tromethamine in Patients With Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cavity Cancer

Conditions: Fallopian Tube Cancer; Ovarian Cancer; Primary Peritoneal Cavity Cancer
Interventions: Biological: bevacizumab; Drug: fosbretabulin tromethamine
Sponsors: National Cancer Institute (NCI); Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
A Safety and Efficacy Study of Patients With Metastatic or Locally Advanced (Unresectable) Chondrosarcoma

Condition: Conventional Chondrosarcoma
Interventions: Drug: IPI-926; Drug: Placebo Arm
Sponsors: Infinity Pharmaceuticals, Inc.; Infinity Pharmaceuticals, Inc.
Recruiting - verified May 2012
Radiation Therapy With Cisplatin or Cetuximab in Treating Patients With Oropharyngeal Cancer

Conditions: Head and Neck Cancer; Precancerous Condition
Interventions: Biological: cetuximab; Drug: cisplatin
Sponsors: National Cancer Institute (NCI); Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Caspofungin Acetate or Fluconazole in Preventing Invasive Fungal Infections in Patients With Acute Myeloid Leukemia Who Are Undergoing Chemotherapy

Conditions: Fungal Infection; Leukemia; Neutropenia
Interventions: Drug: caspofungin acetate; Drug: fluconazole
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Study of BKM120 or BEZ235 and Capecitabine in Patients With Metastatic Breast Cancer

Condition: Metastatic Breast Cancer
Interventions: Drug: BMK120; Drug: Capecitabine; Drug: BEZ235
Sponsors: UNC Lineberger Comprehensive Cancer Center; UNC Lineberger Comprehensive Cancer Center; Novartis Pharmaceuticals
Recruiting - verified April 2012
Study of the P16 Gene as a Predictor of Myelosuppression in Breast Cancer Patients

Condition: Breast Cancer
Intervention:
Sponsors: UNC Lineberger Comprehensive Cancer Center; UNC Lineberger Comprehensive Cancer Center
Recruiting - verified April 2012
Regorafenib+FOLFIRI Versus Placebo+FOLFIRI as 2nd Line Tx in K-RAS/BRAF Mutant Metastatic Colorectal Cancer

Condition: Colorectal Cancer Metastatic
Interventions: Drug: Regorafenib (BAY 73-4506); Drug: FOLFIRI; Drug: Placebo; Drug: FOLFIRI
Sponsors: UNC Lineberger Comprehensive Cancer Center; UNC Lineberger Comprehensive Cancer Center; Bayer
Recruiting - verified April 2012
A Study of VGX-3100 DNA Vaccine With Electroporation in Patients With Cervical Intraepithelial Neoplasia Grade 2/3 or 3

Condition: Cervical Intraepithelial Neoplasia
Interventions: Biological: VGX 3100; Biological: Placebo
Sponsors: Inovio Pharmaceuticals; Inovio Pharmaceuticals
Recruiting - verified May 2012
Low-Dose Naltrexone for Glioma Patients

Condition: Malignant Glioma
Interventions: Drug: Naltrexone; Other: Placebo
Sponsors: Duke University; Duke University; Brain Tumor Fund for the Carolinas
Recruiting - verified March 2012
Safety and Efficacy of BKM120 in Patients With Metastatic Non-small Cell Lung Cancer

Condition: Non-small Cell Lung Cancer
Interventions: Drug: BKM120 or Docetaxel; Drug: BKM120 or Docetaxel or Pemetrexed
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified May 2012
A Study of Oral Sapacitabine in Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia

Condition: Acute Myeloid Leukemia
Interventions: Drug: Sapacitabine and decitabine; Drug: Decitabine
Sponsors: Cyclacel Pharmaceuticals, Inc.; Cyclacel Pharmaceuticals, Inc.
Recruiting - verified November 2011
A Study to Investigate the Safety and Efficacy of AT13387, Alone or in Combination With Imatinib, in Patients With GIST

Condition: Gastrointestinal Stromal Tumor (GIST)
Intervention: Drug: AT13387 and Imatinib
Sponsors: Astex Pharmaceuticals; Astex Pharmaceuticals
Recruiting - verified March 2012
Hormone Therapy Or Chemotherapy Before Surgery Based on Gene Expression Analysis in Treating Patients With Breast Cancer

Conditions: Ductal Breast Carcinoma in Situ; Lobular Breast Carcinoma in Situ; Stage II Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer
Interventions: Procedure: neoadjuvant therapy; Procedure: therapeutic conventional surgery; Other: laboratory biomarker analysis; Other: enzyme-linked immunosorbent assay; Genetic: gene expression analysis; Drug: systemic chemotherapy; Drug: tamoxifen citrate; Drug: aromatase inhibition therapy
Sponsors: Virginia Commonwealth University; Virginia Commonwealth University; National Cancer Institute (NCI)
Recruiting - verified April 2012
A Biomarker Study of Tivozanib in Subjects With Advanced Renal Cell Carcinoma

Condition: Renal Cell Carcinoma
Intervention: Drug: Tivozanib
Sponsors: AVEO Pharmaceuticals, Inc.; AVEO Pharmaceuticals, Inc.
Recruiting - verified September 2011
NP2 Enkephalin For Treatment of Intractable Cancer Pain

Conditions: Intractable Pain; Neoplasms
Interventions: Biological: NP2; Biological: Placebo
Sponsors: Diamyd Inc; Diamyd Inc; Paragon Biomedical; invivodata, Inc.
Recruiting - verified January 2012
A Study of MDV3100 Versus Bicalutamide in Castrate Men With Metastatic Prostate Cancer

Condition: Prostatic Neoplasms
Interventions: Drug: MDV3100; Drug: Bicalutamide
Sponsors: Astellas Pharma Inc; Astellas Pharma Inc; Medivation, Inc.
Recruiting - verified March 2012
Study of US-ATG-F to Prevent Chronic Graft Versus Host Disease (GVHD)

Conditions: GVHD; Adult Acute Myeloid Leukemia; Acute Lymphoid Leukemia; Myelodysplastic Syndrome
Interventions: Biological: Anti-human-T-lymphocyte Immune Globulin, Rabbit; Biological: Placebo
Sponsors: Fresenius Biotech GmbH; Fresenius Biotech GmbH; Fresenius Biotech North America
Recruiting - verified April 2012
Study of Biomarkers Associated With Fatigue in Patients With Early-Stage Breast Cancer Treated With Metformin or Placebo on NCIC-CTG-MA.32

Conditions: Breast Cancer; Depression; Fatigue; Sleep Disorders
Interventions: Drug: metformin hydrochloride; Genetic: DNA analysis; Genetic: RNA analysis; Genetic: polymerase chain reaction; Genetic: polymorphism analysis; Genetic: reverse transcriptase-polymerase chain reaction; Other: enzyme-linked immunosorbent assay; Other: laboratory biomarker analysis; Other: questionnaire administration; Procedure: quality-of-life assessment
Sponsors: National Cancer Institute (NCI); National Surgical Adjuvant Breast and Bowel Project (NSABP); National Cancer Institute (NCI)
Recruiting - verified February 2012
BKM120 as Second-line Therapy for Advanced Endometrial Cancer

Condition: Advanced Endometrial Cancer
Intervention: Drug: BKM120
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified April 2012
A Phase 1 Study of LY2787106 in Cancer and Anemia

Condition: Anemia
Intervention: Drug: LY2787106
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified April 2012
A Study to Evaluate the Efficacy of MuGard for the Amelioration of Oral Mucositis in Head and Neck Cancer Patients

Condition: Oral Mucositis
Interventions: Device: MuGard; Device: Control Rinse
Sponsors: Access Pharmaceuticals, Inc.; Access Pharmaceuticals, Inc.
Recruiting - verified April 2012
Trial in Squamous Non Small Cell Lung Cancer Subjects Comparing Ipilimumab Plus Paclitaxel and Carboplatin Versus Placebo Plus Paclitaxel and Carboplatin

Condition: Lung Cancer - Non Small Cell
Interventions: Drug: Ipilimumab; Drug: Placebo; Drug: Paclitaxel; Drug: Carboplatin
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb
Recruiting - verified April 2012
Ofatumumab and Bendamustine Followed by Maintenance Ofatumumab for Rituximab Relapsed Indolent B-cell Non-Hodgkin's Lymphoma (B-NHL)

Condition: Lymphoma, Non-Hodgkin
Interventions: Biological: Ofatumumab; Drug: Bendamustine
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified December 2011
Gulf Long-Term Follow-Up Study

Conditions: Cardiovascular Disease; Hematologic Diseases; Immunologic Disease; Cancer; Respiratory Function
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Institute of Environmental Health Sciences (NIEHS)
Recruiting - verified November 2011
A Study of Obinutuzumab (RO5072759) in Combination With CHOP Chemotherapy Versus MabThera/Rituxan (Rituximab) With CHOP in Patients With CD20-Positive Diffuse Large B-Cell Lymphoma

Condition: Lymphoma, B-Cell
Interventions: Drug: RO5072759; Drug: rituximab [MabThera/Rituxan]; Drug: CHOP chemotherapy
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified May 2012
Study of BHQ880 in Patients With High Risk Smoldering Multiple Myeloma

Condition: Smoldering Multiple Myeloma
Intervention: Drug: BHQ880
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified May 2012
Study of Pegylated Liposomal Doxorubicin and Temsirolimus in Patients With Advanced Hepatocellular Cancer

Condition: Liver Neoplasms
Intervention: Drug: Temsirolimus 25mg and Pegylated liposomal doxorubicin 25mg/m2
Sponsors: Washington University School of Medicine; Washington University School of Medicine
Recruiting - verified October 2011
Combination Chemotherapy Plus Bevacizumab With or Without Oxaliplatin in Treating Older Patients With Metastatic Colorectal Cancer

Conditions: Cognitive/Functional Effects; Colorectal Cancer; Neurotoxicity
Interventions: Biological: bevacizumab; Drug: capecitabine; Drug: fluorouracil; Drug: leucovorin calcium; Drug: oxaliplatin
Sponsors: National Cancer Institute (NCI); North Central Cancer Treatment Group; National Cancer Institute (NCI); Cancer and Leukemia Group B
Recruiting - verified February 2012
Ofatumumab and Bendamustine Hydrochloride With or Without Bortezomib in Treating Patients With Untreated Follicular Non-Hodgkin Lymphoma

Condition: Lymphoma
Interventions: Biological: ofatumumab; Drug: bendamustine hydrochloride; Drug: bortezomib
Sponsors: National Cancer Institute (NCI); Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified May 2012
Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer

Condition: Breast Cancer
Interventions: Biological: trastuzumab; Drug: cyclophosphamide; Drug: docetaxel; Drug: doxorubicin hydrochloride; Drug: paclitaxel
Sponsors: National Cancer Institute (NCI); National Surgical Adjuvant Breast and Bowel Project (NSABP); National Cancer Institute (NCI)
Recruiting - verified February 2012
A Study of ICT-107 Immunotherapy in Glioblastoma Multiforme (GBM)

Condition: Glioblastoma Multiforme
Interventions: Biological: ICT-107; Biological: Placebo DC
Sponsors: ImmunoCellular Therapeutics, Ltd.; ImmunoCellular Therapeutics, Ltd.
Recruiting - verified May 2012
A Study to Evaluate the Safety and Tolerability of MEDI-565 in Adults With Gastrointestinal Adenocarcinomas

Condition: Gastrointestinal Adenocarcinomas
Interventions: Drug: MEDI-565; Drug: MEDI-565; Drug: MEDI-565; Drug: MEDI-565
Sponsors: MedImmune LLC; MedImmune LLC
Recruiting - verified April 2012
Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer

Condition: Breast Cancer
Interventions: Drug: anastrozole; Drug: exemestane; Drug: letrozole; Drug: systemic chemotherapy; Drug: tamoxifen citrate
Sponsors: National Cancer Institute (NCI); Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified February 2012
AMG 319 Lymphoid Malignancy FIH

Conditions: Cancer; Chronic Lymphocytic Leukemia; Diffuse Large Cell Lymphoma; Hematologic Malignancies; Hematology; Leukemia; Low Grade Lymphoma; Lymphoma; Mantle Cell Lymphoma; Non-Hodgkin's Lymphoma; Oncology; Oncology Patients; T Cell Lymphoma; Tumors
Intervention: Drug: AMG 319
Sponsors: Amgen; Amgen
Recruiting - verified December 2011
Tolerability of the Combination of Lapatinib and Trastuzumab in Adults Age 60 or Older With HER2 Positive Metastatic Breast Cancer

Conditions: Breast Neoplasms; HER2 Protein, Human; Geriatric Health Services
Interventions: Drug: Lapatinib; Drug: Trastuzumab
Sponsors: City of Hope Medical Center; City of Hope Medical Center; GlaxoSmithKline; Genentech
Recruiting - verified January 2012
Trial of Gemcitabine With or Without Bavituximab in Patients With Previously Untreated Stage IV Pancreatic Cancer

Condition: Metastatic Pancreatic Cancer
Interventions: Biological: bavituximab; Drug: Gemcitabine
Sponsors: Peregrine Pharmaceuticals; Peregrine Pharmaceuticals
Recruiting - verified May 2012
Eribulin With Trastuzumab as First-line Therapy for Locally Recurrent or Metastatic HER2 Positive Breast Cancer

Condition: Breast Cancer
Intervention: Drug: Eribulin Mesylate
Sponsors: Eisai Inc.; Eisai Inc.
Recruiting - verified March 2012
Study of HCD122 (Lucatumumab) and Bendamustine Combination Therapy in CD40+ Relapsed Follicular Lymphoma

Condition: Follicular Lymphoma
Intervention: Drug: HCD122
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified March 2012
Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III or Stage IV Melanoma That Has Been Removed by Surgery

Condition: Melanoma (Skin)
Interventions: Biological: ipilimumab; Biological: recombinant interferon alfa-2b
Sponsors: National Cancer Institute (NCI); Eastern Cooperative Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
E7050 in Combination With Sorafenib Versus Sorafenib Alone as First Line Therapy in Patients With Hepatocellular Carcinoma

Condition: Hepatocellular Carcinoma
Interventions: Drug: Sorafenib; Drug: Sorafenib
Sponsors: Eisai Inc.; Eisai Inc.; PharmaBio Development Inc.
Recruiting - verified April 2012
Brivanib in Treating Patients With Persistent or Recurrent Cervical Cancer

Condition: Cervical Cancer
Interventions: Drug: brivanib alaninate; Other: laboratory biomarker analysis
Sponsors: National Cancer Institute (NCI); Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Study of ADI-PEG 20 in Patients With Relapsed Sensitive or Refractory Small Cell Lung Cancer

Condition: Small Cell Lung Cancer
Intervention: Drug: ADI-PEG 20 (Arginine deiminase pegylated)
Sponsors: Ludwig Institute for Cancer Research; Ludwig Institute for Cancer Research; Memorial Sloan-Kettering Cancer Center; Duke University; Polaris Group
Recruiting - verified April 2012
Study of ACE-011 to Determine Safe and Effective Dose of ACE-011 for the Treatment of Chemotherapy Induced Anemia in Patients With Advanced Non-small Cell Lung Cancer

Conditions: Anemia; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small-Cell Lung; Bladder Cancer; Cancer of Head and Neck; Uterine Cervical Cancer
Interventions: Drug: ACE-011 - 15 mg; Drug: ACE-011 - 30 mg; Drug: ACE-011 - 45 mg
Sponsors: Celgene Corporation; Celgene Corporation
Recruiting - verified February 2012
A Study of Carboplatin and Paclitaxel With or Without MEDI-575 in Adults With Previously Untreated, Advanced Non-Small Cell Lung Cancer

Condition: Non-small Cell Lung Cancer
Interventions: Drug: Carboplatin/Paclitaxel/MEDI-575; Drug: Carboplatin/Paclitaxel; Drug: Carboplatin/Paclitaxel/MEDI-575
Sponsors: MedImmune LLC; MedImmune LLC
Recruiting - verified May 2012
Manuka Honey in Preventing Esophagitis-Related Pain in Patients Receiving Chemotherapy and Radiation Therapy For Lung Cancer

Conditions: Dysphagia; Lung Cancer; Pain
Interventions: Drug: Manuka honey; Drug: chemotherapy; Other: questionnaire administration; Procedure: adjuvant therapy; Procedure: assessment of therapy complications; Procedure: quality-of-life assessment; Procedure: standard follow-up care; Radiation: radiation therapy
Sponsors: National Cancer Institute (NCI); Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
MK2206 in Treating Patients With Advanced Gastric or Gastroesophageal Junction Cancer

Conditions: Adenocarcinoma of the Gastroesophageal Junction; Esophageal Cancer; Gastric Cancer
Intervention: Drug: Akt inhibitor MK2206
Sponsors: National Cancer Institute (NCI); Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
A Study of Sativex® for Relieving Persistent Pain in Patients With Advanced Cancer

Condition: Pain
Interventions: Drug: Sativex®; Drug: Placebo (GA-0034)
Sponsors: GW Pharmaceuticals Ltd.; GW Pharmaceuticals Ltd.; Otsuka Pharmaceutical Development & Commercialization, Inc.
Recruiting - verified May 2011
Pazopanib In Stage IIIB/IV NSCLC Lung Cancer After Progression on First Line Therapy Containing Bevacizumab

Condition: Lung Cancer
Intervention: Drug: Pazopanib
Sponsors: UNC Lineberger Comprehensive Cancer Center; UNC Lineberger Comprehensive Cancer Center; GlaxoSmithKline
Recruiting - verified April 2012
Multi-marker Stool Test for Detection of Colorectal Neoplasia: Marker Panel Selection and Technical Development Studies

Conditions: Colorectal Neoplasms; Digestive System Diseases; Colonic Diseases; Colorectal Cancer
Intervention:
Sponsors: Exact Sciences Corporation; Exact Sciences Corporation
Recruiting - verified August 2011
Single-Arm Open-Label Multicenter Study of VB-111 in Patients With Recurrent Glioblastoma Multiforme

Condition: Relapsed Glioblastoma Multiforme
Intervention: Drug: VB-111
Sponsors: Vascular Biogenics Ltd. operating as VBL Therapeutics; Vascular Biogenics Ltd. operating as VBL Therapeutics
Recruiting - verified November 2011
A Study to Evaluate the Safety and Efficacy of Inactivated Varicella-zoster Vaccine (VZV) as a Preventative Treatment for Herpes Zoster (HZ) and HZ-related Complications in Adult Participants With Solid Tumor or Hematologic Malignancy (V212-011 AM1)

Condition: Herpes Zoster
Interventions: Biological: V212; Biological: Placebo
Sponsors: Merck; Merck
Recruiting - verified May 2012
Dasatinib Followed by Stem Cell Transplant in Treating Older Patients With Newly Diagnosed Acute Lymphoblastic Leukemia

Condition: Leukemia
Interventions: Biological: alemtuzumab; Drug: cyclophosphamide; Drug: cytarabine; Drug: dasatinib; Drug: daunorubicin hydrochloride; Drug: dexamethasone; Drug: etoposide phosphate; Drug: fludarabine phosphate; Drug: leucovorin calcium; Drug: melphalan; Drug: mercaptopurine; Drug: methotrexate; Drug: vincristine sulfate; Genetic: polymerase chain reaction; Other: laboratory biomarker analysis; Other: pharmacological study; Procedure: allogeneic hematopoietic stem cell transplantation; Procedure: autologous hematopoietic stem cell transplantation; Procedure: peripheral blood stem cell transplantation
Sponsors: National Cancer Institute (NCI); Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified April 2012
Sorafenib Tosylate and Chemotherapy in Treating Older Patients With Acute Myeloid Leukemia

Condition: Leukemia
Interventions: Drug: cytarabine; Drug: daunorubicin hydrochloride; Drug: sorafenib tosylate; Genetic: cytogenetic analysis; Genetic: mutation analysis; Other: laboratory biomarker analysis
Sponsors: National Cancer Institute (NCI); Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified September 2011
A Study of Two Subcutaneous Regimens of SGI-110, a DNA Hypomethylating Agent, in Subjects With Myelodysplastic Syndromes (MDS) or Acute Myelogenous Leukemia (AML)

Conditions: MDS; CMML; AML
Intervention: Drug: SGI-110
Sponsors: Astex Pharmaceuticals; Astex Pharmaceuticals
Recruiting - verified November 2011
Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of GSK2126458 and GSK1120212 Combination Therapy in Subjects With Advanced Solid Tumors.

Condition: Cancer
Intervention: Drug: GSK2126458 and GSK1120212
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified June 2011
Early Surgery or Standard Palliative Therapy in Treating Patients With Stage IV Breast Cancer

Condition: Breast Cancer
Interventions: Procedure: palliative surgery; Procedure: therapeutic conventional surgery; Radiation: palliative radiation therapy; Radiation: radiation therapy
Sponsors: National Cancer Institute (NCI); Eastern Cooperative Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Diet in Altering Disease Progression in Patients With Prostate Cancer on Active Surveillance

Condition: Prostate Cancer
Interventions: Behavioral: telephone-based intervention; Other: counseling intervention; Other: educational intervention; Procedure: therapeutic dietary intervention
Sponsors: National Cancer Institute (NCI); Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified February 2012
A Study of LCL161 in Combination With Weekly Paclitaxel in Adult Patients With Advanced Solid Tumors

Condition: Solid Tumors
Intervention: Drug: LCL161
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified April 2012
Colonoscopy Versus Fecal Immunochemical Testing in Reducing Mortality From Colorectal Cancer (CONFIRM)

Condition: Colorectal Cancer
Interventions: Procedure: Colonoscopy; Procedure: FIT
Sponsors: Department of Veterans Affairs; Department of Veterans Affairs
Not yet recruiting - verified April 2012
GDC-0449 in Treating Younger Patients With Recurrent or Refractory Medulloblastoma

Condition: Brain and Central Nervous System Tumors
Interventions: Drug: vismodegib; Other: laboratory biomarker analysis; Other: pharmacological study
Sponsors: National Cancer Institute (NCI); Pediatric Brain Tumor Consortium; National Cancer Institute (NCI)
Recruiting - verified April 2012
Studying First Line Treatment of Chronic Myeloid Leukemia (CML) in a Real-world Setting

Condition: Chronic Myeloid Leukemia
Intervention:
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb; ICON Clinical Research
Recruiting - verified May 2012
Yoga Therapy in Treating Patients With Malignant Brain Tumors

Conditions: Adult Anaplastic Astrocytoma; Adult Anaplastic Ependymoma; Adult Anaplastic Meningioma; Adult Anaplastic Oligodendroglioma; Adult Brain Stem Glioma; Adult Choroid Plexus Tumor; Adult Diffuse Astrocytoma; Adult Ependymoblastoma; Adult Ependymoma; Adult Giant Cell Glioblastoma; Adult Glioblastoma; Adult Gliosarcoma; Adult Grade II Meningioma; Adult Medulloblastoma; Adult Meningeal Hemangiopericytoma; Adult Mixed Glioma; Adult Oligodendroglioma; Adult Papillary Meningioma; Adult Pineal Gland Astrocytoma; Adult Pineoblastoma; Adult Pineocytoma; Adult Supratentorial Primitive Neuroectodermal Tumor (PNET); Recurrent Adult Brain Tumor
Interventions: Procedure: yoga therapy; Other: questionnaire administration; Procedure: quality-of-life assessment
Sponsors: Comprehensive Cancer Center of Wake Forest University; Comprehensive Cancer Center of Wake Forest University; National Cancer Institute (NCI)
Not yet recruiting - verified March 2012
Study of IMC-18F1 or Ramucirumab DP in Combination With Capecitabine or Capecitabine on Previously Treated Breast Cancer Patients

Condition: Breast Cancer
Interventions: Biological: Ramucirumab DP; Biological: IMC-18F1; Drug: Capecitabine
Sponsors: ImClone LLC; ImClone LLC
Recruiting - verified May 2012
PH III Relapse or Refractory MM - Open Label With or Without Elotuzumab

Condition: Multiple Myeloma
Interventions: Drug: Lenalidomide; Drug: Dexamethasone; Drug: Dexamethasone (Oral); Drug: Dexamethasone (IV); Biological: Elotuzumab (BMS-901608; HuLuc63)
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb; Abbott Biotherapeutics Corp.
Recruiting - verified May 2012
Benazepril Hydrochloride, Lisinopril, Ramipril, or Losartan Potassium in Treating Hypertension in Patients With Solid Tumors

Conditions: Hypertension; Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Drug: lisinopril; Drug: losartan potassium; Other: laboratory biomarker analysis; Drug: benazepril hydrochloride; Drug: ramipril
Sponsors: Comprehensive Cancer Center of Wake Forest University; Comprehensive Cancer Center of Wake Forest University
Recruiting - verified April 2012
A Study of Tasquinimod in Men With Metastatic Castrate Resistant Prostate Cancer

Condition: Prostate Cancer
Intervention: Drug: tasquinimod
Sponsors: Active Biotech AB; Active Biotech AB
Recruiting - verified April 2012
Combination Chemotherapy and Dasatinib in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia

Condition: Leukemia
Interventions: Drug: cytarabine; Drug: dasatinib; Drug: daunorubicin hydrochloride
Sponsors: National Cancer Institute (NCI); Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified May 2012
Combination Chemotherapy in Treating Patients With Non-Metastatic Extracranial Ewing Sarcoma

Conditions: Brain and Central Nervous System Tumors; Kidney Cancer; Sarcoma
Interventions: Drug: cyclophosphamide; Drug: doxorubicin hydrochloride; Drug: etoposide; Drug: ifosfamide; Drug: topotecan hydrochloride; Drug: vincristine sulfate
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Everolimus and Octreotide With or Without Bevacizumab in Treating Patients With Locally Advanced or Metastatic Pancreatic Neuroendocrine Tumors That Cannot Be Removed By Surgery

Conditions: Islet Cell Tumor; Pancreatic Cancer
Interventions: Biological: bevacizumab; Drug: everolimus; Drug: octreotide acetate
Sponsors: National Cancer Institute (NCI); Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified May 2012
Bendamustine + Rituximab in Older Patients With Previously Untreated Diffuse Large B-cell Lymphoma

Conditions: Diffuse Large B-Cell Lymphoma; Lymphoma, Diffuse Large-Cell; Diffuse Large-Cell Lymphoma; Lymphoma
Interventions: Drug: Bendamustine; Drug: Rituximab
Sponsors: UNC Lineberger Comprehensive Cancer Center; UNC Lineberger Comprehensive Cancer Center; Cephalon
Recruiting - verified April 2012
Vitamin D and Breast Cancer Biomarkers in Female Patients

Condition: Breast Cancer
Interventions: Dietary Supplement: vitamin D; Other: placebo
Sponsors: National Cancer Institute (NCI); Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified May 2012
Study of BMS-754807 Combined With Letrozole or BMS-754807 Alone in Patients With Hormone Receptor-Positive Breast Cancer and Resistance to Non-Steroidal Aromatase Inhibitors

Condition: Breast Cancer
Interventions: Drug: BMS-754807; Drug: letrozole
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb; Mayo Clinic
Recruiting - verified December 2011
A Study Of Inotuzumab Ozogamicin Plus Rituximab For Relapsed/Refractory Aggressive Non-Hodgkin Lymphoma Patients Who Are Not Candidates For Intensive High-Dose Chemotherapy

Conditions: Lymphoma, Non-Hodgkin; Lymphoma, B-cell; Lymphoma, B-cell, Diffuse
Interventions: Drug: Inotuzumab ozogamicin; Drug: Rituximab; Drug: rituximab + gemcitabine; Drug: rituximab +bendamustine
Sponsors: Pfizer; Pfizer; UCB, Inc.
Recruiting - verified April 2012
GAMMA - Gemcitabine and AMG 479 in Metastatic Adenocarcinoma of the Pancreas

Conditions: Adenocarcinoma of the Pancreas; Advanced Solid Tumors; Cancer; Cancer of Pancreas; Cancer of the Pancreas; Metastases; Metastatic Cancer; Metastatic Pancreatic Cancer; Pancreas Cancer; Pancreatic Cancer; Bone Metastases; Endocrine Cancer; Oncology; Oncology Patients; Solid Tumors; Advanced Malignancy
Interventions: Drug: AMG 479; Drug: Placebo; Drug: AMG 479; Drug: gemcitabine
Sponsors: Amgen; Amgen; Takeda Global Research & Development Center, Inc.
Recruiting - verified May 2012
Pilot Study Evaluating Safety & Efficacy of DCBT: NiCord® & UNM CBU to Patients With Hematological Malignancies

Conditions: Acute Lymphoblastic Leukemia (ALL); Acute Myelogenous Leukemia (AML); Myelodysplastic Syndrome (MDS); Non-Hodgkin's Lymphoma; Hodgkin's Disease
Intervention: Drug: NiCord®
Sponsors: Gamida Cell ltd; Gamida Cell ltd
Recruiting - verified May 2012
Tesetaxel as First-line Therapy for Metastatic Breast Cancer

Condition: Breast Neoplasm
Intervention: Drug: Tesetaxel
Sponsors: Genta Incorporated; Genta Incorporated
Recruiting - verified November 2011
A Study to Evaluate Pazopanib as an Adjuvant Treatment for Localized Renal Cell Carcinoma (RCC)

Conditions: Renal Cell Carcinoma; Cancer
Interventions: Drug: pazopanib; Drug: placebo
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified May 2012
Radiation Therapy With or Without Chemotherapy in Treating Patients With High-Risk Malignant Salivary Gland Tumors That Have Been Removed By Surgery

Condition: Head and Neck Cancer
Interventions: Drug: cisplatin; Radiation: 3-dimensional conformal radiation therapy; Radiation: intensity-modulated radiation therapy
Sponsors: National Cancer Institute (NCI); Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
CMR Rate of Newly Diagnosed CML-CP Patients Treated With Nilotinib

Condition: Chronic Myelogenous Leukemia in Chronic Phase
Intervention: Drug: nilotinib
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified April 2012
Study of Abiraterone Acetate in Patients With Advanced Prostate Cancer

Conditions: Prostate Neoplasms; Genital Neoplasms, Male; Urogenital Neoplasms; Genital Diseases, Male
Intervention: Drug: Abiraterone Acetate
Sponsors: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Available - verified April 2012
Evaluation of an Anti-cancer Immunotherapy Combined With Standard Neoadjuvant Treatment in Patients With WT1-positive Primary Invasive Breast Cancer

Conditions: Neoplasms, Breast; WT1-positive Primary Invasive Breast Cancer
Interventions: Biological: GSK Biologicals' recombinant WT1 Antigen-Specific Cancer Immunotherapeutic (ASCI) GSK2302024A; Biological: Placebo
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified May 2012
Temozolomide and Irinotecan Hydrochloride With or Without Bevacizumab in Treating Young Patients With Recurrent or Refractory Medulloblastoma or CNS Primitive Neuroectodermal Tumors

Condition: Brain and Central Nervous System Tumors
Interventions: Biological: bevacizumab; Drug: irinotecan hydrochloride; Drug: temozolomide
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Vinorelbine Ditartrate and Cyclophosphamide in Combination With Bevacizumab or Temsirolimus in Treating Patients With Recurrent or Refractory Rhabdomyosarcoma

Condition: Sarcoma
Interventions: Biological: bevacizumab; Drug: cyclophosphamide; Drug: temsirolimus; Drug: vinorelbine tartrate
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Phase III Trial Comparing Capecitabine in Combination With Sorafenib or Placebo in the Treatment of Locally Advanced or Metastatic HER2-Negative Breast Cancer

Condition: Breast Cancer
Interventions: Drug: Sorafenib(Nexavar, BAY43-9006) / Capecitabine; Drug: Placebo / Capecitabine
Sponsors: Bayer; Bayer; Onyx Therapeutics, Inc.
Recruiting - verified April 2012
Ixabepilone in Treating Patients With Recurrent or Persistent Leiomyosarcoma of the Uterus Previously Treated With Chemotherapy

Condition: Sarcoma
Interventions: Drug: ixabepilone; Other: laboratory biomarker analysis
Sponsors: National Cancer Institute (NCI); Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2012
A Study Combining LY2157299 With Temozolomide-based Radiochemotherapy in Patients With Newly Diagnosed Malignant Glioma

Condition: Glioma
Interventions: Drug: LY2157299; Drug: Radiation; Drug: Temozolomide
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified May 2012
A Safety and Efficacy Study of Oral MDV3100 in Chemotherapy-Naive Patients With Progressive Metastatic Prostate Cancer

Condition: Prostate Cancer
Interventions: Drug: MDV3100; Drug: Placebo
Sponsors: Medivation, Inc.; Medivation, Inc.; Astellas Pharma Inc
Recruiting - verified February 2012
Bendamustine and Rituximab Followed by 90-yttrium (Y) Ibritumomab Tiuxetan for Untreated Follicular Lymphoma

Condition: Lymphoma, Follicular
Interventions: Drug: Bendamustine; Drug: Rituximab; Radiation: Y-90 ibritumomab
Sponsors: Dartmouth-Hitchcock Medical Center; Dartmouth-Hitchcock Medical Center; Cephalon; Spectrum Pharmaceuticals, Inc
Recruiting - verified October 2011
AMG 386 in Treating Patients With Persistent or Recurrent Endometrial Cancer

Condition: Endometrial Cancer
Intervention: Biological: trebananib
Sponsors: National Cancer Institute (NCI); Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Study of Dovitinib Versus Sorafenib in Patients With Metastatic Renal Cell Carcinoma

Condition: Metastatic Renal Cell Carcinoma
Interventions: Drug: Dovitinib; Drug: Sorafenib
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified April 2012
A Study in Patients With Acute Leukemia

Condition: Leukemia
Intervention: Drug: LY2090314
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified March 2012
Randomized Trial of Lenalidomide, Bortezomib, Dexamethasone vs High-Dose Treatment With SCT in MM Patients up to Age 65

Condition: Multiple Myeloma
Interventions: Drug: Lenalidomide; Drug: Bortezomib; Drug: Dexamethasone; Procedure: Autologous Stem Cell Transplant
Sponsors: Dana-Farber Cancer Institute; Dana-Farber Cancer Institute; Celgene Corporation; Millennium Pharmaceuticals, Inc.; Massachusetts General Hospital; Beth Israel Deaconess Medical Center; Emory University; University of Michigan; Fox Chase Cancer Center; Memorial Sloan-Kettering Cancer Center; Fred Hutchinson Cancer Research Center; Barbara Ann Karmanos Cancer Institute; Duke University; University of California, San Francisco; University of Chicago; M.D. Anderson Cancer Center; UNC Lineberger Comprehensive Cancer Center
Recruiting - verified July 2011
Vorinostat and Isotretinoin in Treating Patients With High-Risk Refractory or Recurrent Neuroblastoma

Condition: Neuroblastoma
Interventions: Drug: isotretinoin; Drug: vorinostat; Other: laboratory biomarker analysis; Other: pharmacological study
Sponsors: National Cancer Institute (NCI); New Approaches to Neuroblastoma Therapy Consortium; National Cancer Institute (NCI)
Recruiting - verified August 2011
Study Of Abraxane® And Carboplatin As First-Line Treatment For Triple Negative Metastatic Breast Cancer

Condition: Metastatic Breast Cancer
Interventions: Drug: Abraxane; Drug: Carboplatin
Sponsors: Duke University; Duke University; Celgene Corporation
Recruiting - verified September 2011
Everolimus With or Without Bevacizumab in Treating Patients With Advanced Kidney Cancer That Progressed After First-Line Therapy

Condition: Kidney Cancer
Interventions: Biological: bevacizumab; Drug: everolimus; Other: placebo
Sponsors: National Cancer Institute (NCI); Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified February 2012
Radiation Therapy, Paclitaxel, and Carboplatin With or Without Trastuzumab in Treating Patients With Esophageal Cancer

Conditions: Adenocarcinoma of the Gastroesophageal Junction; Esophageal Cancer
Interventions: Biological: trastuzumab; Drug: carboplatin; Drug: paclitaxel
Sponsors: National Cancer Institute (NCI); Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Temsirolimus, Carboplatin, and Paclitaxel as First-Line Therapy in Treating Patients With Newly Diagnosed Stage III or Stage IV Clear Cell Ovarian Cancer

Condition: Ovarian Cancer
Interventions: Drug: carboplatin; Drug: paclitaxel; Drug: temsirolimus; Other: laboratory biomarker analysis
Sponsors: National Cancer Institute (NCI); Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified November 2011
Paricalcitol, Fluorouracil, and Radiation Therapy in Treating Patients With Rectal Cancer That Can Be Removed in Surgery

Conditions: Mucinous Adenocarcinoma of the Rectum; Stage IIA Rectal Cancer; Stage IIB Rectal Cancer; Stage IIC Rectal Cancer; Stage IIIB Rectal Cancer; Stage IIIC Rectal Cancer
Interventions: Drug: paricalcitol; Radiation: radiation therapy; Other: laboratory biomarker analysis; Drug: fluorouracil
Sponsors: Comprehensive Cancer Center of Wake Forest University; Comprehensive Cancer Center of Wake Forest University; National Cancer Institute (NCI)
Recruiting - verified April 2012
Treatment of Actinic Keratoses of the Face With Imiquimod 3.75% Cream Followed by Photodynamic Therapy

Condition: Actinic Keratosis
Interventions: Drug: Imiquimod/photodynamic therapy; Drug: Imiquimod only
Sponsors: Tennessee Clinical Research Center; Tennessee Clinical Research Center; Graceway Pharmaceuticals, LLC
Recruiting - verified July 2011
Study Comparing Orteronel Plus Prednisone in Patients With Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer

Condition: Prostate Cancer
Interventions: Drug: Orteronel + prednisone; Drug: Placebo + prednisone
Sponsors: Millennium Pharmaceuticals, Inc.; Millennium Pharmaceuticals, Inc.
Recruiting - verified February 2012
Study Comparing Orteronel Plus Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer

Condition: Prostate Cancer
Interventions: Drug: Orteronel + prednisone; Drug: Placebo + prednisone
Sponsors: Millennium Pharmaceuticals, Inc.; Millennium Pharmaceuticals, Inc.
Recruiting - verified February 2012
Single Agent Ofatumumab Vs. Single Agent Rituximab in Follicular Lymphoma Relapsed After Rituximab-Containing Therapy

Condition: Lymphoma, Follicular
Interventions: Biological: Ofatumumab; Biological: Rituximab
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified May 2012
Clinical Evaluation of Bioadhesive Gels for Oral Cancer Chemoprevention

Conditions: Oral Squamous Cell Carcinoma; Oral Epithelial Dysplasia
Interventions: Drug: Bioadhesive 10% freeze-dried black raspberry gel; Drug: Color/consistency matched placebo gel
Sponsors: Ohio State University; Ohio State University; University of Louisville; University of North Carolina, Chapel Hill; National Cancer Institute (NCI)
Recruiting - verified March 2012
TRINOVA-1: A Study of AMG 386 or Placebo, in Combination With Weekly Paclitaxel Chemotherapy, as Treatment for Ovarian Cancer, Primary Peritoneal Cancer and Fallopian Tube Cancer

Conditions: Fallopian Tube Cancer; Ovarian Cancer; Primary Peritoneal Cancer
Interventions: Drug: AMG 386; Drug: AMG 386 Placebo
Sponsors: Amgen; Amgen
Recruiting - verified May 2012
A Phase 1 Study of 1-MT in Combination With Docetaxel in Metastatic Solid Tumors

Condition: Solid Tumor
Interventions: Drug: docetaxel; Drug: 1-Methyl-D-trytophan
Sponsors: H. Lee Moffitt Cancer Center and Research Institute; H. Lee Moffitt Cancer Center and Research Institute; National Cancer Institute (NCI)
Recruiting - verified January 2012
Study of Vosaroxin or Placebo in Combination With Cytarabine in Patients With First Relapsed or Refractory Acute Myeloid Leukemia (AML)

Conditions: Leukemia; Acute Myeloid Leukemia; Acute Nonlymphocytic Leukemia
Interventions: Drug: vosaroxin and cytarabine; Drug: placebo and cytarabine
Sponsors: Sunesis Pharmaceuticals; Sunesis Pharmaceuticals
Recruiting - verified April 2012
Optimal Type of Aerobic Training in Breast Cancer

Condition: Breast Cancer
Interventions: Behavioral: High-Intensity Aerobic Training; Behavioral: Moderate-Intensity Aerobic Training; Behavioral: Progressive Stretching
Sponsors: Duke University; Duke University
Recruiting - verified July 2011
Stereotactic Body Radiation Therapy (SBRT) in Metastatic Non-small Cell Lung Cancer

Conditions: Non-Small-Cell Lung Carcinoma; Liver Cancer; Adrenal Cancer
Intervention: Radiation: stereotactic body radiation therapy
Sponsors: Wake Forest University; Wake Forest University
Recruiting - verified October 2011
Doxorubicin Hydrochloride or Trabectedin in Treating Patients With Previously Untreated Advanced or Metastatic Soft Tissue Sarcoma

Condition: Sarcoma
Interventions: Drug: doxorubicin hydrochloride; Drug: trabectedin; Other: laboratory biomarker analysis; Procedure: quality-of-life assessment
Sponsors: National Cancer Institute (NCI); European Organization for Research and Treatment of Cancer - EORTC; Sarcoma Alliance for Research through Collaboration
Recruiting - verified November 2011
Phase 2 Study of Maintenance OSI-906 Plus Erlotinib (Tarceva®), or Placebo Plus Erlotinib in Patients With Nonprogression Following 4 Cycles of Platinum-based Chemotherapy

Condition: Non-Small Cell Lung Cancer (NSCLC) With Nonprogression Following 4 Cycles of Platinum-based Chemotherapy
Interventions: Drug: OSI-906; Drug: erlotinib; Drug: placebo
Sponsors: Astellas Pharma Inc; Astellas Pharma Inc
Recruiting - verified April 2012
Risk-Adapted Chemotherapy in Younger Patients With Newly Diagnosed Standard-Risk Acute Lymphoblastic Leukemia

Condition: Leukemia
Interventions: Drug: cyclophosphamide; Drug: cytarabine; Drug: dexamethasone; Drug: doxorubicin hydrochloride; Drug: leucovorin calcium; Drug: mercaptopurine; Drug: methotrexate; Drug: pegaspargase; Drug: thioguanine; Drug: vincristine sulfate
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Ofatumumab in Treating Patients With Previously Untreated Stage II, Stage III, or Stage IV Follicular Non-Hodgkin Lymphoma

Condition: Lymphoma
Intervention: Biological: ofatumumab
Sponsors: National Cancer Institute (NCI); Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified April 2012
The Clinical Evaluation of Implantable Pump System For Safety And Delivery Accuracy In Patients Requiring Intrathecal Administration Of Morphine Sulfate For Chronic Pain

Conditions: Cancers; Chronic Pain
Intervention: Device: Implantation of Morphine Sulfate delivring programmable pump
Sponsors: The Alfred E. Mann Foundation for Scientific Research; The Alfred E. Mann Foundation for Scientific Research
Recruiting - verified March 2012
Gliadel, XRT, Temodar, Avastin Followed by Avastin, Temodar for Newly Diagnosed Glioblastoma Multiforme (GBM)

Conditions: Glioblastoma Multiforme; Gliosarcoma
Intervention: Drug: Gliadel, Radiation Therapy, Avastin, Temodar
Sponsors: Duke University; Duke University; Genentech; Eisai Inc.
Recruiting - verified March 2012
Safety and Efficacy Study of TRU-016 Plus Bendamustine vs. Bendamustine in Relapsed Chronic Lymphocytic Leukemia

Condition: Chronic Lymphocytic Leukemia (CLL)
Interventions: Other: TRU-016 and bendamustine; Other: TRU-016 and bendamustine; Drug: Bendamustine
Sponsors: Emergent Product Development Seattle LLC; Emergent Product Development Seattle LLC
Recruiting - verified February 2012
A Study of IMC-3G3 in Soft Tissue Sarcoma

Condition: Sarcoma, Soft Tissue
Interventions: Biological: IMC-3G3; Drug: doxorubicin; Drug: dexrazoxane
Sponsors: ImClone LLC; ImClone LLC
Recruiting - verified April 2012
Reduced Radiation in Patients With Diffuse Large B-cell Lymphoma

Condition: Diffuse Large B-cell Lymphoma
Intervention: Radiation: Radiation Therapy
Sponsors: Duke University; Duke University; department of radiation oncology
Recruiting - verified September 2011
Study Evaluating the Safety and Efficacy of Onartuzumab (Metmab) And/Or Bevacizumab in Combination With Paclitaxel in Patients With Metastatic, Triple Negative Breast Cancer

Condition: Breast Cancer
Interventions: Drug: bevacizumab; Drug: MetMAb; Drug: paclitaxel; Drug: placebo
Sponsors: Genentech; Genentech; Hoffmann-La Roche
Recruiting - verified March 2012
Changes in Performance Status and Symptom Distress in Older Patients With Advanced Ovarian Epithelial Cancer Undergoing Surgery and/or Chemotherapy

Condition: Ovarian Cancer
Interventions: Other: Palliative Performance Scale version 2 (PPSv2); Other: McCorkle Symptom Distress Scale (SDS); Other: Geriatric Assessment; Other: Medical Records Abstraction
Sponsors: UNC Lineberger Comprehensive Cancer Center; UNC Lineberger Comprehensive Cancer Center; National Cancer Institute (NCI)
Recruiting - verified April 2012
A Study in Second Line Metastatic Colorectal Cancer

Condition: Colorectal Cancer
Interventions: Biological: Ramucirumab; Drug: Irinotecan; Biological: Placebo; Drug: Folinic Acid; Drug: 5-Fluorouracil
Sponsors: Eli Lilly and Company; Eli Lilly and Company; ImClone LLC
Recruiting - verified May 2012
A Study Evaluating INIPARIB in Combination With Chemotherapy to Treat Triple Negative Breast Cancer Brain Metastasis

Conditions: Estrogen Receptor Negative (ER-Negative) Breast Cancer; Progesterone Receptor Negative (PR-Negative) Breast Cancer; Human Epidermal Growth Factor Receptor 2 Negative (HER2-Negative) Breast Cancer; Brain Metastases
Intervention: Drug: INIPARIB + irinotecan
Sponsors: Sanofi-Aventis; Sanofi-Aventis; UNC Lineberger Comprehensive Cancer Center
Recruiting - verified October 2011
Safety, Pharmacokinetic and Proof-of-Concept Study of ARN-509 in Castration-Resistant Prostate Cancer (CRPC)

Condition: Prostate Cancer
Intervention: Drug: ARN-509
Sponsors: Aragon Pharmaceuticals, Inc.; Aragon Pharmaceuticals, Inc.
Recruiting - verified March 2012
Efficacy and Safety of Decitabine as Epigenetic Priming With Induction Chemotherapy in Pediatric Acute Myelogenous Leukemia (AML) Subjects

Condition: Pediatric Acute Myelogenous Leukemia (AML)
Interventions: Drug: Decitabine; Drug: Decitabine
Sponsors: Eisai Inc.; Eisai Inc.
Recruiting - verified April 2012
Vaccine Immunotherapy for Recurrent Medulloblastoma and Primitive Neuroectodermal Tumor (PNET)

Conditions: Medulloblastoma; Neuroectodermal Tumors
Intervention: Biological: TTRNA-xALT with TTRNA-DCs
Sponsors: Duke University; Duke University
Recruiting - verified September 2011
A Study of Chemotherapy and Ramucirumab vs. Chemotherapy Alone in Second Line Non-small Cell Lung Cancer Patients Who Received Prior First Line Platinum Based Chemotherapy

Condition: Non Small Cell Lung Cancer
Interventions: Drug: Docetaxel; Biological: Ramucirumab; Drug: Placebo
Sponsors: Eli Lilly and Company; Eli Lilly and Company; ImClone LLC
Recruiting - verified May 2012
Biomarker-Guided Fluorouracil in Treating Patients With Colorectal Cancer Receiving Combination Chemotherapy

Conditions: Colorectal Cancer; Diarrhea; Neutropenia
Interventions: Drug: fluorouracil; Drug: leucovorin calcium; Drug: oxaliplatin
Sponsors: UNC Lineberger Comprehensive Cancer Center; UNC Lineberger Comprehensive Cancer Center; National Cancer Institute (NCI)
Recruiting - verified April 2012
PK Study of Oral and IV Clofarabine in High Risk Myelodysplasia+Acute Leukemias

Conditions: Myelodysplastic Syndrome; Acute Myeloid Leukemia; Acute Lymphoblastic Leukemia; Chronic Myelomonocytic Leukemia
Intervention: Drug: Clofarabine
Sponsors: UNC Lineberger Comprehensive Cancer Center; UNC Lineberger Comprehensive Cancer Center; Genzyme
Recruiting - verified November 2011
Study of Palifosfamide-tris in Combination With Doxorubicin in Patients With Front-line Metastatic Soft Tissue Sarcoma

Condition: Soft Tissue Sarcoma
Interventions: Drug: doxorubicin in combination with palifosfamide-tris; Drug: doxorubicin in combination with placebo
Sponsors: ZIOPHARM; ZIOPHARM
Recruiting - verified April 2012
Busulfan, Fludarabine Phosphate, and Anti-Thymocyte Globulin Followed By Donor Stem Cell Transplant and Azacitidine in Treating Patients With High-Risk Myelodysplastic Syndrome and Older Patients With Acute Myeloid Leukemia

Conditions: Leukemia; Myelodysplastic Syndromes
Interventions: Biological: anti-thymocyte globulin; Drug: azacitidine; Drug: busulfan; Drug: fludarabine phosphate; Drug: methotrexate; Drug: tacrolimus; Other: laboratory biomarker analysis; Other: pharmacological study; Procedure: allogeneic hematopoietic stem cell transplantation
Sponsors: National Cancer Institute (NCI); Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified May 2012
Study for Women With Platinum Resistant Ovarian Cancer Evaluating EC145 in Combination With Doxil® (PROCEED)

Condition: Ovarian Cancer
Interventions: Drug: EC145; Drug: Pegylated Liposomal Doxorubicin (PLD/Doxil®/Caelyx®); Drug: placebo; Drug: EC20
Sponsors: Endocyte; Endocyte
Recruiting - verified March 2012
Doxepin Hydrochloride in Treating Oral Mucositis Pain in Patients With Head and Neck Cancer Undergoing Radiation Therapy With or Without Chemotherapy

Conditions: Head and Neck Cancer; Mucositis; Oral Complications of Radiation Therapy; Pain
Interventions: Drug: doxepin hydrochloride; Other: placebo
Sponsors: National Cancer Institute (NCI); North Central Cancer Treatment Group; National Cancer Institute (NCI)
Recruiting - verified February 2012
MLN8237 in Treating Young Patients With Recurrent or Refractory Solid Tumors or Leukemia

Conditions: Brain and Central Nervous System Tumors; Childhood Germ Cell Tumor; Kidney Cancer; Leukemia; Liver Cancer; Neuroblastoma; Sarcoma
Interventions: Drug: alisertib; Other: laboratory biomarker analysis; Other: pharmacological study
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
A Study to Compare the Safety and Efficacy of an Aromatase Inhibitor in Combination With Lapatinib, Trastuzumab or Both for the Treatment of Hormone Receptor Positive, HER2+ Metastatic Breast Cancer

Condition: Neoplasms, Breast
Interventions: Drug: lapatinib; Drug: trastuzumab; Drug: Aromatase inhibitor; Drug: lapatinib
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified May 2012
Bioavailability and Food Effect Study of TKI258 (CSF Capsule vs. FMI Tablet) in Adult Patients With Advanced Solid Tumors

Conditions: Neoplasm; Cancer; Tumors
Intervention: Drug: TKI258
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified April 2012
Open Vs Robotic-Assisted Radical Cystectomy: A Randomized Trial

Condition: Bladder Cancer Requiring Cystectomy
Interventions: Other: Quality of Life Questionnaires; Other: Get up and Go test; Other: Hand Grip test
Sponsors: The University of Texas Health Science Center at San Antonio; The University of Texas Health Science Center at San Antonio; National Cancer Institute (NCI)
Recruiting - verified May 2012
Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Celecoxib in Treating Patients With Stage III Colon Cancer Previously Treated With Surgery

Condition: Colorectal Cancer
Interventions: Drug: celecoxib; Drug: fluorouracil; Drug: leucovorin calcium; Drug: oxaliplatin; Other: placebo
Sponsors: National Cancer Institute (NCI); Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified February 2012
RO4929097 And Exemestane in Treating Pre- and Postmenopausal Patients With Advanced or Metastatic Breast Cancer

Condition: Breast Cancer
Interventions: Drug: exemestane; Drug: gamma-secretase/Notch signalling pathway inhibitor RO4929097; Drug: goserelin acetate
Sponsors: National Cancer Institute (NCI); H. Lee Moffitt Cancer Center and Research Institute; National Cancer Institute (NCI)
Recruiting - verified June 2011
Utility of Routine Cervical Mediastinoscopy in Clinical Stage I Non-Small Cell Lung Cancer (NSCLC)

Condition: Non-small Cell Lung Cancer
Intervention:
Sponsors: Washington University School of Medicine; Jennifer Bell; University of Virginia; University of North Carolina; Emory University
Recruiting - verified October 2011
HOME Study: Hysteroscopic Office Myomectomy Evaluation

Conditions: Uterine Fibroids; Polyps
Intervention: Device: Hysteroscopic Morcellator (The MyoSure Tissue Removal Device)
Sponsors: Hologic, Inc.; Hologic, Inc.
Recruiting - verified October 2011
Incidence of Cancer in Women at Increased Genetic Risk of Ovarian Cancer

Conditions: Breast Cancer; Fallopian Tube Cancer; Ovarian Cancer; Primary Peritoneal Cavity Cancer
Interventions: Other: questionnaire administration; Procedure: evaluation of cancer risk factors; Procedure: quality-of-life assessment; Procedure: study of high risk factors
Sponsors: National Cancer Institute (NCI); Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Study of the Effect of SNPs in p53 and p53 Response Elements on the Inflammatory Response to DNA Damage

Conditions: Inflammation; Cancer; Cardiomyopathy
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Institute of Environmental Health Sciences (NIEHS)
Recruiting - verified March 2012
Study of the Effect of Innate on the Inflammatory Response to Endotoxin

Conditions: Asthma; Atherosclerosis; Metabolic Syndrome; Insulin Resistance; Cancer
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Institute of Environmental Health Sciences (NIEHS)
Recruiting - verified March 2012
Biomarkers in Blood Samples From Older Breast Cancer Survivors

Condition: Breast Cancer
Interventions: Genetic: gene expression analysis; Genetic: reverse transcriptase-polymerase chain reaction; Other: laboratory biomarker analysis; Other: medical chart review; Other: questionnaire administration
Sponsors: UNC Lineberger Comprehensive Cancer Center; UNC Lineberger Comprehensive Cancer Center; National Cancer Institute (NCI)
Recruiting - verified February 2012
Registry of Older Patients With Cancer

Conditions: Chronic Myeloproliferative Disorders; Cognitive/Functional Effects; Leukemia; Lymphoma; Lymphoproliferative Disorder; Multiple Myeloma and Plasma Cell Neoplasm; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Neoplasms; Unspecified Adult Solid Tumor, Protocol Specific
Intervention:
Sponsors: UNC Lineberger Comprehensive Cancer Center; UNC Lineberger Comprehensive Cancer Center; National Cancer Institute (NCI)
Recruiting - verified April 2012
Tissue, Blood, and Body Fluid Sample Collection From Patients With Hematologic Cancer

Conditions: Chronic Myeloproliferative Disorders; Leukemia; Lymphoma; Lymphoproliferative Disorder; Multiple Myeloma and Plasma Cell Neoplasm; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Neoplasms; Nonmalignant Neoplasm
Interventions: Other: biologic sample preservation procedure; Other: cytology specimen collection procedure
Sponsors: UNC Lineberger Comprehensive Cancer Center; UNC Lineberger Comprehensive Cancer Center; National Cancer Institute (NCI)
Recruiting - verified January 2012
Risk-Based Classification System of Patients With Newly Diagnosed Acute Lymphoblastic Leukemia

Condition: Leukemia
Interventions: Genetic: DNA ploidy analysis; Genetic: chromosomal translocation analysis; Genetic: cytogenetic analysis; Genetic: fluorescence in situ hybridization; Other: cytology specimen collection procedure; Other: flow cytometry; Other: laboratory biomarker analysis
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Specimen Collection for Agricultural Health Study Cohort Pesticide Exposure Study

Conditions: Multiple Myeloma; Leukemia; MGUS; MBL
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Recruiting - verified October 2011
Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer

Condition: Endometrial Cancer
Interventions: Drug: cediranib maleate; Other: laboratory biomarker analysis
Sponsors: National Cancer Institute (NCI); Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified November 2011
Biomarkers Related to Thrombosis in Patients With Newly Diagnosed Multiple Myeloma Receiving Chemotherapy

Conditions: Multiple Myeloma and Plasma Cell Neoplasm; Thromboembolism
Interventions: Other: enzyme-linked immunosorbent assay; Other: laboratory biomarker analysis; Other: medical chart review
Sponsors: UNC Lineberger Comprehensive Cancer Center; UNC Lineberger Comprehensive Cancer Center; National Cancer Institute (NCI)
Recruiting - verified April 2012
Interactive Cancer Communication System (ICCS) Directed Physical Activity Enhancement for Colon Cancer Survivors

Condition: Colon Cancer
Interventions: Behavioral: Survivorship CHESS; Other: Control
Sponsors: University of Wisconsin, Madison; University of Wisconsin, Madison; University of North Carolina, Chapel Hill; M.D. Anderson Cancer Center; Hartford Hospital
Recruiting - verified November 2011
Cyproheptadine in Preventing Weight Loss in Children Receiving Chemotherapy for Cancer

Conditions: Cachexia; Nausea and Vomiting; Unspecified Childhood Solid Tumor, Protocol Specific; Weight Changes
Interventions: Drug: cyproheptadine hydrochloride; Other: placebo
Sponsors: National Cancer Institute (NCI); University of South Florida; National Cancer Institute (NCI)
Recruiting - verified December 2011
Effectiveness of a Cancer Center Based Physical Activity Intervention

Conditions: Breast Cancer; Quality of Life; Physical Activity
Intervention: Behavioral: Physical activity counseling
Sponsors: East Carolina University; East Carolina University
Recruiting - verified June 2011
A Study in Subjects With Recurrent Malignant Glioma

Condition: Glioma
Interventions: Drug: E7080; Drug: E7080; Drug: E7080
Sponsors: Eisai Inc.; Eisai Inc.
Recruiting - verified April 2012
A Study of Ramucirumab (IMC-1121B) Drug Product (DP) and Best Supportive Care (BSC) Versus Placebo and BSC as 2nd-Line Treatment in Patients With Hepatocellular Carcinoma After 1st-Line Therapy With Sorafenib

Condition: Hepatocellular Carcinoma
Interventions: Biological: Placebo; Biological: Ramucirumab DP (IMC-1121B)
Sponsors: ImClone LLC; ImClone LLC
Recruiting - verified February 2012
Chemotherapy Based on Positron Emission Tomography Scan in Treating Patients With Stage I or Stage II Hodgkin Lymphoma

Condition: Lymphoma
Interventions: Biological: bleomycin sulfate; Drug: ABVD regimen; Drug: BEACOPP regimen; Drug: cyclophosphamide; Drug: dacarbazine; Drug: doxorubicin hydrochloride; Drug: etoposide; Drug: prednisone; Drug: procarbazine hydrochloride; Drug: vinblastine sulfate; Drug: vincristine sulfate; Other: laboratory biomarker analysis; Procedure: computed tomography; Radiation: fludeoxyglucose F 18; Radiation: radiation therapy
Sponsors: National Cancer Institute (NCI); Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified May 2012
Tamoxifen Citrate in Treating Patients With Metastatic or Recurrent Breast Cancer

Condition: Breast Cancer
Interventions: Drug: tamoxifen citrate; Other: laboratory biomarker analysis
Sponsors: National Cancer Institute (NCI); Eastern Cooperative Oncology Group; National Cancer Institute (NCI)
Recruiting - verified February 2012
Evaluate Safety/Tolerability Intra-Arterial Temozolomide in Patients w/Extremity Melanoma by Isolated Limb Infusion

Condition: Melanoma
Intervention: Drug: Temozolomide
Sponsors: Duke University; Duke University; Merck; M.D. Anderson Cancer Center; H. Lee Moffitt Cancer Center and Research Institute
Recruiting - verified February 2012
RO4929097 in Treating Patients With Recurrent or Progressive Glioblastoma

Condition: Brain and Central Nervous System Tumors
Interventions: Drug: gamma-secretase inhibitor RO4929097; Other: laboratory biomarker analysis; Other: pharmacological study; Procedure: adjuvant therapy; Procedure: neoadjuvant therapy; Procedure: therapeutic conventional surgery
Sponsors: Sidney Kimmel Comprehensive Cancer Center; Sidney Kimmel Comprehensive Cancer Center; National Cancer Institute (NCI)
Recruiting - verified May 2012
LUX-Breast 1: BIBW 2992 (Afatinib) in HER2-positive Metastatic Breast Cancer Patients After One Prior Herceptin Treatment

Condition: Breast Neoplasms
Interventions: Drug: BIBW 2992; Drug: trastuzumab; Drug: vinorelbine; Drug: vinorelbine
Sponsors: Boehringer Ingelheim Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals
Recruiting - verified May 2012
Everolimus in Treating Patients With Kidney Cancer Who Have Undergone Surgery

Condition: Kidney Cancer
Interventions: Drug: everolimus; Other: placebo
Sponsors: National Cancer Institute (NCI); Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified February 2012
Bicalutamide and Goserelin or Leuprolide Acetate With or Without Cixutumumab in Treating Patients With Newly Diagnosed Metastatic Prostate Cancer

Condition: Prostate Cancer
Interventions: Biological: cixutumumab; Drug: bicalutamide; Drug: goserelin acetate; Drug: leuprolide acetate
Sponsors: National Cancer Institute (NCI); Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified December 2011
A Dose Finding and Safety Study of Oral LDE225 in Children

Conditions: Medulloblastoma,; Rhabdomyosarcoma,; Neuroblastoma,; Hepatoblastoma,; High Grade Glioma,; Astrocytoma
Intervention: Drug: LDE225
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified April 2012
Safety and Efficacy of BKM120 in Combination With Trastuzumab in Patients With Relapsing HER2 Overexpressing Breast Cancer Who Have Previously Failed Trastuzumab

Conditions: Metastatic Breast Cancer; Trastuzumab; BKM120; HER2+
Intervention: Drug: BKM120
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified April 2012
A Study of Trastuzumab Emtansine (T-DM1) Plus Pertuzumab/Pertuzumab Placebo Versus Trastuzumab [Herceptin] Plus a Taxane in Patients With Metastatic Breast Cancer (MARIANNE)

Condition: Breast Cancer
Interventions: Drug: trastuzumab emtansine; Drug: pertuzumab; Drug: pertuzumab-placebo; Drug: trastuzumab [Herceptin]; Drug: docetaxel; Drug: paclitaxel
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche; Genentech
Recruiting - verified March 2012
Breast Cancer Rehabilitation Program in Improving Quality of Life in Breast Cancer Survivors

Conditions: Stage I Breast Cancer; Stage II Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer; Stage IV Breast Cancer
Interventions: Other: questionnaire administration; Behavioral: exercise intervention; Procedure: quality-of-life assessment; Other: survey administration; Procedure: management of therapy complications; Procedure: psychosocial assessment and care
Sponsors: Comprehensive Cancer Center of Wake Forest University; Comprehensive Cancer Center of Wake Forest University
Recruiting - verified April 2012
Response-Based Therapy Assessed By PET Scan in Treating Patients With Bulky Stage I and Stage II Classical Hodgkin Lymphoma

Condition: Lymphoma
Interventions: Biological: bleomycin sulfate; Drug: ABVD regimen; Drug: BEACOPP regimen; Drug: cyclophosphamide; Drug: dacarbazine; Drug: doxorubicin hydrochloride; Drug: etoposide; Drug: prednisone; Drug: procarbazine hydrochloride; Drug: vinblastine sulfate; Drug: vincristine sulfate; Other: laboratory biomarker analysis; Procedure: computed tomography; Radiation: fludeoxyglucose F 18; Radiation: radiation therapy
Sponsors: National Cancer Institute (NCI); Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified April 2012
Bevacizumab or Pemetrexed Disodium Alone or In Combination After Induction Therapy in Treating Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer

Condition: Lung Cancer
Interventions: Biological: bevacizumab; Drug: pemetrexed disodium
Sponsors: National Cancer Institute (NCI); Eastern Cooperative Oncology Group; National Cancer Institute (NCI)
Recruiting - verified February 2012
AMG 102 and Avastin for Recurrent Malignant Glioma

Conditions: Grade IV Malignant Glioma; Glioblastoma Multiforme; Gliosarcoma
Intervention: Drug: AMG 102 plus Avastin (bevacizumab)
Sponsors: Duke University; Duke University; Amgen
Recruiting - verified April 2012
Fast Spectral Imaging Device for Tumor Margin Mapping

Condition: Breast Cancer
Intervention:
Sponsors: Duke University; Duke University; National Institutes of Health (NIH); National Cancer Institute (NCI)
Recruiting - verified June 2011
Study of E7080 in Subjects With Advanced Endometrial Cancer and Disease Progression

Condition: Endometrial Cancer
Intervention: Drug: E7080
Sponsors: Eisai Inc.; Eisai Inc.
Recruiting - verified April 2012
Stem Cell Transplant With Lenalidomide Maintenance in Patients With Multiple Myeloma (BMT CTN 0702)

Condition: Multiple Myeloma
Interventions: Drug: Lenalidomide; Drug: lenalidomide, bortezomib and dexamethasone; Drug: Lenalidomide
Sponsors: National Heart, Lung, and Blood Institute (NHLBI); National Heart, Lung, and Blood Institute (NHLBI); Blood and Marrow Transplant Clinical Trials Network; National Cancer Institute (NCI)
Recruiting - verified March 2012
Panobinostat and Letrozole in Treating Patients With Metastatic Breast Cancer

Condition: Breast Cancer
Interventions: Drug: letrozole; Drug: panobinostat; Genetic: RNA analysis; Genetic: microarray analysis; Genetic: reverse transcriptase-polymerase chain reaction; Other: enzyme-linked immunosorbent assay; Other: immunohistochemistry staining method; Other: laboratory biomarker analysis
Sponsors: National Cancer Institute (NCI); North Central Cancer Treatment Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Phase II Study of Afinitor vs. Sutent in Patients With Metastatic Non-Clear Cell Renal Cell Carcinoma

Condition: Advanced Non-clear Cell Renal Cell Carcinoma
Interventions: Drug: Everolimus; Drug: Sunitinib
Sponsors: Duke University; Duke University; Novartis; Pfizer
Recruiting - verified February 2012
Comprehensive Oncology Measures for Peripheral T-cell Lymphoma Treatment Registry

Condition: Peripheral T-cell Lymphoma
Intervention:
Sponsors: Allos Therapeutics; Allos Therapeutics
Recruiting - verified December 2011
Erlotinib Hydrochloride and Isotretinoin in Treating Patients With Recurrent Malignant Glioma

Conditions: Adult Anaplastic Astrocytoma; Adult Anaplastic Oligodendroglioma; Adult Diffuse Astrocytoma; Adult Giant Cell Glioblastoma; Adult Glioblastoma; Adult Gliosarcoma; Adult Mixed Glioma; Adult Oligodendroglioma; Recurrent Adult Brain Tumor
Interventions: Drug: erlotinib hydrochloride; Drug: isotretinoin; Other: laboratory biomarker analysis; Genetic: protein expression analysis
Sponsors: Comprehensive Cancer Center of Wake Forest University; Comprehensive Cancer Center of Wake Forest University; National Cancer Institute (NCI)
Recruiting - verified March 2012
Radiation Therapy With or Without Chemotherapy in Patients With Stage I or Stage II Cervical Cancer Who Previously Underwent Surgery

Condition: Cervical Cancer
Interventions: Drug: cisplatin; Radiation: external beam radiation therapy; Radiation: intensity-modulated radiation therapy
Sponsors: National Cancer Institute (NCI); Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified February 2012
A Phase III Randomized Trial of Metformin vs Placebo in Early Stage Breast Cancer

Condition: Breast Cancer
Interventions: Drug: metformin hydrochloride; Other: placebo
Sponsors: NCIC Clinical Trials Group; NCIC Clinical Trials Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Evaluating the Safety and Tolerability of the Poly-ADP Ribose (PARP) Inhibitor With FOLFIRI in Subjects With Solid Tumor

Condition: Colorectal Cancer
Intervention: Drug: Veliparib
Sponsors: Abbott; Abbott
Recruiting - verified January 2012
Calcium Gluconate and Magnesium Sulfate in Preventing Neurotoxicity in Patients With Colon Cancer or Rectal Cancer Receiving Oxaliplatin-Based Combination Chemotherapy

Conditions: Chemotherapeutic Agent Toxicity; Colorectal Cancer; Neuropathy; Neurotoxicity
Interventions: Drug: calcium gluconate; Drug: magnesium sulfate; Other: placebo
Sponsors: National Cancer Institute (NCI); North Central Cancer Treatment Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Study of Elacytarabine Versus Investigator's Choice in Patients With Late Stage Acute Myeloid Leukaemia (AML)

Condition: Acute Myeloid Leukemia (AML)
Interventions: Drug: Elacytarabine; Drug: Investigator's Choice
Sponsors: Clavis Pharma; Clavis Pharma
Recruiting - verified April 2012
Study in Head and Neck Cancer

Condition: Head and Neck Neoplasms
Interventions: Drug: Cetuximab; Drug: Cisplatin; Drug: 5 - Fluorouracil
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified February 2012
Maintenance Chemotherapy or Observation Following Induction Chemotherapy and Radiation Therapy in Treating Younger Patients With Newly Diagnosed Ependymoma

Condition: Brain and Central Nervous System Tumors
Interventions: Drug: cisplatin; Drug: cyclophosphamide; Drug: etoposide; Drug: vincristine sulfate; Other: clinical observation; Radiation: 3-dimensional conformal radiation therapy
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
A Phase 3 Study of Brentuximab Vedotin (SGN-35) in Patients at High Risk of Residual Hodgkin Lymphoma Following Stem Cell Transplant (The AETHERA Trial)

Condition: Disease, Hodgkin
Interventions: Drug: brentuximab vedotin; Drug: placebo
Sponsors: Seattle Genetics, Inc.; Seattle Genetics, Inc.; Millennium Pharmaceuticals, Inc.
Recruiting - verified April 2012
MEK Inhibitor AZD6244 in Treating Young Patients With Recurrent or Refractory Low Grade Glioma

Condition: Brain and Central Nervous System Tumors
Intervention: Drug: AZD6244
Sponsors: Pediatric Brain Tumor Consortium; Pediatric Brain Tumor Consortium; National Cancer Institute (NCI)
Recruiting - verified March 2012
A Study for Patients With Recurrent or Metastatic Squamous Cell Head and Neck Cancer

Condition: Head and Neck Neoplasms
Interventions: Drug: Pemetrexed; Drug: Cetuximab; Drug: Carboplatin; Drug: Cisplatin
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified October 2011
Trial of Gemcitabine/Carboplatin With or Without Iniparib (SAR240550) (a PARP1 Inhibitor) in Subjects With Previously Untreated Stage IV Squamous Non-Small-Cell Lung Cancer (NSCLC)

Condition: Squamous Cell Lung Cancer
Interventions: Drug: gemcitabine/carboplatin; Drug: gemcitabine/carboplatin plus Iniparib
Sponsors: Sanofi-Aventis; Sanofi-Aventis; BiPar Sciences
Recruiting - verified March 2012
Carboplatin and Paclitaxel or Oxaliplatin and Capecitabine, With or Without Bevacizumab, as First-Line Therapy in Treating Patients With Newly Diagnosed Stage II, Stage III, Stage IV, or Recurrent Stage I Epithelial Ovarian Cancer or Fallopian Tube Cancer

Conditions: Fallopian Tube Cancer; Ovarian Cancer
Interventions: Biological: bevacizumab; Drug: capecitabine; Drug: carboplatin; Drug: oxaliplatin; Drug: paclitaxel; Procedure: quality-of-life assessment
Sponsors: University College, London; University College, London; National Cancer Institute (NCI); Gynecologic Oncology Group
Recruiting - verified December 2011
Study of XL147 (SAR245408) or XL765 (SAR245409) in Combination With Letrozole in Subjects With Breast Cancer

Condition: Breast Cancer
Interventions: Drug: XL147 (SAR245408); Drug: XL765 (SAR245409); Drug: letrozole (Femara)
Sponsors: Sanofi-Aventis; Sanofi-Aventis
Recruiting - verified April 2012
Changes in Brain Function in Patients With Stage I, Stage II, Stage III, or Stage IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Who Are Receiving Chemotherapy

Conditions: Cognitive/Functional Effects; Fallopian Tube Cancer; Ovarian Cancer; Primary Peritoneal Cavity Cancer
Interventions: Drug: systemic chemotherapy; Other: questionnaire administration; Procedure: assessment of therapy complications; Procedure: cognitive assessment; Procedure: quality-of-life assessment
Sponsors: National Cancer Institute (NCI); Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified October 2011
A Study in Head and Neck Cancer

Condition: Head and Neck Cancer
Interventions: Drug: cetuximab; Drug: Cisplatin; Drug: Carboplatin; Drug: 5-fluorouracil
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified May 2012
Pemetrexed Disodium or Observation in Treating Patients With Malignant Pleural Mesothelioma Without Progressive Disease After First-Line Chemotherapy

Condition: Malignant Mesothelioma
Interventions: Drug: pemetrexed disodium; Other: clinical observation
Sponsors: National Cancer Institute (NCI); Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified January 2012
Dose Escalation Study of Safety and Tolerability of AT-406 in Patients With Advanced Solid Tumors and Lymphomas

Conditions: Cancer; Solid Tumors; Lymphoma; Malignancy
Intervention: Drug: AT-406
Sponsors: Ascenta Therapeutics; Ascenta Therapeutics
Recruiting - verified January 2012
Connect® MM- The Multiple Myeloma Disease Registry

Condition: Multiple Myeloma
Intervention:
Sponsors: Celgene Corporation; Celgene Corporation
Recruiting - verified June 2011
PARP Inhibition for Triple Negative Breast Cancer (ER-/PR-/HER2-)With BRCA1/2 Mutations

Condition: Breast Cancer
Interventions: Drug: Cisplatin; Drug: Rucaparib; Drug: Cisplatin
Sponsors: Hoosier Oncology Group; Hoosier Oncology Group; Clovis Oncology, Inc.
Recruiting - verified March 2012
Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry

Condition: Chronic Lymphocytic Leukemia
Intervention:
Sponsors: Celgene Corporation; Celgene Corporation
Recruiting - verified March 2011
Immunotherapy Study for Surgically Resected Pancreatic Cancer

Condition: Pancreatic Cancer
Interventions: Biological: HyperAcute-Pancreas Immunotherapy; Drug: Gemcitabine; Radiation: 5FU Chemoradiation
Sponsors: NewLink Genetics Corporation; NewLink Genetics Corporation
Recruiting - verified May 2012
A Pharmacokinetic (PK) Study of Nilotinib in Pediatric Patients With Philadelphia Chromosome-positive (Ph+) Chronic Myelogenous Leukemia (CML) or Acute Lymphoblastic Leukemia (ALL)

Conditions: Chronic Myeloid Leukemia; Acute Lymphoblastic Leukemia
Intervention: Drug: Nilotinib
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified April 2012
Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML)

Condition: Acute Myeloid Leukemia
Interventions: Drug: A: Azacitidine (Vidaza); Drug: B: Conventional Care Regimen
Sponsors: Celgene Corporation; Celgene Corporation
Recruiting - verified March 2012
Study of Denosumab as Adjuvant Treatment for Women With High Risk Early Breast Cancer Receiving Neoadjuvant or Adjuvant Therapy (D-CARE)

Condition: Breast Cancer
Interventions: Drug: Placebo; Drug: Denosumab
Sponsors: Amgen; Amgen; Daiichi Sankyo Inc.
Recruiting - verified May 2012
A Trial of AMG 479, Everolimus (RAD001) and Panitumumab in Patients With Advanced Cancer

Condition: Advanced Solid Tumors
Intervention: Drug: AMG 479, Everolimus, Panitumumab
Sponsors: Duke University; Duke University; Amgen; Novartis Pharmaceuticals
Recruiting - verified December 2011
Epigenetic Modulation in Relapsed/Refractory Follicular Lymphoma and Marginal Zone Lymphoma

Conditions: Follicular Lymphoma; Marginal Zone Lymphoma
Interventions: Drug: azacitidine; Drug: lenalidomide
Sponsors: Duke University; Duke University; Celgene Corporation
Recruiting - verified June 2011
A Study of KW-2478 in Combination With Bortezomib in Subjects With Relapsed and/or Refractory Multiple Myeloma

Condition: Multiple Myeloma
Intervention: Drug: KW-2478 and bortezomib
Sponsors: Kyowa Hakko Kirin Pharma, Inc.; Kyowa Hakko Kirin Pharma, Inc.; Kyowa Hakko Kirin Company, Limited
Recruiting - verified March 2012
Phase 3 Study of Immunotherapy to Treat Advanced Prostate Cancer

Condition: Prostate Cancer
Interventions: Drug: Ipilimumab; Drug: Placebo
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb
Recruiting - verified March 2012
To Evaluate the Characteristics of a Breast Cancer

Condition: Breast Cancer
Interventions: Drug: EF5; Procedure: Partial or Total Mastectomy
Sponsors: Duke University; Duke University; National Institutes of Health (NIH); National Cancer Institute (NCI)
Not yet recruiting - verified June 2011
Radiation Therapy in Treating Patients With Extensive Stage Small Cell Lung Cancer

Condition: Lung Cancer
Interventions: Radiation: prophylactic cranial irradiation; Radiation: selective external radiation therapy
Sponsors: National Cancer Institute (NCI); Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Recruiting - verified April 2012
Cinacalcet Hydrochloride in Treating Men With Recurrent Prostate Cancer

Conditions: Adenocarcinoma of the Prostate; Recurrent Prostate Cancer
Interventions: Other: laboratory biomarker analysis; Procedure: quality-of-life assessment; Other: questionnaire administration; Drug: cinacalcet hydrochloride
Sponsors: Comprehensive Cancer Center of Wake Forest University; Comprehensive Cancer Center of Wake Forest University; National Cancer Institute (NCI)
Recruiting - verified April 2012
Transoral Robotic Surgery (TORS) for Oral and Laryngopharyngeal Lesions Using Da Vinci Robotic Surgical System

Condition: Head and Neck Neoplasms
Intervention: Device: Da Vinci Robotic Transoral Robotic Surgical System
Sponsors: Comprehensive Cancer Center of Wake Forest University; Comprehensive Cancer Center of Wake Forest University
Recruiting - verified April 2012
Safety Study for Refractory or Relapsed Neuroblastoma With DFMO Alone and in Combination With Etoposide

Condition: Neuroblastoma
Interventions: Drug: DFMO; Drug: Etoposide
Sponsors: Van Andel Research Institute; Giselle Sholler; Cancer Prevention Pharmaceuticals, Inc.; University of Arizona; University of Hawaii; University of Hawaii Cancer Research Center
Recruiting - verified April 2012
Rosuvastatin in Treating Women With Cardiovascular Complications Who Are Undergoing Chemotherapy For Breast Cancer

Conditions: Cardiovascular Complications; Recurrent Breast Cancer; Stage I Breast Cancer; Stage II Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer; Stage IV Breast Cancer
Interventions: Drug: rosuvastatin; Other: placebo; Other: survey administration; Procedure: management of therapy complications
Sponsors: Comprehensive Cancer Center of Wake Forest University; Comprehensive Cancer Center of Wake Forest University; National Cancer Institute (NCI)
Recruiting - verified April 2012
A Pilot C11-Choline PET-CT Imaging Study in Patients With Locally Advanced Esophageal Cancer

Condition: Esophageal Cancer
Intervention: Drug: C11-Choline
Sponsors: Comprehensive Cancer Center of Wake Forest University; Comprehensive Cancer Center of Wake Forest University
Recruiting - verified September 2010
Temozolomide, Cixutumumab, and Combination Chemotherapy in Treating Patients With Metastatic Rhabdomyosarcoma

Condition: Sarcoma
Interventions: Biological: cixutumumab; Biological: dactinomycin; Drug: cyclophosphamide; Drug: doxorubicin hydrochloride; Drug: etoposide; Drug: ifosfamide; Drug: irinotecan hydrochloride; Drug: temozolomide; Drug: vincristine sulfate
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Liver MRI With Primovist/Eovist in Pediatric Subjects Who Are Suspected or Have Focal Liver Lesions.

Conditions: Liver Neoplasms; Adenoma; Carcinoma; Liver Abscess
Intervention: Drug: Gadoxetic Acid Disodium (Primovist/Eovist, BAY86-4873)
Sponsors: Bayer; Bayer
Recruiting - verified May 2012
Outlook Quality of Life Intervention Study

Conditions: Cancer; Congestive Heart Failure (CHF); Chronic Obstructive Pulmonary Disease (COPD); End Stage Renal Disease (ESRD)
Interventions: Other: Life Completion; Other: Attention Control; Other: True control
Sponsors: Department of Veterans Affairs; Department of Veterans Affairs
Recruiting - verified March 2012
Paclitaxel and Carboplatin or Bleomycin Sulfate, Etoposide Phosphate, and Cisplatin in Treating Patients With Advanced or Recurrent Sex Cord-Ovarian Stromal Tumors

Condition: Ovarian Cancer
Interventions: Biological: bleomycin sulfate; Drug: carboplatin; Drug: cisplatin; Drug: etoposide phosphate; Drug: paclitaxel
Sponsors: National Cancer Institute (NCI); Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Gemcitabine Hydrochloride or Pemetrexed Disodium and Carboplatin With or Without Celecoxib in Treating Patients With Advanced Non-Small Cell Lung Cancer

Condition: Lung Cancer
Interventions: Drug: carboplatin; Drug: celecoxib; Drug: gemcitabine hydrochloride; Drug: pemetrexed disodium; Other: placebo
Sponsors: National Cancer Institute (NCI); Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified February 2012
Phase 2A Study of NPC-1C Chimeric Monoclonal Antibody to Treat Pancreatic and Colorectal Cancer

Conditions: Metastatic Pancreatic Cancer; Metastatic Colorectal Cancer
Intervention: Drug: NPC-1C
Sponsors: Neogenix Oncology, Inc.; Neogenix Oncology, Inc.
Recruiting - verified January 2012
Monoclonal Antibody Ch14.18, Sargramostim, Aldesleukin, and Isotretinoin After Autologous Stem Cell Transplant in Treating Patients With Neuroblastoma

Condition: Neuroblastoma
Interventions: Biological: aldesleukin; Biological: monoclonal antibody Ch14.18; Biological: sargramostim; Drug: isotretinoin; Other: laboratory biomarker analysis
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified April 2011
Clofarabine or Daunorubicin Hydrochloride and Cytarabine Followed By Decitabine or Observation in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia

Condition: Leukemia
Interventions: Drug: clofarabine; Drug: cytarabine; Drug: daunorubicin hydrochloride; Drug: decitabine; Other: clinical observation
Sponsors: National Cancer Institute (NCI); Eastern Cooperative Oncology Group; National Cancer Institute (NCI)
Recruiting - verified January 2012
Aspirin in Reducing Events in the Elderly

Conditions: Functional Disability; Dementia; Heart Disease; Stroke; Cancer; Bleeding
Interventions: Drug: 100 mg enteric-coated aspirin; Drug: Placebo
Sponsors: Minneapolis Medical Research Foundation; Minneapolis Medical Research Foundation; National Health and Medical Research Council, Australia; Bayer; Monash University; Berman Center for Outcomes and Clinical Research
Recruiting - verified July 2011
Study to Evaluate Safety, Tolerability, Maximum Tolerated Dose (MTD), Efficacy, and Pharmacokinetics (PKs) of CPI-613 Given Twice Weekly for Three Consecutive Weeks in Patients With Advanced Hematologic Malignancies

Condition: Advanced Hematologic Malignancies
Intervention: Drug: CPI-613
Sponsors: Comprehensive Cancer Center of Wake Forest University; Comprehensive Cancer Center of Wake Forest University
Recruiting - verified April 2012
Ofatumumab Maintenance Treatment vs No Further Treatment in Relapsed CLL Responding to Induction Therapy

Condition: Leukaemia, Lymphocytic, Chronic
Interventions: Biological: Ofatumumab; Other: No Intervention
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified May 2012
A Study of Elacytarabine (CP-4055) Plus Idarubicin as Second Course Remission-Induction Therapy in Patients With Acute Myeloid Leukaemia

Condition: Acute Myeloid Leukemia
Intervention: Drug: Elacytarabine plus idarubicin
Sponsors: Clavis Pharma; Clavis Pharma; Theradex; INC Research Limited
Recruiting - verified February 2012
Global Study Looking at the Combination of RAD001 Plus Best Supportive Care (BSC) and Placebo Plus BSC to Treat Patients With Advanced Hepatocellular Carcinoma.

Condition: Carcinoma
Intervention: Drug: Everolimus
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified March 2012
Frailty Index and Geriatric Assessment in Predicting Toxicity to Front-Line Chemotherapy in Treating Patients With Stage IV Non-Small Cell Lung Cancer

Conditions: Recurrent Non-small Cell Lung Cancer; Stage IV Non-small Cell Lung Cancer
Interventions: Drug: cisplatin; Drug: carboplatin; Other: questionnaire administration
Sponsors: Comprehensive Cancer Center of Wake Forest University; Comprehensive Cancer Center of Wake Forest University; National Cancer Institute (NCI)
Recruiting - verified April 2012
Ofatumumab, Pentostatin, and Cyclophosphamide in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Conditions: Hematopoietic/Lymphoid Cancer; B-cell Chronic Lymphocytic Leukemia; Contiguous Stage II Small Lymphocytic Lymphoma; Noncontiguous Stage II Small Lymphocytic Lymphoma; Stage 0 Chronic Lymphocytic Leukemia; Stage I Chronic Lymphocytic Leukemia; Stage I Small Lymphocytic Lymphoma; Stage II Chronic Lymphocytic Leukemia; Stage III Chronic Lymphocytic Leukemia; Stage III Small Lymphocytic Lymphoma; Stage IV Chronic Lymphocytic Leukemia; Stage IV Small Lymphocytic Lymphoma
Interventions: Drug: pentostatin; Drug: cyclophosphamide; Biological: ofatumumab; Procedure: laboratory biomarker analysis; Other: flow cytometry; Genetic: protein expression analysis
Sponsors: Mayo Clinic; Mayo Clinic
Recruiting - verified April 2012
A Study of AMNN107 in the Treatment of Metastatic and/or Inoperable Melanoma Harboring a c-Kit Mutation

Condition: Melanoma
Intervention: Drug: nilotinib (AMN107)
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified May 2012
Panobinostat or Placebo With Bortezomib and Dexamethasone in Patients With Relapsed Multiple Myeloma

Condition: Multiple Myeloma
Interventions: Drug: Panobinostat; Drug: Bortezomib
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified April 2012
Seneca Valley Virus-001 After Chemotherapy in Treating Patients With Extensive-Stage Small Cell Lung Cancer

Condition: Lung Cancer
Interventions: Biological: Seneca Valley virus-001; Other: placebo
Sponsors: National Cancer Institute (NCI); North Central Cancer Treatment Group; National Cancer Institute (NCI)
Recruiting - verified January 2012
Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer

Condition: Liver Cancer
Interventions: Drug: doxorubicin hydrochloride; Drug: sorafenib tosylate
Sponsors: National Cancer Institute (NCI); Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified September 2011
N2007-03: Vorinostat and 131-I MIBG in Treating Patients With Resistant or Relapsed Neuroblastoma

Condition: Neuroblastoma
Interventions: Drug: Vorinostat; Radiation: 131- I Metaiodobenzylguanidine; Procedure: Peripheral Blood Stem Cell Infusion; Drug: Filgrastim
Sponsors: New Approaches to Neuroblastoma Therapy Consortium; New Approaches to Neuroblastoma Therapy Consortium; National Cancer Institute (NCI)
Recruiting - verified April 2012
Gemcitabine Hydrochloride With or Without Erlotinib Hydrochloride Followed By the Same Chemotherapy Regimen With or Without Radiation Therapy and Capecitabine or Fluorouracil in Treating Patients With Pancreatic Cancer That Has Been Removed By Surgery

Condition: Pancreatic Cancer
Interventions: Drug: capecitabine; Drug: erlotinib hydrochloride; Drug: fluorouracil; Drug: gemcitabine hydrochloride; Radiation: 3-dimensional conformal radiation therapy; Radiation: intensity-modulated radiation therapy
Sponsors: National Cancer Institute (NCI); Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Rosuvastatin in Treating Patients With Stage I or Stage II Colon Cancer That Was Removed By Surgery

Conditions: Colorectal Cancer; Precancerous Condition
Interventions: Drug: rosuvastatin; Other: placebo
Sponsors: National Cancer Institute (NCI); National Surgical Adjuvant Breast and Bowel Project (NSABP); National Cancer Institute (NCI)
Recruiting - verified February 2012
Paclitaxel, Carboplatin, and Panitumumab in Treating Patients With Metastatic Breast Cancer

Conditions: Breast Cancer; Recurrent Breast Cancer; Stage IV Breast Cancer
Interventions: Biological: panitumumab; Drug: paclitaxel; Drug: carboplatin; Procedure: laboratory biomarker analysis; Procedure: immunohistochemistry staining method
Sponsors: Comprehensive Cancer Center of Wake Forest University; Comprehensive Cancer Center of Wake Forest University
Recruiting - verified April 2012
Study of Immunotoxin, MR1-1

Condition: Supratentorial Malignant Brain Tumor
Intervention: Biological: MR1-1
Sponsors: Duke University; Duke University; National Institute of Neurological Disorders and Stroke (NINDS)
Recruiting - verified December 2011
Phase II Randomized Trial Evaluating Neoadjuvant Therapy With Neratinib or Trastuzumab Followed by Postoperative Trastuzumab in Women With Locally Advanced HER2-positive Breast Cancer

Condition: Breast Cancer
Interventions: Drug: Paclitaxel; Drug: Trastuzumab; Drug: Neratinib; Drug: Trastuzumab (post surgery); Drug: Doxorubicin; Drug: Cyclophosphamide
Sponsors: National Surgical Adjuvant Breast and Bowel Project (NSABP); National Surgical Adjuvant Breast and Bowel Project (NSABP); Wyeth Pharmaceuticals, Inc., a Pfizer Company
Recruiting - verified February 2012
Gemcitabine Hydrochloride and Docetaxel With or Without Bevacizumab in Treating Patients With Advanced or Recurrent Uterine Leiomyosarcoma

Condition: Sarcoma
Interventions: Biological: bevacizumab; Biological: filgrastim; Biological: pegfilgrastim; Drug: docetaxel; Drug: gemcitabine hydrochloride; Other: placebo
Sponsors: National Cancer Institute (NCI); Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Stage IV Surgery Versus Best Medical Therapy

Condition: Stage IV Resectable Melanoma
Interventions: Procedure: Surgery; Procedure: Surgery plus 2 adjuvant doses of BCG; Other: best medical therapy
Sponsors: John Wayne Cancer Institute; John Wayne Cancer Institute; Melanoma Research Alliance
Recruiting - verified May 2012
Rituximab and Alemtuzumab in Treating Older Patients With Progressive Chronic Lymphocytic Leukemia

Condition: Leukemia
Interventions: Biological: alemtuzumab; Biological: rituximab
Sponsors: National Cancer Institute (NCI); Eastern Cooperative Oncology Group; National Cancer Institute (NCI)
Recruiting - verified February 2012
Daily Everolimus in Combination With Trastuzumab and Vinorelbine in HER2/Neu Positive Women With Locally Advanced or Metastatic Breast Cancer

Conditions: HER2/Neu Over-expressing Locally Advanced Breast Cancer; Metastatic Breast Cancer
Interventions: Drug: everolimus, vinorelbine, trastuzumab; Drug: Placebo + vinorelbine + trastuzumab
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified May 2012
Chemoembolization With or Without Sorafenib Tosylate in Treating Patients With Liver Cancer That Cannot Be Removed By Surgery

Condition: Liver Cancer
Interventions: Drug: cisplatin; Drug: doxorubicin hydrochloride; Drug: doxorubicin-eluting beads; Drug: mitomycin C; Drug: sorafenib tosylate; Other: placebo
Sponsors: National Cancer Institute (NCI); Eastern Cooperative Oncology Group; National Cancer Institute (NCI)
Recruiting - verified April 2012
Ofatumumab Versus Rituximab Salvage Chemoimmunotherapy Followed by Autologous Stem Cell Transplant in Relapsed or Refractory Diffuse Large B Cell Lymphoma

Condition: Lymphoma, Large-Cell, Diffuse
Interventions: Drug: OFATUMUMAB + DHAP; Drug: RITUXIMAB + DHAP
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified May 2012
Nipple Sparing Mastectomy - Cosmetic Outcomes

Conditions: Breast Cancer; Breast Reconstruction; Cosmesis
Intervention: Procedure: Nipple Sparing Mastectomy
Sponsors: Carolinas Healthcare System; Carolinas Healthcare System
Recruiting - verified June 2011
Study Evaluating Two Dose Levels of Targretin Capsules in Patients With Refractory Cutaneous T-cell Lymphoma (CTCL)

Condition: Refractory Cutaneous T-cell Lymphoma
Interventions: Drug: bexarotene; Drug: bexarotene
Sponsors: Eisai Inc.; Eisai Inc.
Recruiting - verified January 2012
Tissue Repository for Correlation of Molecular Markers With Response to Neoadjuvant and Metastatic Chemotherapy

Condition: Breast Cancer
Interventions: Other: biologic sample preservation procedure; Other: laboratory biomarker analysis; Procedure: biopsy
Sponsors: UNC Lineberger Comprehensive Cancer Center; UNC Lineberger Comprehensive Cancer Center; National Cancer Institute (NCI)
Recruiting - verified March 2012
Study of Biomarkers in Blood and Bone Marrow Samples From Patients With Previously Untreated Chronic Lymphocytic Leukemia

Condition: Leukemia
Interventions: Genetic: fluorescence in situ hybridization; Genetic: mutation analysis; Genetic: nucleic acid sequencing; Genetic: polymerase chain reaction; Genetic: western blotting; Other: flow cytometry; Other: laboratory biomarker analysis
Sponsors: National Cancer Institute (NCI); Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified May 2012
Omega-3 Fatty Acids in Treating Patients With Advanced Prostate Cancer

Condition: Stage III Prostate Cancer
Interventions: Dietary Supplement: omega-3 fatty acid; Other: bone scan; Other: dual x-ray absorptometry; Other: laboratory biomarker analysis; Procedure: biopsy
Sponsors: Comprehensive Cancer Center of Wake Forest University; Comprehensive Cancer Center of Wake Forest University; National Cancer Institute (NCI)
Recruiting - verified April 2012
Collecting and Storing Tissue Samples From Patients With Rare or Cutaneous Non-Hodgkin Lymphoma

Conditions: Lymphoma; Lymphoproliferative Disorder
Interventions: Other: biologic sample preservation procedure; Other: informational intervention
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
The FIRSTT: Comparing MRgFUS(MR-guided Focused Ultrasound) Versus UAE (Uterine Artery Embolization)for Uterine Fibroids.

Conditions: Symptomatic Uterine Leiomyomas; Fibroid; Myomas
Interventions: Procedure: Focused ultrasound (MRgFUS); Procedure: Uterine artery embolization (UAE)
Sponsors: Mayo Clinic; Mayo Clinic; Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Recruiting - verified March 2012
Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Liver Cancer

Condition: Liver Cancer
Interventions: Drug: cisplatin; Drug: doxorubicin hydrochloride; Drug: fluorouracil; Drug: irinotecan hydrochloride; Drug: vincristine sulfate; Procedure: liver transplantation; Procedure: therapeutic conventional surgery
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified November 2011
Chemotherapy and Pelvic Radiation Therapy With or Without Additional Chemotherapy in Treating Patients With High-Risk Early-Stage Cervical Cancer After Radical Hysterectomy

Condition: Cervical Cancer
Interventions: Drug: carboplatin; Drug: cisplatin; Drug: paclitaxel
Sponsors: National Cancer Institute (NCI); Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Cediranib Maleate and Cilengitide in Treating Patients With Progressive or Recurrent Glioblastoma

Condition: Brain and Central Nervous System Tumors
Interventions: Drug: cediranib maleate; Drug: cilengitide; Other: enzyme-linked immunosorbent assay; Other: flow cytometry; Other: laboratory biomarker analysis; Procedure: magnetic resonance imaging
Sponsors: Sidney Kimmel Comprehensive Cancer Center; Sidney Kimmel Comprehensive Cancer Center; National Cancer Institute (NCI)
Recruiting - verified May 2012
Radiation Therapy With or Without Temozolomide in Treating Patients With Low-Grade Glioma

Conditions: Brain and Central Nervous System Tumors; Neurotoxicity
Interventions: Drug: temozolomide; Radiation: 3-dimensional conformal radiation therapy; Radiation: intensity-modulated radiation therapy
Sponsors: National Cancer Institute (NCI); Eastern Cooperative Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
A Study of YM155 Plus Rituximab in Subjects With Non-Hodgkin's Lymphoma Who Have Received Prior Treatment

Condition: Non-Hodgkin's Lymphoma
Interventions: Drug: YM155; Biological: Rituximab
Sponsors: Astellas Pharma Inc; Astellas Pharma Inc
Recruiting - verified March 2012
Paclitaxel, Carboplatin, and Bevacizumab or Paclitaxel, Carboplatin, and Temsirolimus or Ixabepilone, Carboplatin, and Bevacizumab in Treating Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer

Condition: Endometrial Cancer
Interventions: Biological: bevacizumab; Drug: carboplatin; Drug: ixabepilone; Drug: paclitaxel; Drug: temsirolimus
Sponsors: National Cancer Institute (NCI); Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified July 2011
A Study of MGCD265 Given With Erlotinib or Docetaxel in Subjects With Advanced Malignancies or Non-Small Cell Lung Cancer

Condition: Advanced Malignancies, Non-small Cell Lung Cancer
Interventions: Drug: MGCD265+erlotinib; Drug: MGCD265+docetaxel
Sponsors: MethylGene Inc.; MethylGene Inc.
Recruiting - verified November 2011
Impact of Aggressive Versus Standard Drainage Regimen Using a Long Term Indwelling Pleural Catheter

Condition: Pleural Effusion, Malignant
Interventions: Other: Standard Drainage Instructions; Other: Aggressive Drainage Instructions
Sponsors: Duke University; Duke University; CareFusion
Recruiting - verified March 2012
An Exploratory Trial to Assess the Improvement of Adverse Events in Chronic Myelogenous Leukemia Patients Treated With Imatinib When Switched to Nilotinib Treatment

Condition: Chronic Myelogenous Leukemia
Intervention: Drug: Nilotinib
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified April 2012
Study of GC33 and Sorafenib in Combination in Advanced or Metastatic Liver Cancer (Hepatocellular Carcinoma)

Condition: Hepatocellular Carcinoma
Interventions: Drug: GC33; Drug: Sorafenib
Sponsors: Chugai Pharmaceutical; Chugai Pharmaceutical; Hoffmann-La Roche
Recruiting - verified April 2012
Epigenetic Modulation in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

Condition: Diffuse Large B-cell Lymphoma
Interventions: Drug: RAD001; Drug: LBH589; Drug: RAD001 and LBH589 as a doublet
Sponsors: Duke University; Duke University; Novartis
Recruiting - verified February 2012
Dose-Escalation Study of GSK2126458

Conditions: Advanced Solid Tumor; Solid Tumours
Intervention: Drug: GSK2126458
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified September 2011
Trial of Nelarabine, Etoposide and Cyclophosphamide in Relapsed T-cell ALL and T-cell LL

Conditions: Relapsed T-Cell Acute Lymphoblastic Leukemia; Relapsed T-Cell Lymphoblastic Lymphoma
Interventions: Drug: Nelarabine; Drug: Etoposide; Drug: Cyclophosphamide; Drug: Methotrexate; Drug: Filgrastim
Sponsors: Therapeutic Advances in Childhood Leukemia Consortium; Therapeutic Advances in Childhood Leukemia Consortium; GlaxoSmithKline
Recruiting - verified November 2011
Continued HER2 Suppression With Lapatinib Plus Trastuzumab Versus Trastuzumab Alone

Conditions: Adenocarcinoma; Her2+; Advanced Metastatic Breast Cancer; Metastatic ErbB2; Invasive Breast Cancer; Advanced Breast Cancer; Cancer; ErbB2+
Interventions: Drug: Lapatinib; Biological: Trastuzumab
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified May 2012
T-cell Depleted Alternative Donor Transplantation

Conditions: Acute Lymphoblastic Leukemia; Acute Myeloid Leukemia; Chronic Myeloid Leukemia; Myelodysplastic Syndrome; Lymphomas; Bone Marrow Failure; Hemoglobinopathy; Immune Deficiency; Osteopetrosis
Intervention: Device: CliniMACS® (T cell depletion)
Sponsors: Carolinas Healthcare System; Andrew Gilman
Recruiting - verified April 2012
Bortezomib and Romidepsin in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Conditions: Leukemia; Lymphoma
Interventions: Drug: Bortezomib; Drug: Romidepsin
Sponsors: Virginia Commonwealth University; Virginia Commonwealth University; National Cancer Institute (NCI)
Recruiting - verified April 2012
Study of Lenalidomide to Evaluate Safety and Efficacy in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia

Condition: Relapsed or Refractory Chronic Lymphocytic Leukemia
Intervention: Drug: lenalidomide
Sponsors: Celgene Corporation; Celgene Corporation
Recruiting - verified February 2012
Radiation Therapy With or Without Cetuximab in Treating Patients Who Have Undergone Surgery for Locally Advanced Head and Neck Cancer

Condition: Head and Neck Cancer
Interventions: Biological: cetuximab; Radiation: intensity-modulated radiation therapy
Sponsors: National Cancer Institute (NCI); Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Paclitaxel and Carboplatin or Ifosfamide in Treating Patients With Newly Diagnosed Persistent or Recurrent Uterine or Ovarian Cancer

Conditions: Ovarian Cancer; Sarcoma
Interventions: Drug: carboplatin; Drug: ifosfamide; Drug: paclitaxel
Sponsors: National Cancer Institute (NCI); Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Study of Blood Samples From Newborns With Down Syndrome

Condition: Leukemia
Interventions: Genetic: DNA analysis; Genetic: RNA analysis; Genetic: cytogenetic analysis; Genetic: fluorescence in situ hybridization; Genetic: gene expression analysis; Genetic: microarray analysis; Genetic: mutation analysis; Genetic: polymerase chain reaction; Genetic: polymorphism analysis; Other: flow cytometry; Other: laboratory biomarker analysis; Other: pharmacological study
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified December 2011
Treatment of Blood Clots in Children With Cancer

Condition: Venous Thromboembolism
Intervention: Drug: Fragmin
Sponsors: Eisai Inc.; Eisai Inc.
Recruiting - verified April 2012
Study of Patients With Advanced Non-Small Cell Lung Cancer

Condition: Advanced Non-Small Cell Lung Cancer
Interventions: Drug: Pemetrexed; Drug: Carboplatin; Drug: Paclitaxel; Biological: Bevacizumab
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified May 2012
A Study of CDX-1401 in Patients With Malignancies Known to Express NY-ESO-1

Condition: Advanced Malignancies
Intervention: Biological: CDX-1401 in combination with Resiquimod and/or Poly-ICLC
Sponsors: Celldex Therapeutics; Celldex Therapeutics
Recruiting - verified November 2011
Bevacizumab Plus Irinotecan Plus Carboplatin for Recurrent Malignant Glioma (MG)

Condition: Malignant Glioma
Intervention: Drug: bevacizumab and CPT-11 and Carboplatin
Sponsors: Duke University; Duke University
Recruiting - verified October 2011
Carboplatin and Paclitaxel With or Without Bevacizumab and/or Cetuximab in Treating Patients With Stage IV or Recurrent Non-Small Cell Lung Cancer

Condition: Lung Cancer
Interventions: Biological: bevacizumab; Biological: cetuximab; Drug: carboplatin; Drug: paclitaxel
Sponsors: National Cancer Institute (NCI); Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract Cancer

Conditions: Bladder Cancer; Prostate Cancer; Transitional Cell Cancer of the Renal Pelvis and Ureter; Urethral Cancer
Interventions: Biological: bevacizumab; Drug: cisplatin; Drug: gemcitabine hydrochloride; Drug: placebo administration
Sponsors: National Cancer Institute (NCI); Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified August 2011
Carboplatin and Paclitaxel With or Without Cisplatin and Radiation Therapy in Treating Patients With Stage I, Stage II, Stage III, or Stage IVA Endometrial Cancer

Condition: Endometrial Cancer
Interventions: Drug: carboplatin; Drug: cisplatin; Drug: paclitaxel
Sponsors: National Cancer Institute (NCI); Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified February 2012
Stereotactic Body Radiotherapy (SBRT) for Prostate Cancer

Condition: Prostate Cancer
Intervention: Radiation: SBRT Prostate
Sponsors: Duke University; Duke University
Recruiting - verified September 2011
Analysis of Surgery in Patients Presenting With Stage IV Breast Cancer

Condition: Breast Cancer
Intervention:
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center; University of Chicago; Dana-Farber Cancer Institute; Georgetown University; Johns Hopkins University; M.D. Anderson Cancer Center; University of Alabama at Birmingham; University of California, San Francisco; University of North Carolina; Duke University; Vanderbilt-Ingram Cancer Center; Indiana University Melvin and Bren Simon Cancer Center; Mayo Clinic; University of Pittsburgh; University of Michigan Health System
Recruiting - verified March 2012
GDC-0449 in Treating Adult Patients With Recurrent or Refractory Medulloblastoma

Condition: Brain and Central Nervous System Tumors
Intervention: Drug: Hedgehog antagonist GDC-0449
Sponsors: Pediatric Brain Tumor Consortium; Pediatric Brain Tumor Consortium; National Cancer Institute (NCI)
Recruiting - verified March 2012
Docetaxel, Oxaliplatin, Capecitabine, Fluorouracil, and Radiation Therapy in Treating Patients With Locally Advanced Cancer of the Esophagus or Gastroesophageal Junction

Conditions: Adenocarcinoma of the Gastroesophageal Junction; Esophageal Cancer; Gastric Cancer
Interventions: Drug: capecitabine; Drug: docetaxel; Drug: fluorouracil; Drug: oxaliplatin
Sponsors: National Cancer Institute (NCI); North Central Cancer Treatment Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Enhanced Self-Efficacy Training

Condition: Neoplasms
Interventions: Other: Self-Efficacy Training for Caregivers; Other: Comparison Conditions for Caregivers
Sponsors: Duke University; Duke University; National Institute of Nursing Research (NINR)
Recruiting - verified June 2011
Radiation Therapy With or Without Androgen-Deprivation Therapy in Treating Patients With Prostate Cancer

Condition: Prostate Cancer
Interventions: Drug: bicalutamide; Drug: buserelin; Drug: flutamide; Drug: goserelin acetate; Drug: leuprolide acetate; Drug: triptorelin; Radiation: 3-dimensional conformal radiation therapy; Radiation: intensity-modulated radiation therapy
Sponsors: National Cancer Institute (NCI); Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Outlook: An Intervention to Improve Quality of Life in Serious Illness

Conditions: Neoplasms; Pulmonary Disease, Chronic Obstructive; Heart Failure; Renal Disease
Interventions: Other: Outlook Attention Control; Other: Outlook Intervention
Sponsors: Duke University; Duke University; National Institute of Nursing Research (NINR)
Recruiting - verified June 2011
A Study of Trastuzumab Emtansine (T-DM1) in Combination With Docetaxel, and Potentially Pertuzumab, in Patients With Advanced Breast Cancer

Condition: Breast Cancer
Interventions: Drug: trastuzumab emtansine; Drug: docetaxel; Drug: pertuzumab
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified May 2012
Myelodysplastic Syndromes (MDS) Event Free Survival With Iron Chelation Therapy Study

Condition: Myelodysplastic Syndromes
Interventions: Drug: Deferasirox; Drug: Deferasirox placebo
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified March 2012
Gynaecological Follow-up of a Subset of 580299/008 (NCT 00122681) Study Subjects

Conditions: Human Papillomavirus (HPV) Type 16/18 Infections; Cervical Neoplasia
Intervention: Procedure: Gynaecological follow-up
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified March 2012
Tailored Intervention Protocol for Oral Chemotherapy Adherence

Condition: Cancer
Intervention: Behavioral: Nurse Coaching
Sponsors: Duke University; Duke University; National Cancer Institute (NCI)
Recruiting - verified June 2011
An Investigational Drug, PF-02341066, Is Being Studied In Patients With Advanced Non-Small Cell Lung Cancer With A Specific Gene Profile Involving The Anaplastic Lymphoma Kinase (ALK) Gene

Condition: Carcinoma, Non-Small-Cell Lung
Intervention: Drug: PF-02341066
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2012
An Investigational Drug, PF-02341066 Is Being Studied Versus Standard Of Care In Patients With Advanced Non-Small Cell Lung Cancer With A Specific Gene Profile Involving The Anaplastic Lymphoma Kinase (ALK) Gene

Condition: Carcinoma, Non-Small-Cell Lung
Interventions: Drug: PF-02341066; Drug: Pemetrexed; Drug: Docetaxel
Sponsors: Pfizer; Pfizer
Recruiting - verified April 2012
A Study of the Safety and Effectiveness of JNJ-42160443 as add-on Treatment in Patients With Cancer-related Pain

Conditions: Pain, Burning; Pain, Crushing; Pain, Migratory; Pain, Radiating; Pain, Splitting
Interventions: Drug: JNJ-42160443; Drug: Placebo
Sponsors: Janssen Research & Development, LLC; Janssen Research & Development, LLC
Recruiting - verified May 2012
Study to Assess the Effectiveness of RCHOP With or Without VELCADE in Previously Untreated Non-Germinal Center B-Cell-like Diffuse Large B-Cell Lymphoma Patients

Condition: Non-Germinal B-Cell-like (GCB) Diffuse Large B-cell Lymphoma (DLBCL)
Interventions: Drug: Vc-RCHOP; Drug: RCHOP
Sponsors: Millennium Pharmaceuticals, Inc.; Millennium Pharmaceuticals, Inc.
Recruiting - verified January 2012
Trial of Dasatinib Plus Ixabepilone in 2nd or 3rd Line Metastatic Breast Cancer

Condition: Metastatic Breast Cancer
Interventions: Drug: Dasatinib; Drug: Ixabepilone
Sponsors: Accelerated Community Oncology Research Network; Accelerated Community Oncology Research Network; Bristol-Myers Squibb
Recruiting - verified February 2012
Image-Guided Radiosurgery or Stereotactic Body Radiation Therapy in Treating Patients With Localized Spine Metastasis

Conditions: Metastatic Cancer; Pain
Interventions: Radiation: external beam radiation therapy; Radiation: image-guided radiation therapy; Radiation: radiosurgery; Radiation: stereotactic body radiation therapy
Sponsors: National Cancer Institute (NCI); Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Esophageal Sparing Intensity-modulated Radiation Therapy (IMRT) for Locally-Advanced Thoracic Malignancies

Conditions: Non Small Cell Lung Cancer; Small Cell Lung Cancer; Thymoma; Thymus Neoplasms
Intervention: Radiation: Esophageal sparing IMRT
Sponsors: Duke University; Duke University
Recruiting - verified September 2011
Collecting and Storing Blood and Brain Tumor Tissue Samples From Children With Brain Tumors

Condition: Brain and Central Nervous System Tumors
Intervention: Other: biologic sample preservation procedure
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Axitinib (AG-013736) For the Treatment of Metastatic Renal Cell Cancer

Condition: Kidney Neoplasms
Interventions: Drug: Axitinib (AG-013736); Drug: Sorafenib
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2012
Open-label Study to Evaluate the Safety, PK, and PD of MEK Inhibitor GSK1120212 in Subjects With Relapsed or Refractory Leukemias

Conditions: Leukemia-relapsed or Refractory; Cancer
Interventions: Drug: GSK1120212; Drug: GSK1120212
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified April 2012
Collecting and Storing Tissue, Blood, and Bone Marrow Samples From Patients With Rhabdomyosarcoma or Other Soft Tissue Sarcoma

Conditions: Chordoma; Desmoid Tumor; Sarcoma
Interventions: Genetic: reverse transcriptase-polymerase chain reaction; Other: biologic sample preservation procedure; Other: laboratory biomarker analysis
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
A Study of Paclitaxel/Carboplatin With or Without IMC-3G3 in Previously Untreated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

Condition: Non-Small Cell Lung Cancer
Interventions: Biological: IMC-3G3; Drug: Paclitaxel; Drug: carboplatin
Sponsors: ImClone LLC; ImClone LLC
Recruiting - verified February 2012
A Study of BMS-833923 With Carboplatin and Etoposide Followed by BMS-833923 Alone in Subjects With Extensive-Stage Small Cell Lung Cancer

Condition: Small Cell Lung Carcinoma
Interventions: Drug: BMS-833923; Drug: Carboplatin; Drug: Etoposide
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb; Exelixis
Recruiting - verified February 2012
Effect of NovoTTF-100A Together With Temozolomide in Newly Diagnosed Glioblastoma Multiforme (GBM)

Condition: Glioblastoma Multiforme
Interventions: Device: NovoTTF-100A device; Drug: Temozolomide
Sponsors: NovoCure Ltd.; NovoCure Ltd.
Recruiting - verified March 2012
Evaluation of Sentinel Lymph Nodes in Head and Neck Squamous Cell Carcinoma

Condition: Head and Neck Squamous Cell Carcinoma
Intervention: Drug: Lymphoseek
Sponsors: Navidea Biopharmaceuticals; Navidea Biopharmaceuticals
Recruiting - verified March 2012
Combination Study of BMS-754807 and Erbitux® in Subjects With Advanced or Metastatic Solid Tumors

Conditions: Colorectal Cancer; Head and Neck Cancer; Neoplasm Metastasis
Interventions: Drug: BMS-754807; Drug: cetuximab (Erbitux®)
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb
Recruiting - verified February 2012
Effectiveness of a Blood Stem Cell Transplant That Uses Low Dose Chemotherapy in People With Relapsed Follicular Non-Hodgkin's Lymphoma (BMT CTN #0701)

Condition: Lymphoma, Non-Hodgkin
Intervention: Biological: Hematopoietic Stem Cell Transplant
Sponsors: National Heart, Lung, and Blood Institute (NHLBI); National Heart, Lung, and Blood Institute (NHLBI); Blood and Marrow Transplant Clinical Trials Network; National Cancer Institute (NCI)
Recruiting - verified January 2012
PAVES: Pegfilgrastim Anti-VEGF Evaluation Study

Conditions: Cancer; Colon Cancer; Colorectal Cancer; Fever; Locally Advanced; Metastatic Colorectal Cancer; Neutropenia; Rectal Cancer
Interventions: Drug: Pegfilgrastim; Drug: Placebo
Sponsors: Amgen; Amgen
Recruiting - verified January 2012
A Prospective Study for the Assessment of Recurrence Risk in Stage II Colon Cancer Patients Using ColoPrint

Condition: Colon Cancer
Intervention:
Sponsors: Agendia; Agendia
Recruiting - verified March 2012
Biomarkers in Tumor Tissue Samples From Patients With Newly Diagnosed Neuroblastoma or Ganglioneuroblastoma

Condition: Neuroblastoma
Interventions: Genetic: fluorescence in situ hybridization; Genetic: gene expression analysis; Genetic: nucleic acid amplification; Genetic: polymerase chain reaction; Genetic: reverse transcriptase-polymerase chain reaction; Other: cytology specimen collection procedure; Other: flow cytometry; Procedure: biopsy
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Cervical Cancer Detection Using Optical Spectroscopy

Condition: Cervical Cancer
Intervention:
Sponsors: Duke University; Duke University; Family Health Ministries
Recruiting - verified January 2012
Tumor Marker YKL-40 in Patients With Newly Diagnosed Stage III or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer Undergoing Chemotherapy

Conditions: Fallopian Tube Cancer; Ovarian Cancer; Primary Peritoneal Cavity Cancer
Intervention: Other: diagnostic laboratory biomarker analysis
Sponsors: National Cancer Institute (NCI); Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Collecting and Storing Tissue From Young Patients With Cancer

Condition: Cancer
Interventions: Genetic: DNA analysis; Genetic: reverse transcriptase-polymerase chain reaction; Other: biologic sample preservation procedure; Other: flow cytometry; Other: laboratory biomarker analysis
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Study of Kidney Tumors in Young Patients

Conditions: Kidney Cancer; Nonneoplastic Condition
Interventions: Genetic: loss of heterozygosity analysis; Genetic: polymerase chain reaction; Genetic: polymorphism analysis; Other: immunohistochemistry staining method; Procedure: computed tomography; Procedure: magnetic resonance imaging
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Collecting and Storing Malignant, Borderline Malignant Neoplasms, and Related Samples From Young Patients With Cancer

Conditions: Leukemia; Neoplasm of Uncertain Malignant Potential; Unspecified Childhood Solid Tumor, Protocol Specific
Intervention: Other: cytology specimen collection procedure
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Collecting Tumor Samples From Patients With Gynecological Tumors

Condition: Cancer
Intervention: Other: biologic sample preservation procedure
Sponsors: National Cancer Institute (NCI); Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified December 2011
Gene Expression in Normal Tissue and Tumor Tissue From Patients Who Have Undergone Surgery For Kidney Cancer

Condition: Kidney Cancer
Interventions: Genetic: gene expression analysis; Genetic: protein expression analysis; Other: laboratory biomarker analysis
Sponsors: Comprehensive Cancer Center of Wake Forest University; Comprehensive Cancer Center of Wake Forest University; National Cancer Institute (NCI)
Recruiting - verified January 2012
Collection and Storage of Blood and Tissue Samples From Patients Who Are Undergoing Surgery For Lung Cancer

Condition: Lung Cancer
Intervention: Other: biologic sample preservation procedure
Sponsors: National Cancer Institute (NCI); Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified May 2012
Collection and Storage of Tissue Samples From Patients Undergoing Surgery For Suspected Solid Tumors

Conditions: Unspecified Adult Solid Tumor, Protocol Specific; Unspecified Childhood Solid Tumor, Protocol Specific
Interventions: Other: biologic sample preservation procedure; Other: medical chart review
Sponsors: Comprehensive Cancer Center of Wake Forest University; Comprehensive Cancer Center of Wake Forest University; National Cancer Institute (NCI)
Recruiting - verified April 2012
Collecting and Storing Blood, Bone Marrow, and Other Samples From Patients With Acute Leukemia, Chronic Leukemia, or Myelodysplastic Syndromes

Conditions: Leukemia; Lymphoma; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Neoplasms
Intervention: Other: biologic sample preservation procedure
Sponsors: National Cancer Institute (NCI); Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified May 2012
Study of Denosumab in the Treatment of Hypercalcemia of Malignancy in Subjects With Elevated Serum Calcium

Conditions: Breast Cancer; Hypercalcemia of Malignancy; Colon Cancer; Endocrine Cancer; Head and Neck Cancer; Kidney Cancer; Lung Cancer; Lymphoma; Metastatic Cancer; Multiple Myeloma; Parathyroid Neoplasms; Renal Cancer; Thyroid Cancer; Hodgkin's Lymphoma; Non-Hodgkin's Lymphoma; Non-Small Cell Lung Cancer
Intervention: Drug: denosumab
Sponsors: Amgen; Amgen
Recruiting - verified May 2012
Collecting and Storing Biological Samples From Patients With Ewing Sarcoma

Condition: Sarcoma
Interventions: Other: biologic sample preservation procedure; Other: medical chart review
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Ramucirumab or Anti-PDGFR Alpha Monoclonal Antibody IMC-3G3 in Treating Patients With Recurrent Glioblastoma Multiforme

Condition: Brain and Central Nervous System Tumors
Interventions: Biological: anti-PDGFR alpha monoclonal antibody IMC-3G3; Biological: ramucirumab
Sponsors: Sidney Kimmel Comprehensive Cancer Center; Sidney Kimmel Comprehensive Cancer Center; National Cancer Institute (NCI); ImClone LLC
Recruiting - verified April 2012
Collecting and Storing Samples of Blood and Tumor Tissue From Patients With Osteosarcoma

Condition: Sarcoma
Intervention: Other: biologic sample preservation procedure
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Intravenous Palonosetron With Radiotherapy and Concomitant Temozolomide

Condition: Malignant Glioma
Intervention: Drug: Palonosetron (PALO)
Sponsors: Duke University; Duke University; Eisai Inc.; National Institute of Neurological Disorders and Stroke (NINDS)
Recruiting - verified June 2011
Studying Tissue and Blood Samples From Patients With Acute Myeloid Leukemia

Condition: Leukemia
Interventions: Genetic: DNA analysis; Genetic: DNA methylation analysis; Genetic: gene expression analysis; Genetic: mutation analysis; Genetic: polymerase chain reaction; Genetic: reverse transcriptase-polymerase chain reaction; Other: high performance liquid chromatography; Other: laboratory biomarker analysis
Sponsors: National Cancer Institute (NCI); Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified May 2012
Studying Biomarkers in Diagnosing Cervical Lesions in Patients With Abnormal Cervical Cells

Conditions: Cervical Cancer; Precancerous Condition
Interventions: Genetic: DNA analysis; Genetic: gene expression analysis; Other: diagnostic laboratory biomarker analysis; Other: immunohistochemistry staining method; Procedure: cone biopsy; Procedure: endocervical curettage; Procedure: histopathologic examination; Procedure: loop electrosurgical excision procedure
Sponsors: National Cancer Institute (NCI); Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified December 2011
Augmentation of Screening Colonoscopy With Fecal Immunochemical Testing

Condition: Colon Cancer
Interventions: Device: Fecal Immunochemical Testing; Device: Fecal Immunochemical Testing
Sponsors: Forsyth Medical Center; Forsyth Medical Center
Recruiting - verified October 2011
Collecting and Storing Biological Samples From Young Patients With Hodgkin's Lymphoma

Condition: Lymphoma
Intervention: Other: biologic sample preservation procedure
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Collecting and Storing Samples of Bone Marrow and Blood From Patients With Relapsed Acute Lymphoblastic Leukemia or Non-Hodgkin Lymphoma

Conditions: Leukemia; Lymphoma
Intervention: Other: biologic sample preservation procedure
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Vaccine Therapy in Treating Patients Undergoing Surgery for Recurrent Glioblastoma Multiforme

Condition: Brain and Central Nervous System Tumors
Interventions: Biological: autologous CD133-positive BTSC mRNA-pulsed autologous dendritic cell vaccine; Procedure: adjuvant therapy; Procedure: therapeutic conventional surgery
Sponsors: Duke University; Duke University; National Cancer Institute (NCI)
Recruiting - verified September 2011
Bevacizumab With or Without Everolimus in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer

Conditions: Fallopian Tube Cancer; Ovarian Cancer; Primary Peritoneal Cavity Cancer
Interventions: Biological: bevacizumab; Drug: everolimus; Other: placebo
Sponsors: National Cancer Institute (NCI); Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified August 2011
A Study of Ixabepilone as Second Line Therapy for Locally Advanced, Recurrent or Metastatic Endometrial Cancer

Condition: Endometrial Cancer
Interventions: Drug: Ixabepilone; Drug: Doxorubicin; Drug: Paclitaxel
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb
Recruiting - verified February 2012
Bevacizumab and Erlotinib or Sorafenib as First-Line Therapy in Treating Patients With Advanced Liver Cancer

Condition: Liver Cancer
Interventions: Biological: bevacizumab; Drug: erlotinib hydrochloride; Drug: sorafenib tosylate
Sponsors: Medical University of South Carolina; Medical University of South Carolina
Recruiting - verified June 2010
N2007-02:Bevacizumab,Cyclophosphamide,& Zoledronic Acid in Patients W/ Recurrent or Refractory High-Risk Neuroblastoma

Condition: Neuroblastoma
Interventions: Drug: Bevacizumab; Drug: cyclophosphamide; Drug: zoledronic acid
Sponsors: New Approaches to Neuroblastoma Therapy Consortium; New Approaches to Neuroblastoma Therapy Consortium; National Cancer Institute (NCI)
Recruiting - verified April 2012
A Study Evaluating Intermittent and Continuous OSI-906 and Weekly Paclitaxel in Patients With Recurrent Epithelial Ovarian Cancer (and Other Solid Tumors)

Conditions: Solid Tumors; Ovarian Cancer
Interventions: Drug: OSI-906; Drug: Paclitaxel
Sponsors: Astellas Pharma Inc; Astellas Pharma Inc
Recruiting - verified May 2012
Everolimus in Combination With Trastuzumab and Paclitaxel in the Treatment of HER2 Positive Locally Advanced or Metastatic Breast Cancer

Condition: Breast Cancer
Interventions: Drug: Everolimus; Drug: Placebo
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified April 2012
Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Conditions: Breast Cancer; Lung Cancer; Metastatic Cancer; Multiple Myeloma and Plasma Cell Neoplasm; Prostate Cancer; Unspecified Adult Solid Tumor, Protocol Specific
Intervention: Procedure: assessment of therapy complications
Sponsors: National Cancer Institute (NCI); Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Helping African American Prostate Cancer Survivors and Their Partners Cope With Challenges After Surgery for Prostate Cancer

Conditions: Cancer Survivor; Depression; Gastrointestinal Complications; Male Erectile Disorder; Prostate Cancer; Psychosocial Effects of Cancer and Its Treatment; Urinary Complications
Interventions: Behavioral: telephone-based intervention; Other: educational intervention; Other: partner-assisted coping skills training; Other: questionnaire administration; Procedure: psychosocial assessment and care; Procedure: quality-of-life assessment
Sponsors: East Carolina University; East Carolina University; National Cancer Institute (NCI)
Recruiting - verified March 2012
Vorinostat, Isotretinoin, and Combination Chemotherapy in Treating Young Patients Who Have Undergone Surgery for Embryonal Tumors of the Central Nervous System

Condition: Brain and Central Nervous System Tumors
Interventions: Drug: carboplatin; Drug: cisplatin; Drug: cyclophosphamide; Drug: etoposide; Drug: isotretinoin; Drug: thiotepa; Drug: vincristine sulfate; Drug: vorinostat; Radiation: Conformal radiation
Sponsors: Pediatric Brain Tumor Consortium; Pediatric Brain Tumor Consortium; National Cancer Institute (NCI)
Recruiting - verified March 2012
Alternate Dosing Schedules Study for HPV Vaccine

Conditions: Cervical Cancer; Genital Warts
Intervention:
Sponsors: Duke University; Duke University; Centers for Disease Control and Prevention
Recruiting - verified June 2011
Paclitaxel With or Without Carboplatin and/or Bevacizumab Followed By Doxorubicin and Cyclophosphamide in Treating Patients With Breast Cancer That Can Be Removed by Surgery

Condition: Breast Cancer
Interventions: Biological: bevacizumab; Drug: carboplatin; Drug: cyclophosphamide; Drug: doxorubicin hydrochloride; Drug: paclitaxel
Sponsors: National Cancer Institute (NCI); Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified May 2012
Study of Immunotherapy to Treat Advanced Prostate Cancer

Condition: Prostate Cancer
Interventions: Drug: Ipilimumab; Drug: Placebo
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb
Recruiting - verified December 2011
Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Promyelocytic Leukemia

Condition: Leukemia
Interventions: Drug: arsenic trioxide; Drug: cytarabine; Drug: idarubicin; Drug: mercaptopurine; Drug: methotrexate; Drug: mitoxantrone hydrochloride; Drug: tretinoin; Genetic: cytogenetic analysis; Genetic: polymerase chain reaction; Other: laboratory biomarker analysis
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy

Conditions: Non-Small Cell Lung Cancer; Anemia; Cancer; Lung Cancer
Interventions: Drug: darbepoetin alfa 500 mcg Q3W; Drug: placebo
Sponsors: Amgen; Amgen
Recruiting - verified May 2012
OPT-821 With or Without Vaccine Therapy in Treating Patients With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer in Second or Third Complete Remission

Conditions: Fallopian Tube Cancer; Ovarian Cancer; Primary Peritoneal Cavity Cancer
Interventions: Biological: immunological adjuvant OPT-821; Biological: polyvalent antigen-KLH conjugate vaccine
Sponsors: National Cancer Institute (NCI); Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Paclitaxel Albumin-Stabilized Nanoparticle Formulation, Doxorubicin, Cyclophosphamide, and Pegfilgrastim With or Without Bevacizumab in Treating Women With Inflammatory or Locally Advanced Breast Cancer

Condition: Breast Cancer
Interventions: Biological: bevacizumab; Biological: pegfilgrastim; Drug: cyclophosphamide; Drug: doxorubicin hydrochloride; Drug: paclitaxel albumin-stabilized nanoparticle formulation
Sponsors: National Cancer Institute (NCI); Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
An Open-Label Study of Trastuzumab Emtansine (T-DM1) vs Capecitabine+Lapatinib in Patients With HER2-Positive Locally Advanced or Metastatic Breast Cancer (EMILIA)

Condition: Breast Cancer
Interventions: Drug: trastuzumab emtansine; Drug: lapatinib; Drug: capecitabine [Xeloda]
Sponsors: Genentech; Genentech
Recruiting - verified April 2012
Lenalidomide and Decitabine in High Grade Myelodysplastic Syndromes

Condition: Myelodysplastic Syndromes
Intervention: Drug: Lenalidomide, Decitabine
Sponsors: Duke University; Duke University; Celgene Corporation
Recruiting - verified February 2012
Fludeoxyglucose F 18-PET/CT Imaging and Combination Chemotherapy With or Without Additional Chemotherapy and G-CSF in Treating Patients With Stage III or Stage IV Hodgkin Lymphoma

Condition: Lymphoma
Interventions: Biological: bleomycin sulfate; Biological: filgrastim; Drug: ABVD regimen; Drug: BEACOPP regimen; Drug: cyclophosphamide; Drug: dacarbazine; Drug: doxorubicin hydrochloride; Drug: etoposide; Drug: prednisone; Drug: procarbazine hydrochloride; Drug: vinblastine sulfate; Drug: vincristine sulfate; Radiation: fludeoxyglucose F 18
Sponsors: National Cancer Institute (NCI); Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified January 2012
PF-00299804 As A Single Oral Agent In Selected Patients With Adenocarcinoma Of The Lung

Condition: Carcinoma, Non-small Cell
Intervention: Drug: Dacomitinib (PF-00299804)
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2012
Stereotactic Radiosurgery in Treating Patients With Brain Metastases

Conditions: Metastatic Cancer; Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Procedure: therapeutic conventional surgery; Radiation: stereotactic radiosurgery
Sponsors: Duke University; Duke University; National Cancer Institute (NCI)
Recruiting - verified September 2011
Pelvic Radiation Therapy or Vaginal Implant Radiation Therapy, Paclitaxel, and Carboplatin in Treating Patients With High-Risk Stage I or Stage II Endometrial Cancer

Conditions: Endometrial Cancer; Fatigue; Neurotoxicity
Interventions: Drug: carboplatin; Drug: paclitaxel; Radiation: brachytherapy; Radiation: intensity-modulated radiation therapy; Radiation: radiation therapy
Sponsors: National Cancer Institute (NCI); Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified February 2012
Paclitaxel and Cisplatin or Topotecan With or Without Bevacizumab in Treating Patients With Stage IVB, Recurrent, or Persistent Cervical Cancer

Condition: Cervical Cancer
Interventions: Biological: bevacizumab; Drug: cisplatin; Drug: paclitaxel; Drug: topotecan hydrochloride
Sponsors: National Cancer Institute (NCI); Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified December 2011
Trastuzumab in Treating Older Women With Early-Stage Breast Cancer

Condition: Breast Cancer
Interventions: Biological: trastuzumab; Other: laboratory biomarker analysis; Procedure: adjuvant therapy; Procedure: quality-of-life assessment
Sponsors: Case Comprehensive Cancer Center; Case Comprehensive Cancer Center; National Cancer Institute (NCI)
Recruiting - verified December 2011
Continuation Study of Lapatinib Monotherapy or Lapatinib in Combination With Other Anti-cancer Agents

Conditions: Solid Tumors; Neoplasms, Breast; Cancer
Interventions: Drug: Lapatinib in combination with an anti-cancer agent; Drug: Lapatinib; Drug: Lapatinib in combination with an anti-cancer agent as specified by parent protocol
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified February 2012
Capecitabine, Gemcitabine, and Radiation Therapy in Treating Patients With Cholangiocarcinoma of the Gallbladder or Bile Duct

Conditions: Extrahepatic Bile Duct Cancer; Gallbladder Cancer
Interventions: Drug: capecitabine; Drug: gemcitabine hydrochloride; Procedure: adjuvant therapy; Radiation: 3-dimensional conformal radiation therapy; Radiation: intensity-modulated radiation therapy
Sponsors: National Cancer Institute (NCI); Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Combination Chemotherapy With or Without Donor Stem Cell Transplant in Treating Patients With Acute Lymphoblastic Leukemia

Condition: Leukemia
Interventions: Biological: filgrastim; Biological: graft versus host disease prophylaxis/therapy; Drug: cyclophosphamide; Drug: cytarabine; Drug: dasatinib; Drug: dexamethasone; Drug: doxorubicin hydrochloride; Drug: etoposide; Drug: leucovorin calcium; Drug: methotrexate; Drug: methylprednisolone; Drug: prednisone; Drug: vincristine sulfate; Genetic: cytogenetic analysis; Genetic: polymerase chain reaction; Other: flow cytometry; Procedure: allogeneic hematopoietic stem cell transplantation; Procedure: peripheral blood stem cell transplantation; Radiation: total-body irradiation
Sponsors: National Cancer Institute (NCI); Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Community Cancer Centers Pilot Patient Survey

Condition: Malignant Neoplasms
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Recruiting - verified June 2011
Phase III Study of RAD001 Adjuvant Therapy in Poor Risk Patients With Diffuse Large B-Cell Lymphoma (DLBCL) of RAD001 Versus Matching Placebo After Patients Have Achieved Complete Response With First-line Rituximab-chemotherapy

Condition: Diffuse Large B-cell Lymphoma
Interventions: Drug: RAD001; Drug: Placebo
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified April 2012
Neuropsychological and Behavioral Testing in Young Patients With Medulloblastoma or Supratentorial Primitive Neuroectodermal Tumor (PNET)

Conditions: Brain and Central Nervous System Tumors; Chemotherapeutic Agent Toxicity; Cognitive/Functional Effects; Neurotoxicity; Psychosocial Effects of Cancer and Its Treatment; Radiation Toxicity; Therapy-related Toxicity
Interventions: Other: questionnaire administration; Procedure: cognitive assessment; Procedure: psychosocial assessment and care; Procedure: quality-of-life assessment
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
A Phase 1b Study of AMG 386 in Combination With Either Pegylated Liposomal Doxorubicin or Topotecan in Subjects With Advanced Recurrent Epithelial Ovarian Cancer

Conditions: Cancer; Carcinoma; Fallopian Tube Cancer; Gynecological Malignancies; Metastases; Oncology; Ovarian Cancer; Solid Tumors; Tumors
Interventions: Drug: A1: AMG 386 10 mg/kg + Liposomal doxorubicin; Drug: A3: AMG 386 15mg/kg + Liposomal doxorubicin; Drug: B1: AMG 386 10 mg/kg + Topotecan; Drug: B3: AMG 386 15mg/kg + Topotecan
Sponsors: Amgen; Amgen
Recruiting - verified September 2011
Radiation Therapy With or Without Trastuzumab in Treating Women With Ductal Carcinoma In Situ Who Have Undergone Lumpectomy

Condition: Breast Cancer
Interventions: Biological: trastuzumab; Radiation: radiation therapy
Sponsors: National Cancer Institute (NCI); National Surgical Adjuvant Breast and Bowel Project (NSABP); National Cancer Institute (NCI)
Recruiting - verified April 2012
A Study to Evaluate the Efficacy and Safety of Lenalidomide as Maintenance Therapy for Patients With B-Cell CLL Following Second Line Therapy (THE CONTINUUM TRIAL)

Condition: B-cell Chronic Lymphocytic Leukemia
Interventions: Drug: Lenalidomide; Drug: Placebo
Sponsors: Celgene Corporation; Celgene Corporation
Recruiting - verified May 2012
A Study of Pemetrexed, Carboplatin and Bevacizumab in Patients With Nonsquamous Non-Small Cell Lung Cancer

Condition: Non-small Cell Lung Cancer
Interventions: Drug: Pemetrexed; Drug: Pemetrexed; Drug: Paclitaxel; Drug: Carboplatin; Biological: Bevacizumab; Biological: Bevacizumab
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified May 2012
Panitumumab, Docetaxel, Cisplatin, Radiation Therapy, and Surgery in Treating Patients With Newly Diagnosed, Locally Advanced Esophageal Cancer or Cancer of the Gastroesophageal Junction

Conditions: Adenocarcinoma of the Gastroesophageal Junction; Esophageal Cancer
Interventions: Biological: panitumumab; Drug: cisplatin; Drug: docetaxel; Procedure: neoadjuvant therapy; Procedure: therapeutic conventional surgery; Radiation: radiation therapy
Sponsors: National Cancer Institute (NCI); American College of Surgeons; National Cancer Institute (NCI)
Recruiting - verified June 2011
Stereotactic Body Radiation Therapy in Treating Patients With Stage I Non-Small Cell Lung Cancer

Condition: Lung Cancer
Intervention: Radiation: stereotactic body radiation therapy
Sponsors: National Cancer Institute (NCI); Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
CryoSpray Ablation (TM) GI Patient Registry

Conditions: Barrett's Esophagus With or Without Dysplasia; Squamous Dysplasia of the Esophagus; Esophageal Cancer (Any Stage)
Intervention:
Sponsors: CSA Medical, Inc.; CSA Medical, Inc.
Recruiting - verified January 2012
Optical Spectroscopy During Breast Cancer Surgery and Core Needle Biopsy

Condition: Breast Cancer
Intervention:
Sponsors: Duke University; Duke University
Recruiting - verified February 2012
An Optical Assay System for Intra Operative Assessment of Tumor Margins in Patients

Conditions: Partial Mastectomy; Lumpectomy; Mastectomy
Intervention:
Sponsors: Duke University; Duke University
Recruiting - verified February 2012
A Phase 1b Study of MDX-1106 in Subjects With Advanced or Recurrent Malignancies

Conditions: Metastatic Castration-resistant Prostrate Cancer (mCRPC); Renal Cell Carcinoma (RCC); Metastatic Melanoma (MEL); Non-small Cell Lung Cancer (NSCLC)
Interventions: Biological: BMS-936558 (MDX-1106); Biological: BMS-936558 (MDX-1106); Biological: BMS-936558 (MDX-1106); Biological: BMS-936558 (MDX-1106); Biological: BMS-936558 (MDX-1106)
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb; Ono Pharmaceutical Company, Ltd.
Recruiting - verified October 2011
FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer

Conditions: Colorectal Cancer; Colorectal Carcinoma; Liver Metastases
Interventions: Drug: Systemic chemotherapy (FOLFOX); Device: SIR-Spheres yttrium-90 microspheres; Drug: Systemic chemotherapy (FOLFOX)
Sponsors: Sirtex Medical; Sirtex Medical
Recruiting - verified May 2012
Docetaxel, Cisplatin, and Fluorouracil Followed By Cetuximab and Radiation Therapy in Treating Patients With Locally Advanced Head and Neck Cancer

Condition: Head and Neck Cancer
Interventions: Biological: cetuximab; Drug: cisplatin; Drug: docetaxel; Drug: fluorouracil; Procedure: computed tomography; Procedure: positron emission tomography; Procedure: quality-of-life assessment; Radiation: 3-dimensional conformal radiation therapy; Radiation: intensity-modulated radiation therapy
Sponsors: Comprehensive Cancer Center of Wake Forest University; Comprehensive Cancer Center of Wake Forest University; National Cancer Institute (NCI)
Recruiting - verified April 2012
Study of Adding AMG 479 to First Line Chemotherapy in Patients With Optimally Debulked Epithelial Ovarian Cancer

Condition: Ovarian Neoplasms
Interventions: Drug: AMG 479; Drug: AMG 479 Placebo
Sponsors: Cancer International Research Group; Cancer International Research Group
Recruiting - verified March 2012
Sodium Thiosulfate in Preventing Hearing Loss in Young Patients Receiving Cisplatin for Newly Diagnosed Germ Cell Tumor, Hepatoblastoma, Medulloblastoma, Neuroblastoma, Osteosarcoma, or Other Malignancy

Conditions: Brain and Central Nervous System Tumors; Childhood Germ Cell Tumor; Extragonadal Germ Cell Tumor; Liver Cancer; Neuroblastoma; Ototoxicity; Ovarian Cancer; Sarcoma
Interventions: Drug: sodium thiosulfate; Procedure: examination
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Safety and Efficacy of Talactoferrin in Addition to Standard Chemotherapy in Patients With Non-small Cell Lung Cancer

Condition: Non Small Cell Lung Cancer
Interventions: Drug: Talactoferrin; Drug: Placebo
Sponsors: Agennix; Agennix
Recruiting - verified March 2012
Most Closely HLA Matched Allogeneic Virus Specific Cytotoxic T-Lymphocytes (CTL)

Conditions: Adenovirus Infection; EBV Infection
Intervention: Biological: Most Closely Matched CTLs with Adenovirus
Sponsors: Baylor College of Medicine; Baylor College of Medicine; Texas Children's Hospital; The Methodist Hospital System; Brigham and Women's Hospital; Massachusetts General Hospital; M.D. Anderson Cancer Center; National Marrow Donor Program; The EMMES Corporation; Duke University; Beth Israel Deaconess Medical Center; Children's Hospital Los Angeles; National Heart, Lung, and Blood Institute (NHLBI); Children's Hospital Boston; University of Miami; Hackensack University Medical Center; University of California, Los Angeles
Recruiting - verified April 2012
Bortezomib and Vorinostat in Treating Patients With Recurrent Mantle Cell Lymphoma or Recurrent and/or Refractory Diffuse Large B-Cell Lymphoma

Condition: Lymphoma
Interventions: Drug: bortezomib; Drug: vorinostat; Other: immunohistochemistry staining method; Other: laboratory biomarker analysis
Sponsors: National Cancer Institute (NCI); H. Lee Moffitt Cancer Center and Research Institute; National Cancer Institute (NCI)
Recruiting - verified June 2009
Oxaliplatin, Capecitabine, Cetuximab, and Radiation Therapy Followed By Surgery in Treating Patients With Stage II or Stage III Rectal Cancer

Condition: Colorectal Cancer
Interventions: Biological: cetuximab; Drug: capecitabine; Drug: oxaliplatin; Genetic: gene expression analysis; Genetic: polymorphism analysis; Other: laboratory biomarker analysis; Procedure: neoadjuvant therapy; Procedure: therapeutic surgical procedure; Radiation: radiation therapy
Sponsors: National Cancer Institute (NCI); Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Genetic Mutations and Environmental Exposure in Young Patients With Retinoblastoma and in Their Parents and Young Healthy Unrelated Volunteers

Condition: Retinoblastoma
Interventions: Genetic: DNA ploidy analysis; Genetic: DNA stability analysis; Genetic: Southern blotting; Genetic: genetic linkage analysis; Genetic: loss of heterozygosity analysis; Genetic: mutation analysis; Genetic: polymorphism analysis; Genetic: reverse transcriptase-polymerase chain reaction; Other: environmental carcinogenesis study; Other: questionnaire administration; Other: study of socioeconomic and demographic variables; Procedure: evaluation of cancer risk factors; Procedure: mutation carrier screening
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Efficacy and Safety of Nilotinib Patients With Newly Diagnosed CML - CP (Chronic Myelogenous Leukemia - Chronic Phase)

Condition: Myelogenous Leukemia, Chronic
Interventions: Drug: Nilotinib; Drug: Imatinib
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified April 2012
Study of the Poly (ADP-ribose) Polymerase-1 (PARP-1) Inhibitor BSI-201 in Patients With Newly Diagnosed Malignant Glioma

Condition: Glioblastoma
Intervention: Drug: bsi-201 plus temozolomide
Sponsors: Sanofi-Aventis; Sanofi-Aventis; BiPar Sciences
Recruiting - verified June 2011
Unrelated Umbilical Cord Blood Transplantation Augmented With ALDHbr Umbilical Cord Blood Cells

Conditions: MDS; Anemia, Aplastic; Inborn Errors of Metabolism; Congenital Marrow Failure; Congenital Immunodeficiency Syndrome
Intervention: Biological: ALDHbr Umbilical Cord Blood Cells
Sponsors: Duke University; Duke University; Aldagen
Recruiting - verified August 2011
Safety Study of Oral MGCD265 Administered Without Interruption to Subjects With Advanced Malignancies

Condition: Advanced Malignancies
Intervention: Drug: MGCD265
Sponsors: MethylGene Inc.; MethylGene Inc.
Recruiting - verified April 2010
Safety and Efficacy of Pasireotide Long Acting Release vs. Octreotide Long Acting Release in Patients With Metastatic Carcinoid Disease

Condition: Symptomatic Refractory Resistant Carcinoid Disease
Interventions: Drug: Pasireotide; Drug: Octreotide
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified March 2012
Phase III Lucanix™ Vaccine Therapy in Advanced Non-small Cell Lung Cancer (NSCLC) Following Front-line Chemotherapy

Conditions: Lung Neoplasm; Carcinoma Non-small Cell Lung Cancer Stage IIIA; Carcinoma Non-small Cell Lung Cancer Stage IIIB; Carcinoma Non-small Cell Lung Cancer Stage IV
Interventions: Biological: Lucanix™; Other: Placebo Comparator
Sponsors: NovaRx Corporation; NovaRx Corporation
Recruiting - verified April 2012
A Phase I Study of WT1 Peptides to Induce Anti-Leukemia Immune Responses Following Autologous or Allogeneic Transplantation for AML, CML, ALL, MDS, and B Cell Malignancies

Conditions: Acute Myelogenous Leukemia (AML); Chronic Myelogenous Leukemia (CML); Acute Lymphoblastic Leukemia (ALL); Myelodysplastic Syndrome (MDS); B Cell Malignancies
Intervention: Biological: WT1 derived peptides
Sponsors: Duke University; Duke University
Recruiting - verified January 2012
ChemoFx® PRO - A Post-Market Data Collection Study

Conditions: Ovarian Cancer; Fallopian Tube Cancer; Peritoneal Cancer; Uterine Neoplasms; Endometrial Cancer; Vaginal Cancer; Vulvar Cancer; Cervical Cancer; Lung Cancer; Carcinoid Tumor of Lung; Sarcoma of Lung; Mesothelioma; Colorectal Cancer
Intervention:
Sponsors: Precision Therapeutics; Precision Therapeutics
Recruiting - verified June 2011
Paclitaxel, Cisplatin, and Radiation Therapy With or Without Cetuximab in Treating Patients With Locally Advanced Esophageal Cancer

Condition: Esophageal Cancer
Interventions: Biological: cetuximab; Drug: cisplatin; Drug: paclitaxel; Radiation: radiation therapy
Sponsors: National Cancer Institute (NCI); Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Combination Chemotherapy, Radiation Therapy, and an Autologous Peripheral Blood Stem Cell Transplant in Treating Young Patients With Atypical Teratoid/Rhabdoid Tumor of the Central Nervous System

Condition: Brain and Central Nervous System Tumors
Interventions: Biological: filgrastim; Drug: carboplatin; Drug: cisplatin; Drug: cyclophosphamide; Drug: etoposide; Drug: etoposide phosphate; Drug: methotrexate; Drug: thiotepa; Drug: vincristine sulfate; Genetic: mutation analysis; Other: immunohistochemistry staining method; Procedure: autologous hematopoietic stem cell transplantation; Procedure: peripheral blood stem cell transplantation; Radiation: 3-dimensional conformal radiation therapy
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Lenalidomide and Dexamethasone With or Without Bortezomib in Treating Patients With Previously Untreated Multiple Myeloma

Condition: Multiple Myeloma and Plasma Cell Neoplasm
Interventions: Drug: bortezomib; Drug: dexamethasone; Drug: lenalidomide
Sponsors: National Cancer Institute (NCI); Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified June 2011
Paricalcitol in Treating Patients With Advanced Prostate Cancer and Bone Metastases

Conditions: Metastatic Cancer; Prostate Cancer
Interventions: Drug: paricalcitol; Other: immunoenzyme technique; Other: laboratory biomarker analysis; Procedure: dual x-ray absorptometry; Procedure: quality-of-life assessment
Sponsors: Comprehensive Cancer Center of Wake Forest University; Comprehensive Cancer Center of Wake Forest University; National Cancer Institute (NCI)
Recruiting - verified October 2010
Early Detection of Breast Cancer Using Tomosynthesis Imaging

Condition: Breast Neoplasms
Intervention: Radiation: Mammography and tomosynthesis imaging
Sponsors: Duke University; Duke University
Recruiting - verified June 2011
Tissue Expander/Implant Reconstruction: A Single-Blinded, Randomized, Controlled Trial

Condition: Breast Cancer
Interventions: Procedure: Alloderm, Questionnaires; Procedure: Without ALLODERM, Questionnaires
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center; University of Michigan; University of North Carolina, Chapel Hill
Recruiting - verified December 2011
Three Different Radiation Therapy Regimens in Treating Patients With Limited-Stage Small Cell Lung Cancer Receiving Cisplatin and Etoposide

Condition: Lung Cancer
Interventions: Radiation: 3-dimensional conformal radiation therapy; Radiation: intensity-modulated radiation therapy
Sponsors: National Cancer Institute (NCI); Cancer and Leukemia Group B; National Cancer Institute (NCI); Radiation Therapy Oncology Group
Recruiting - verified May 2012
Aloxi for Prevention of Acute and Delayed Chemotherapy Induced Nausea and Vomiting (CINV) in Malignant Glioma (MG) Patients Receiving Irinotecan With Bevacizumab

Condition: Brain Cancer
Intervention: Drug: Palonosetron (Aloxi) and Dexamethasone
Sponsors: Duke University; Duke University; Eisai Inc.; National Institute of Neurological Disorders and Stroke (NINDS)
Recruiting - verified March 2012
Everolimus, Fluorouracil, Leucovorin, Panitumumab, and Oxaliplatin in Treating Patients With Solid Tumors That Did Not Respond to Treatment

Condition: Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Biological: panitumumab; Drug: everolimus; Drug: fluorouracil; Drug: leucovorin calcium; Drug: oxaliplatin
Sponsors: UNC Lineberger Comprehensive Cancer Center; UNC Lineberger Comprehensive Cancer Center; National Cancer Institute (NCI)
Recruiting - verified February 2012
Erlotinib and Surgery in Treating Patients With Head and Neck Cancer That Can Be Removed by Surgery

Condition: Head and Neck Cancer
Interventions: Drug: erlotinib hydrochloride; Genetic: protein analysis; Genetic: western blotting; Other: immunohistochemistry staining method; Other: laboratory biomarker analysis; Other: liquid chromatography; Other: mass spectrometry; Procedure: neoadjuvant therapy; Procedure: therapeutic conventional surgery
Sponsors: Comprehensive Cancer Center of Wake Forest University; Comprehensive Cancer Center of Wake Forest University; National Cancer Institute (NCI)
Recruiting - verified April 2012
Study of Nifurtimox to Treat Refractory or Relapsed Neuroblastoma or Medulloblastoma

Conditions: Neuroblastoma; Medulloblastoma
Interventions: Drug: Nifurtimox; Drug: Cyclophosphamide; Drug: Topotecan
Sponsors: Van Andel Research Institute; Giselle Sholler; Bayer
Recruiting - verified April 2012
Efficacy Study of T Cell Depleted Allogeneic Non-myeloablative Stem Cell Transplant

Conditions: Hodgkin's Disease; Non Hodgkin's Lymphoma; Myeloma; Leukemia; Myelodysplasia
Intervention: Drug: Non-myeloablative Stem Cell Transplantation
Sponsors: Duke University; Duke University
Recruiting - verified February 2012
Chemotherapy With or Without Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Cancer

Condition: Head and Neck Cancer
Interventions: Biological: bevacizumab; Drug: carboplatin; Drug: cisplatin; Drug: docetaxel; Drug: fluorouracil
Sponsors: National Cancer Institute (NCI); Eastern Cooperative Oncology Group; National Cancer Institute (NCI)
Recruiting - verified February 2012
Unrelated Cord Blood Transplant Plus a Haplo-Identical (Half-Matched), T-Cell Depleted Stem Transplant From a Related Donor for Subjects With High Risk Malignancies

Conditions: Hematologic Malignancy; MDS; Aplastic Anemia
Intervention: Procedure: haplo/cord transplant
Sponsors: Duke University; Duke University; Miltenyi Biotec GmbH
Recruiting - verified August 2011
Intensity-Modulated Radiation Therapy, Pemetrexed, and Erlotinib in Treating Patients With Recurrent or Second Primary Head and Neck Cancer

Condition: Head and Neck Cancer
Interventions: Drug: erlotinib hydrochloride; Drug: pemetrexed disodium; Procedure: quality-of-life assessment; Radiation: intensity-modulated radiation therapy
Sponsors: Comprehensive Cancer Center of Wake Forest University; Comprehensive Cancer Center of Wake Forest University; National Cancer Institute (NCI)
Recruiting - verified April 2012
Statin Therapy Versus Placebo Prior to Prostatectomy

Conditions: Cancer; Prostate
Interventions: Drug: Simvastatin; Other: Placebo
Sponsors: Department of Veterans Affairs; Department of Veterans Affairs; Oregon Health and Science University
Recruiting - verified May 2012
Prostate Radiation Therapy or Short-Term Androgen Deprivation Therapy and Pelvic Lymph Node Radiation Therapy With or Without Prostate Radiation Therapy in Treating Patients With a Rising PSA After Surgery for Prostate Cancer

Condition: Prostate Cancer
Interventions: Drug: bicalutamide; Drug: flutamide; Radiation: radiation therapy
Sponsors: National Cancer Institute (NCI); Radiation Therapy Oncology Group; National Cancer Institute (NCI); Cancer and Leukemia Group B
Recruiting - verified May 2012
Octreotide and Interferon Alfa-2b or Bevacizumab in Treating Patients With Metastatic or Locally Advanced, High-Risk Neuroendocrine Tumor

Condition: Neuroendocrine Carcinoma
Interventions: Biological: bevacizumab; Biological: recombinant interferon alfa-2b; Drug: octreotide acetate
Sponsors: National Cancer Institute (NCI); Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified January 2012
Dasatinib in Combination With Zoledronic Acid for the Treatment of Breast Cancer With Bone Metastasis

Conditions: Breast Cancer; Bone Metastases
Interventions: Drug: Dasatinib; Drug: Zoledronic Acid
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; Bristol-Myers Squibb
Recruiting - verified March 2012
Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia

Condition: Leukemia
Interventions: Drug: cyclophosphamide; Drug: cytarabine; Drug: daunorubicin hydrochloride; Drug: dexamethasone; Drug: doxorubicin hydrochloride; Drug: mercaptopurine; Drug: methotrexate; Drug: pegaspargase; Drug: thioguanine; Drug: vincristine sulfate; Radiation: radiation therapy
Sponsors: National Cancer Institute (NCI); Cancer and Leukemia Group B; National Cancer Institute (NCI); Eastern Cooperative Oncology Group; Southwest Oncology Group
Recruiting - verified May 2012
Combination Chemotherapy With or Without Lestaurtinib in Treating Infants With Newly Diagnosed Acute Lymphoblastic Leukemia

Condition: Leukemia
Interventions: Drug: asparaginase; Drug: cyclophosphamide; Drug: cytarabine; Drug: daunorubicin hydrochloride; Drug: dexamethasone; Drug: etoposide; Drug: lestaurtinib; Drug: leucovorin calcium; Drug: mercaptopurine; Drug: methotrexate; Drug: methylprednisolone; Drug: pegaspargase; Drug: prednisone; Drug: therapeutic hydrocortisone; Drug: vincristine sulfate
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Combination Chemotherapy, Autologous Stem Cell Transplant, and/or Radiation Therapy in Treating Young Patients With Extraocular Retinoblastoma

Condition: Retinoblastoma
Interventions: Biological: filgrastim; Drug: carboplatin; Drug: cisplatin; Drug: cyclophosphamide; Drug: etoposide; Drug: thiotepa; Drug: vincristine sulfate; Procedure: autologous bone marrow transplantation; Procedure: autologous hematopoietic stem cell transplantation; Procedure: peripheral blood stem cell transplantation; Radiation: radiation therapy
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Gemtuzumab and Combination Chemotherapy in Treating Patients With Previously Untreated Acute Promyelocytic Leukemia

Condition: Leukemia
Interventions: Drug: arsenic trioxide; Drug: gemtuzumab ozogamicin; Drug: mercaptopurine; Drug: methotrexate; Drug: tretinoin
Sponsors: National Cancer Institute (NCI); Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified November 2011
Vaccine Therapy in Treating Patients With Breast Cancer

Condition: Breast Cancer
Interventions: Biological: GP2 peptide + GM-CSF vaccine; Biological: GM-CSF (sargramostim); Biological: AE37 + GM-CSF vaccine; Biological: GM-CSF (sargramostim)
Sponsors: San Antonio Military Medical Center; San Antonio Military Medical Center; Antigen Express, Inc.; Norwell, Inc.
Recruiting - verified March 2012
Comparison of Different Types of Surgery in Treating Patients With Stage IA Non-Small Cell Lung Cancer

Condition: Lung Cancer
Interventions: Procedure: therapeutic thoracoscopy; Procedure: videothoracoscopy
Sponsors: National Cancer Institute (NCI); Cancer and Leukemia Group B; National Cancer Institute (NCI); Radiation Therapy Oncology Group; American College of Surgeons; Southwest Oncology Group
Recruiting - verified April 2012
Vitamin D and Soy Supplements in Treating Patients With Recurrent Prostate Cancer

Condition: Prostate Cancer
Interventions: Dietary Supplement: cholecalciferol; Dietary Supplement: genistein; Dietary Supplement: soy isoflavones; Genetic: polymerase chain reaction; Genetic: protein expression analysis; Other: immunologic technique; Other: laboratory biomarker analysis
Sponsors: Comprehensive Cancer Center of Wake Forest University; Comprehensive Cancer Center of Wake Forest University; National Cancer Institute (NCI)
Recruiting - verified April 2012
Radiation Therapy With or Without Cisplatin in Treating Patients With Recurrent Endometrial Cancer

Condition: Endometrial Cancer
Interventions: Drug: cisplatin; Radiation: brachytherapy; Radiation: external beam radiation therapy
Sponsors: National Cancer Institute (NCI); Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Strength and Range of Motion in Women Undergoing Surgery for Breast Cancer

Condition: Breast Cancer
Intervention: Other: physiologic testing
Sponsors: Comprehensive Cancer Center of Wake Forest University; Comprehensive Cancer Center of Wake Forest University; National Cancer Institute (NCI)
Recruiting - verified November 2011
Phase II Study With Abraxane, Bevacizumab and Carboplatin in Triple Negative Metastatic Breast Cancer

Condition: Breast Cancer
Interventions: Drug: Abraxane; Drug: Bevacizumab; Drug: Carboplatin
Sponsors: Duke University; Duke University; Genentech
Recruiting - verified June 2011
Assessment Tool for Older Patients With Cancer

Conditions: Cognitive/Functional Effects; Psychosocial Effects of Cancer and Its Treatment; Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Other: questionnaire administration; Procedure: cognitive assessment; Procedure: psychosocial assessment and care
Sponsors: City of Hope Medical Center; City of Hope Medical Center; National Cancer Institute (NCI)
Recruiting - verified March 2012
Assessing Ear Damage in Young Cancer Patients Treated With Cisplatin

Conditions: Ototoxicity; Unspecified Childhood Solid Tumor, Protocol Specific
Intervention: Procedure: management of therapy complications
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Cisplatin or Carboplatin, and Etoposide With or Without Sunitinib in Treating Patients With Extensive-Stage Small Cell Lung Cancer

Condition: Lung Cancer
Interventions: Drug: carboplatin; Drug: cisplatin; Drug: etoposide; Drug: sunitinib malate
Sponsors: National Cancer Institute (NCI); Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified November 2011
Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer or Other Diseases

Conditions: Chronic Myeloproliferative Disorders; Leukemia; Lymphoma; Multiple Myeloma and Plasma Cell Neoplasm; Myelodysplastic Syndromes
Interventions: Procedure: allogeneic bone marrow transplantation; Procedure: allogeneic hematopoietic stem cell transplantation; Procedure: nonmyeloablative allogeneic hematopoietic stem cell transplantation; Procedure: peripheral blood stem cell transplantation
Sponsors: Comprehensive Cancer Center of Wake Forest University; Comprehensive Cancer Center of Wake Forest University
Recruiting - verified April 2012
Phase II Trial of Pulsed Paclitaxel With Concurrent Thoracic Radiotherapy, and Adjuvant Gemcitabine and Carboplatin in Stage IIIA and IIIB Non-Small Cell Lung Cancer

Condition: Non Small Cell Lung Cancer
Interventions: Drug: Taxol (paclitaxel); Procedure: Radiotherapy; Drug: Carboplatin; Drug: Gemcitabine
Sponsors: Leo W. Jenkins Cancer Center; Leo W. Jenkins Cancer Center
Recruiting - verified January 2012
Oxaliplatin, Capecitabine and Avastin for Metastatic Esophagogastric Adenocarcinoma

Conditions: Esophageal Neoplasms; Stomach Neoplasms; Neoplasm Metastasis
Intervention: Drug: capecitabine (Xeloda), oxaliplatin and bevacizumab (Avastin)
Sponsors: Duke University; Duke University; Hoffmann-La Roche; Sanofi-Aventis; Genentech
Recruiting - verified December 2011
Testing the Helpfulness of 2 Decision Aids for Prostate Cancer

Condition: Prostate Cancer
Intervention: Behavioral: type of decision aid
Sponsors: Department of Veterans Affairs; Department of Veterans Affairs
Recruiting - verified November 2011
Surgery With or Without Docetaxel and Leuprolide or Goserelin in Treating Patients With High-Risk Localized Prostate Cancer

Condition: Prostate Cancer
Interventions: Drug: docetaxel; Drug: goserelin acetate; Drug: leuprolide acetate; Procedure: conventional surgery
Sponsors: National Cancer Institute (NCI); Cancer and Leukemia Group B; National Cancer Institute (NCI); Eastern Cooperative Oncology Group; NCIC Clinical Trials Group
Recruiting - verified September 2011
Cisplatin and Radiation Therapy With or Without Erlotinib Hydrochloride in Treating Patients With Stage III or Stage IV Head and Neck Cancer

Conditions: Stage III Squamous Cell Carcinoma of the Hypopharynx; Stage III Squamous Cell Carcinoma of the Larynx; Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity; Stage III Squamous Cell Carcinoma of the Nasopharynx; Stage III Squamous Cell Carcinoma of the Oropharynx; Stage IV Squamous Cell Carcinoma of the Hypopharynx; Stage IV Squamous Cell Carcinoma of the Larynx; Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity; Stage IV Squamous Cell Carcinoma of the Nasopharynx; Stage IV Squamous Cell Carcinoma of the Oropharynx
Interventions: Drug: erlotinib hydrochloride; Drug: cisplatin; Radiation: 3-dimensional conformal radiation therapy; Radiation: intensity-modulated radiation therapy; Procedure: quality-of-life assessment
Sponsors: Fred Hutchinson Cancer Research Center; Fred Hutchinson Cancer Research Center; National Cancer Institute (NCI)
Recruiting - verified January 2012
Combination Chemotherapy in Treating Young Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma

Conditions: Leukemia; Lymphoma
Interventions: Drug: cyclophosphamide; Drug: cytarabine; Drug: dexamethasone; Drug: doxorubicin hydrochloride; Drug: leucovorin calcium; Drug: mercaptopurine; Drug: methotrexate; Drug: nelarabine; Drug: pegaspargase; Drug: prednisone; Drug: thioguanine; Drug: vincristine sulfate; Radiation: radiation therapy
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Chemotherapy and Radiation Therapy in Treating Young Patients With Newly Diagnosed, Previously Untreated, High-Risk Medulloblastoma or Supratentorial Primitive Neuroectodermal Tumor

Condition: Brain and Central Nervous System Tumors
Interventions: Biological: filgrastim; Drug: carboplatin; Drug: cisplatin; Drug: cyclophosphamide; Drug: isotretinoin; Drug: vincristine sulfate; Radiation: radiation therapy
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
A Randomized Trial of Unruptured Brain AVMs

Condition: Unruptured Brain Arteriovenous Malformation
Intervention: Procedure: invasive therapy [endovascular procedures, neurosurgery, or radiotherapy, alone or in combination]
Sponsors: Columbia University; Columbia University; National Institute of Neurological Disorders and Stroke (NINDS)
Recruiting - verified September 2011
Combination Chemotherapy With or Without Radiation Therapy in Treating Young Patients With Newly Diagnosed Stage III or Stage IV Wilms Tumor

Conditions: Kidney Cancer; Metastatic Cancer
Interventions: Biological: dactinomycin; Drug: cyclophosphamide; Drug: doxorubicin hydrochloride; Drug: etoposide; Drug: vincristine sulfate; Procedure: therapeutic conventional surgery; Radiation: radiation therapy
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified January 2012
Low-Dose or High-Dose Vincristine and Combination Chemotherapy in Treating Young Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia

Condition: Leukemia
Interventions: Biological: filgrastim; Drug: asparaginase; Drug: cyclophosphamide; Drug: cytarabine; Drug: dexamethasone; Drug: doxorubicin hydrochloride; Drug: etoposide phosphate; Drug: leucovorin calcium; Drug: mercaptopurine; Drug: methotrexate; Drug: pegaspargase; Drug: prednisone; Drug: therapeutic hydrocortisone; Drug: vincristine sulfate; Radiation: radiation therapy
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified February 2012
Stereotactic Radiation Therapy With or Without Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases

Conditions: Breast Cancer; Cognitive/Functional Effects; Lung Cancer; Metastatic Cancer; Prostate Cancer
Interventions: Radiation: radiation therapy; Radiation: stereotactic radiosurgery
Sponsors: National Cancer Institute (NCI); North Central Cancer Treatment Group; National Cancer Institute (NCI); American College of Surgeons; Eastern Cooperative Oncology Group; Radiation Therapy Oncology Group
Recruiting - verified July 2011
Education With or Without Exercise and Counseling in Preventing Lymphedema in Women With Stage I, Stage II, or Stage III Breast Cancer Who Are Undergoing Axillary Lymph Node Dissection

Conditions: Breast Cancer; Lymphedema; Perioperative/Postoperative Complications
Interventions: Behavioral: exercise intervention; Other: educational intervention; Procedure: assessment of therapy complications; Procedure: complementary or alternative medicine procedure; Procedure: management of therapy complications; Procedure: quality-of-life assessment; Procedure: therapeutic conventional surgery
Sponsors: National Cancer Institute (NCI); Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified May 2012
A Clinical Trial Comparing Efficacy And Safety Of Sunitinib Versus Placebo For TheTreatment Of Patients At High Risk Of Recurrent Renal Cell Cancer

Condition: Kidney Neoplasms
Interventions: Drug: Sunitinib malate; Other: Placebo
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2012
Imatinib Mesylate and Temozolomide in Treating Patients With Malignant Glioma

Condition: Brain and Central Nervous System Tumors
Interventions: Drug: imatinib mesylate; Drug: temozolomide; Other: pharmacological study
Sponsors: National Cancer Institute (NCI); Duke Cancer Institute; National Cancer Institute (NCI)
Recruiting - verified October 2007
Imatinib Mesylate and Hydroxyurea in Treating Patients With Recurrent or Progressive Meningioma

Condition: Brain and Central Nervous System Tumors
Interventions: Drug: hydroxyurea; Drug: imatinib mesylate
Sponsors: National Cancer Institute (NCI); Duke Cancer Institute; National Cancer Institute (NCI)
Recruiting - verified August 2008
Temperature-Sensitive Liposomal Doxorubicin and Hyperthermia in Treating Women With Locally Recurrent Breast Cancer

Condition: Breast Cancer
Interventions: Biological: filgrastim; Biological: pegfilgrastim; Drug: lyso-thermosensitive liposomal doxorubicin; Procedure: hyperthermia treatment
Sponsors: National Cancer Institute (NCI); Duke Cancer Institute; National Cancer Institute (NCI)
Recruiting - verified October 2007
EAP (Expanded Access Protocol) Of Lapatinib Combined With Capecitabine In Metastatic Breast Cancer

Condition: Neoplasms, Breast
Intervention: Drug: lapatinib + capecitabine
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified April 2012
Combination Chemotherapy Followed By Peripheral Stem Cell Transplant in Treating Young Patients With Newly Diagnosed Supratentorial Primitive Neuroectodermal Tumors or High-Risk Medulloblastoma

Condition: Brain and Central Nervous System Tumors
Interventions: Drug: carboplatin; Drug: cisplatin; Drug: cyclophosphamide; Drug: etoposide; Drug: leucovorin calcium; Drug: methotrexate; Drug: thiotepa; Drug: vincristine sulfate
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified August 2011
Chemotherapy With or Without Bevacizumab in Treating Patients With Stage IB, Stage II, or Stage IIIA Non-Small Lung Cancer That Was Removed By Surgery

Condition: Lung Cancer
Interventions: Biological: bevacizumab; Drug: cisplatin; Drug: docetaxel; Drug: gemcitabine hydrochloride; Drug: pemetrexed disodium; Drug: vinorelbine tartrate
Sponsors: National Cancer Institute (NCI); Eastern Cooperative Oncology Group; National Cancer Institute (NCI); Southwest Oncology Group; Cancer and Leukemia Group B; NCIC Clinical Trials Group; North Central Cancer Treatment Group
Recruiting - verified February 2012
Efficacy and Safety of Zoledronic Acid ( Every 4 Weeks vs. Every 12 Weeks) in Patients With Documented Bone Metastases From Bone Cancer

Condition: Breast Cancer
Intervention: Drug: Zometa® (zoledronic acid)
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified April 2012
Androgen Ablation Therapy With or Without Chemotherapy in Treating Patients With Metastatic Prostate Cancer

Condition: Prostate Cancer
Interventions: Drug: antiandrogen therapy; Drug: docetaxel
Sponsors: National Cancer Institute (NCI); Eastern Cooperative Oncology Group; National Cancer Institute (NCI)
Recruiting - verified February 2012
Hormone Therapy With or Without Combination Chemotherapy in Treating Women Who Have Undergone Surgery for Node-Negative Breast Cancer (The TAILORx Trial)

Condition: Breast Cancer
Interventions: Drug: anastrozole; Drug: chemotherapy; Drug: exemestane; Drug: letrozole; Drug: tamoxifen citrate
Sponsors: National Cancer Institute (NCI); Eastern Cooperative Oncology Group; National Cancer Institute (NCI); Southwest Oncology Group; Cancer and Leukemia Group B; American College of Surgeons; North Central Cancer Treatment Group; NCIC Clinical Trials Group; National Surgical Adjuvant Breast and Bowel Project (NSABP)
Recruiting - verified July 2011
Cisplatin-Based Chemotherapy and/or Surgery in Treating Young Patients With Adrenocortical Tumor

Condition: Adrenocortical Carcinoma
Interventions: Biological: filgrastim; Biological: pegfilgrastim; Drug: cisplatin; Drug: doxorubicin hydrochloride; Drug: etoposide; Drug: mitotane; Procedure: conventional surgery
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified July 2011
Combination Chemotherapy in Treating Patients With Stage III or Stage IV Malignant Peripheral Nerve Sheath Tumors

Conditions: Neurofibromatosis Type 1; Sarcoma
Interventions: Biological: filgrastim; Drug: doxorubicin hydrochloride; Drug: etoposide; Drug: ifosfamide; Procedure: conventional surgery; Radiation: radiation therapy
Sponsors: Sarcoma Alliance for Research through Collaboration; Sarcoma Alliance for Research through Collaboration; National Cancer Institute (NCI)
Recruiting - verified March 2012
Multicenter Selective Lymphadenectomy Trial II (MSLT-II)

Condition: Melanoma
Interventions: Procedure: Completion Lymphadenectomy; Procedure: Monitoring with nodal ultrasound
Sponsors: John Wayne Cancer Institute; John Wayne Cancer Institute; National Institutes of Health (NIH)
Recruiting - verified January 2012
Biomarkers in Patients With Rectal Cancer Undergoing Chemotherapy and Radiation Therapy

Condition: Colorectal Cancer
Interventions: Drug: capecitabine; Drug: 5-fluorouracil; Procedure: Surgical Resection; Radiation: Radiation therapy
Sponsors: UNC Lineberger Comprehensive Cancer Center; UNC Lineberger Comprehensive Cancer Center; National Cancer Institute (NCI)
Recruiting - verified April 2012
Computer Program in Improving Communication Between Doctors and Patients With Stage IV Cancer

Condition: Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Procedure: psychosocial assessment and care; Procedure: supportive care
Sponsors: National Cancer Institute (NCI); Duke Cancer Institute; National Cancer Institute (NCI)
Recruiting - verified July 2009
Vaccine Therapy, Trastuzumab, and Vinorelbine in Treating Patients With Locally Recurrent or Metastatic Breast Cancer

Condition: Breast Cancer
Interventions: Biological: sargramostim; Biological: therapeutic autologous dendritic cells; Biological: trastuzumab; Drug: vinorelbine ditartrate
Sponsors: UNC Lineberger Comprehensive Cancer Center; UNC Lineberger Comprehensive Cancer Center; National Cancer Institute (NCI)
Recruiting - verified March 2012
Paclitaxel and Radiation Therapy With or Without Trastuzumab in Treating Patients Who Have Undergone Surgery for Bladder Cancer

Condition: Bladder Cancer
Interventions: Biological: trastuzumab; Drug: paclitaxel; Radiation: radiation therapy
Sponsors: National Cancer Institute (NCI); Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Chemotherapy After Prostatectomy (CAP) For High Risk Prostate Carcinoma

Condition: Prostate Cancer
Interventions: Drug: Docetaxel; Drug: Prednisone
Sponsors: Department of Veterans Affairs; Department of Veterans Affairs; Sanofi-Aventis
Recruiting - verified September 2011
Doxorubicin, Cyclophosphamide, and/or Paclitaxel in Treating Women With Nonmetastatic Breast Cancer

Condition: Breast Cancer
Interventions: Drug: AC regimen; Drug: cyclophosphamide; Drug: doxorubicin hydrochloride; Drug: paclitaxel
Sponsors: National Cancer Institute (NCI); Duke Cancer Institute; National Cancer Institute (NCI)
Recruiting - verified April 2008
Combination Chemotherapy, PEG-Interferon Alfa-2b, and Surgery in Treating Patients With Osteosarcoma

Condition: Sarcoma
Interventions: Biological: PEG-interferon alfa-2b; Drug: cisplatin; Drug: doxorubicin hydrochloride; Drug: etoposide; Drug: ifosfamide; Drug: methotrexate
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI); University College London Hospitals
Recruiting - verified June 2011
Radiation Therapy in Treating Women Who Have Undergone Surgery For Ductal Carcinoma In Situ or Stage I or Stage II Breast Cancer

Condition: Breast Cancer
Interventions: Radiation: 3-dimensional conformal accelerated partial breast irradiation; Radiation: brachytherapy; Radiation: whole breast irradiation
Sponsors: National Cancer Institute (NCI); National Surgical Adjuvant Breast and Bowel Project (NSABP); National Cancer Institute (NCI); Radiation Therapy Oncology Group; Southwest Oncology Group
Recruiting - verified May 2012
Treatment of Patients With Newly Diagnosed Medulloblastoma, Supratentorial Primitive Neuroectodermal Tumor, or Atypical Teratoid Rhabdoid Tumor

Condition: Brain and Central Nervous System Tumors
Interventions: Biological: filgrastim; Drug: cisplatin; Drug: cyclophosphamide; Drug: vincristine sulfate; Procedure: autologous hematopoietic stem cell transplantation; Radiation: radiation therapy
Sponsors: St. Jude Children's Research Hospital; St. Jude Children's Research Hospital
Recruiting - verified January 2012
Comparison of Two Salvage Chemotherapy Regimens Before Autologous Stem Cell Transplantation With or Without Maintenance Rituximab in Treating Patients With Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma

Condition: Lymphoma
Interventions: Biological: rituximab; Drug: cisplatin; Drug: cytarabine; Drug: dexamethasone; Drug: gemcitabine hydrochloride; Other: clinical observation
Sponsors: NCIC Clinical Trials Group; NCIC Clinical Trials Group
Recruiting - verified May 2012
Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer

Conditions: Glioblastoma Multiforme; Glioblastoma; GBM; Grade IV Astrocytoma; Glioma; Brain Cancer; Brain Tumor
Intervention: Drug: Dendritic cell immunotherapy
Sponsors: Northwest Biotherapeutics; Northwest Biotherapeutics
Recruiting - verified May 2012
Isotretinoin With or Without Monoclonal Antibody, Interleukin-2, and Sargramostim Following Stem Cell Transplantation in Treating Patients With Neuroblastoma

Condition: Neuroblastoma
Interventions: Biological: aldesleukin; Biological: monoclonal antibody Ch14.18; Biological: sargramostim; Drug: isotretinoin
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Combination Chemotherapy With or Without Peripheral Stem Cell Transplantation, Radiation Therapy, and/or Surgery in Treating Patients With Ewing's Sarcoma

Condition: Sarcoma
Interventions: Biological: dactinomycin; Drug: busulfan; Drug: doxorubicin hydrochloride; Drug: etoposide; Drug: ifosfamide; Drug: melphalan; Drug: vincristine sulfate; Procedure: autologous hematopoietic stem cell transplantation; Procedure: conventional surgery; Radiation: radiation therapy
Sponsors: National Cancer Institute (NCI); University Hospitals, Leicester; National Cancer Institute (NCI); Children's Cancer and Leukaemia Group; Societe Francaise Oncologie Pediatrique; European Organization for Research and Treatment of Cancer - EORTC; Gesellschaft fur Padiatrische Onkologie und Hamatologie - Germany; Gesellschaft fur Padiatrische Onkologie und Hamatologie - Austria; Swiss Group for Clinical Cancer Research; EBMT Solid Tumors Working Party; Children's Oncology Group
Recruiting - verified December 2011
Paclitaxel in Treating Patients With Ovarian Stromal Cancer

Condition: Ovarian Cancer
Intervention: Drug: paclitaxel
Sponsors: National Cancer Institute (NCI); Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Diagnostic Study of Patients With Acute Lymphoblastic Leukemia or Acute Promyelocytic Leukemia

Condition: Leukemia
Interventions: Genetic: reverse transcriptase-polymerase chain reaction; Other: flow cytometry
Sponsors: National Cancer Institute (NCI); Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified April 2012